External Grants by School/Department   

Anesthesiology

• Fedias L Christofi Purinergic regulation of enteric neural reflexes Nat In Diabetes & Digestive & Kidney Diseases $42,270
• Fedias L Christofi Purinergic regulation of enteric neural reflexes Nat In Diabetes & Digestive & Kidney Diseases $192,016
• Fedias L Christofi Purinergic regulation of enteric neural reflexes Nat In Diabetes & Digestive & Kidney Diseases $2,429
• Fedias L Christofi Purinergic regulation of enteric neural reflexes Nat In Diabetes & Digestive & Kidney Diseases $11,035
• Fedias L Christofi Purinergic regulation of enteric neural reflexes Nat In Diabetes & Digestive & Kidney Diseases $3,887
• Fedias L Christofi Purinergic regulation of enteric neural reflexes Nat In Diabetes & Digestive & Kidney Diseases $17,657
• Sergio Bergese A multi-center, randomized, double-blind, place-controlled, parallel-group study of intravenous Methylnaltrexone (MOA-728) for the treatment of post operative ileus following ventral hernia repair WYETH PHARMACEUTICALS INC $0
• Sergio Bergese A multi-center, randomized, double-blind, place-controlled, parallel-group study of intravenous Methylnaltrexone (MOA-728) for the treatment of post operative ileus following ventral hernia repair WYETH PHARMACEUTICALS INC $15,378
• Sergio Bergese A phase III randomized, double-blind, placebo-controlled, multi-center, parallel-group, multiple-dose study of the analgesic efficacy and safety of intravenous Acetaminophen versus placebo over 48 hours for the treatment of postoperative pain after gynec Cadence Pharmaceuticals, Inc $0
• Sergio Bergese A phase III randomized, double-blind, placebo-controlled, multi-center, parallel-group, multiple-dose study of the analgesic efficacy and safety of intravenous Acetaminophen versus placebo over 48 hours for the treatment of postoperative pain after gynec Cadence Pharmaceuticals, Inc $43,449
• Sergio Bergese A phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of Dexmedetomidine in the prevention of postoperative delirium in patients undergoing heart valve surgery with cardiopulmonary bypass PRA Intl $0
• Sergio Bergese A phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of Dexmedetomidine in the prevention of postoperative delirium in patients undergoing heart valve surgery with cardiopulmonary bypass PRA Intl $2,250
• Sergio Bergese A randomized, double-blind, double-dummy, dose-ranging, active- and placebo-controlled study of single-dose oral rolapitant monotherapy for the prevention of postoperative nausea and vomiting (PONV) Schering-Plough Res Inst $0
• Sergio Bergese Awake intubation: Why not Dexmedetomidine for airway management? Hospira, Inc $12,750
• Sergio Bergese Awake intubation: Why not Dexmedetomidine for airway management? Hospira, Inc $12,750
• Sergio Bergese Evaluating the efficacy and safety of dexmedetomidine in the prevention of postoperative delirium in subjects undergoing surgery for fractured hip with general anesthesia Hospira, Inc $2,250
• Sergio Bergese Evaluating the safety and efficacy of Dexmedetomidine for sedation during monitored anesthesia care Hospira, Inc $0
• Sergio Bergese Evaluating the safety and efficacy of Dexmedetomidine for sedation during monitored anesthesia care Hospira, Inc $74,393
• Sergio Bergese Evaluating the safety and efficacy of Dexmedetomidine for sedation during monitored anesthesia care Hospira, Inc $67,889
• Sergio Bergese Evaluating the safety and efficacy of Dexmedetomidine for sedation during monitored anesthesia care Hospira, Inc $44,906
• Sergio Bergese Evaluating the safety and efficacy of Dexmedetomidine for sedation during monitored anesthesia care Hospira, Inc $17,464
• Sergio Bergese Evaluating the safety and efficacy of dexmedetomidine used for sedation during elective awake fiberoptic intubation Hospira, Inc $19,485
• Sergio Bergese Evaluating the safety and efficacy of dexmedetomidine used for sedation during elective awake fiberoptic intubation Hospira, Inc $2,925
• Sergio Bergese Evaluating the safety and efficacy of dexmedetomidine used for sedation during elective awake fiberoptic intubation Hospira, Inc $5,558
• Yun Xia A multi-center, randomized, double-blind, placebo-controlled, parallel-group study of intravenous Methylnaltrexone (MOA-728) for the treatment of post operative ileus WYETH PHARMACEUTICALS INC $15,780
• Yun Xia GDNF in the enteric nervous system Nat In Diabetes & Digestive & Kidney Diseases $130,113

Biomedical Informatics

• Daniel A Janies Novel analytical and empirical approaches to the origin and prediction of pathogenicity Am Museum of Natural History $260,162
• Daniel A Janies Novel analytical and empirical approaches to the origin and prediction of pathogenicity Am Museum of Natural History $35,585
• Daniel A Janies Novel analytical and empirical approaches to the origin and prediction of pathogenicity Am Museum of Natural History $136,071
• Dhabaleswar K Panda High-end computing and networking research testbed for next generation data driven, interactive applications NSF Div of Computer & Network Systems $227,585
• George F Heine Understanding the role of BCRA1 in response to DNA damage. National Institutes of Health $46,826
• Ilya P Ioschikhes High resolution mapping of functional elements in the yeast genome Pennsylvania State Univ $64,926
• Ilya P Ioschikhes Micro-RNA Regulation in Ischemia PhRMA Fdn $30,000
• Jeffrey Parvin BRCA1 function National Cancer Institute $89,940
• Jeffrey Parvin Centrosomes and BRCA1 National Cancer Institute $224,690
• Jeffrey Parvin Centrosomes and BRCA1 National Cancer Institute $26,514
• Joel H Saltz A distributed community resource for multi-scale cardiovascular data integration discovery Johns Hopkins Univ $461,917
• Joel H Saltz ARCH DEV - caGrid 1.0 design and implementation Booz Allen Hamilton Inc $2,500
• Joel H Saltz ARCH DEV - caGrid 1.0 design and implementation Booz Allen Hamilton Inc $150,000
• Joel H Saltz ARCH DEV - caGrid 1.0 design and implementation Booz Allen Hamilton Inc $165,000
• Joel H Saltz caBIG architecture workspace Booz Allen Hamilton Inc $178,400
• Joel H Saltz caBIG architecture workspace Booz Allen Hamilton Inc $25,000
• Joel H Saltz caBIG in vivo imaging workspace developer core middleware development Booz Allen Hamilton Inc $154,000
• Joel H Saltz caBIG in vivo imaging workspace subject matter expert Booz Allen Hamilton Inc $52,150
• Joel H Saltz caBIG in vivo imaging workspace subject matter expert Booz Allen Hamilton Inc $52,500
• Joel H Saltz caBIG Task 4: Strategic planning strategic level working group participation Booz Allen Hamilton Inc $9,426
• Joel H Saltz caBIG Task 4: Strategic planning strategic level working group participation Booz Allen Hamilton Inc $13,112
• Joel H Saltz caGrid Developer-Task Order 12 Booz Allen Hamilton Inc $600,000
• Joel H Saltz CSR--AES: Collaborative research: Intelligent optimization of parallel and distributed applications (WP2) NSF Div of Computer & Network Systems $68,169
• Joel H Saltz Tightly-coupled heterogeneous supercomputing NSF Div of Computer & Network Systems $30,170
• Joel H Saltz caBIG Task 4: Strategic planning strategic level working group participation Booz Allen Hamilton Inc $2,357
• Joel H Saltz caBIG Task 4: Strategic planning strategic level working group participation Booz Allen Hamilton Inc $3,278
• Marymegan Daly Assembling the tree of life: An integrative approach to investigating cnidarian phylogeny NSF Div Emerging Frontiers $48,839
• Umit V Catalyurek CAREER: Scalable Combinatorial Scientific Computing NSF Div of Computer & Network Systems $80,000

Comprehensive Cancer Center

• En-Ju Lin The role of Neuropeptide Y mediated neurogenesis in epilepsies and depression Fdn for Research, Science and Technology $152,780
• En-Ju Lin The role of Neuropeptide Y mediated neurogenesis in epilepsies and depression Fdn for Research, Science and Technology $16,976
• Georgette N Jones Molecular interactions of the carney complex gene PRKAR1A and the neurofibromatosis genes in peripheral nerve sheath tumors Children's Tumor Fdn $25,000
• Georgette N Jones Molecular interactions of the carney complex gene PRKAR1A and the neurofibromatosis genes in peripheral nerve sheath tumors Children's Tumor Fdn $2,575
• Huating Wang Mechanistic studies of NF-kB inhibition of myogenesis Nat In Arthritis&Muscoskeletal&Skin Ds $51,278
• Hui Wang E2F2b, a novel tumor suppressor in Myc-induced lymphomagenesis Am Cancer Soc Inc $46,000
• Kaisa-Mari Elina Sotamaa Predisposition of heritable germline methylation of MLH1 Am Cancer Soc-Ohio $9,600
• Krystian Arseniusz Jazdzewski The role of mir-146a in papillary thyroid cancer American Thyroid Association $25,000
• Paolo Neviani Pharmacologic activation of PP2A as a potential therapy for imatinhib sensitive and resistant Ph1 leukemia American-Italian Cancer Fdn $31,500
• Paolo Neviani Pharmacologic activation of PP2A as a potential therapy for imatinhib sensitive and resistant Ph1 leukemia American-Italian Cancer Fdn $3,500
• Young C Lin Epigenetic modulation of PTPG by Zeranol in beef increases breast cancer risk Nat Inst of Environ Health Scis $78,462
• Young C Lin Epigenetic modulation of PTPG by Zeranol in beef increases breast cancer risk Nat Inst of Environ Health Scis $77,494

Emergency Medicine

• Brian C Hiestand Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidlines: The CRUSADE national quality initiative Duke Univ $1,620
• Brian C Hiestand Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidlines: The CRUSADE national quality initiative Duke Univ $60
• Brian C Hiestand Emergency Medicine Pulmonary Embolism in the Real World Registry: A National Quality Improvement Initiative for the ED (EMPEROR) Pennsylvania Hospital $1,325
• Brian C Hiestand Emergency Medicine Pulmonary Embolism in the Real World Registry: A National Quality Improvement Initiative for the ED (EMPEROR) Pennsylvania Hospital $4,125
• Brian C Hiestand Emergency Medicine Pulmonary Embolism in the Real World Registry: A National Quality Improvement Initiative for the ED (EMPEROR) Pennsylvania Hospital $1,375
• Brian C Hiestand Heart failure and audicor technology for rapid diagnosis and initial treatment Inovise Medical, Inc $23,960
• Carlos A Torres Unraveling the inotropic effects of pyruvate Emergency Medicine Fdn $50,000
• James F Neuenschwander Can pacemakers, defibrillators, and internal heart failure devices be used to evaluate and guide management in the Emergency Department Medtronic Inc $0
• James F Neuenschwander Can pacemakers, defibrillators, and internal heart failure devices be used to evaluate and guide management in the Emergency Department Medtronic Inc $10,044
• James F Neuenschwander Can pacemakers, defibrillators, and internal heart failure devices be used to evaluate and guide management in the Emergency Department Medtronic Inc $15,067
• James F Neuenschwander Myeloperoxidase and multi-markers in the diagnosis of acute coronary syndrome (MIDAS) - specimen procurement Biosite Incorporated $0
• Jeffrey M Caterino Infected elders in the ED: Outcome and Processes of Care Am Geriatrics Society $150,000
• Jeffrey M Caterino Usefulness and accuracy of the field glasgow coma scale in elderly trauma victims OH Dept of Public Safety $33,123
• Mark G Angelos Hypoxic reperfusion and induction of myocardial reactive oxygen species Am Heart Assn-Great Rivers Affiliate $60,500
• Michael R Sayre Induction of mild hypothermia in resuscitated cardiac arrest patients using traditional cooling techniques vs. the Medivance Arctic Sun Temperature Management System Medivance, Inc $16,407
• Michael R Sayre The Pulse assist trial. Univ of Washington $3,993
• Robert M Guthrie A 12-week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and rosuvastatin compared to ABT-335 and rosuvastatin monotherapy in subjects with type IIa or IIb Dyslipidemia Icon Clinical Res Inc $0
• Robert M Guthrie A long-term, open-label, safety extension study of the combination of fenofibric acid and statin therapy for subjects with mixed dyslipidemia Covance Inc $8,784
• Robert M Guthrie A long-term, open-label, safety extension study of the combination of fenofibric acid and statin therapy for subjects with mixed dyslipidemia Covance Inc $10,860
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $16,391
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $4,000
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $21,077
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $8,646
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $1,756
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $2,531
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $5,405
• Robert M Guthrie A randomized, double-dummy, placebo-controlled, 3x4 factorial design to evaluate telmisartan 20 and 80 mg in combination with ramipril 1.25, 10, and 20 mg capsules, after eight weeks of treatment in Boehringer Ingelheim Pharmaceuticals Inc $5,405
• Robert M Guthrie Study comparing the safety and efficacy of fenofibric acid and rosuvastatin calcium combination therapy to fenofibric acid and rosuvastatin calcium monotherapy Covance Inc $6,302
• Robert M Guthrie Trial to evaluate telmisartan 20,40 and 80 mg tablets in combination with amlodipine 2.5, 5 and 10 mg capsules after eight weeks of treatment in patients with stage I or II hypertension, with an ABPM sub-study Boehringer Ingelheim Pharmaceuticals Inc $3,127
• Robert M Guthrie Trial to evaluate telmisartan 20,40 and 80 mg tablets in combination with amlodipine 2.5, 5 and 10 mg capsules after eight weeks of treatment in patients with stage I or II hypertension, with an ABPM sub-study Boehringer Ingelheim Pharmaceuticals Inc $4,528

Family Medicine

• Douglas Knutson Pre-doctoral training in primary care (Teaching to the CORE) Health Resources & Services Admin $226,035
• Douglas M Post Efficacy of web-based training in skin cancer triage. Rhode Island Hosp $14,332
• Patrick J Fahey Multicenter, randomized, double-blind study to evaluate the efficacy and safety of ezetimibe.Simvastatin and niacin (extended release tablet)co-administered in patients with Type IIa or Type IIb hyperlipidemia Merck & Co Inc $237
• Patrick J Fahey Multicenter, randomized, double-blind study to evaluate the efficacy and safety of ezetimibe.Simvastatin and niacin (extended release tablet)co-administered in patients with Type IIa or Type IIb hyperlipidemia Merck & Co Inc $1,018
• Patrick J Fahey Multicenter, randomized, double-blind study to evaluate the efficacy and safety of ezetimibe.Simvastatin and niacin (extended release tablet)co-administered in patients with Type IIa or Type IIb hyperlipidemia Merck & Co Inc $1,500
• Patrick J Fahey Multicenter, randomized, double-blind study to evaluate the efficacy and safety of ezetimibe.Simvastatin and niacin (extended release tablet)co-administered in patients with Type IIa or Type IIb hyperlipidemia Merck & Co Inc $466
• Patrick J Fahey Multicenter, randomized, double-blind study to evaluate the efficacy and safety of ezetimibe.Simvastatin and niacin (extended release tablet)co-administered in patients with Type IIa or Type IIb hyperlipidemia Merck & Co Inc $485
• Patrick J Fahey Multicenter, randomized, double-blind study to evaluate the efficacy and safety of ezetimibe.Simvastatin and niacin (extended release tablet)co-administered in patients with Type IIa or Type IIb hyperlipidemia Merck & Co Inc $485
• Randell Wexler Pfizer fellowship in health disparities Pfizer Inc $130,000
• William F Miser A multicenter randomized, double-blind study to evaluate the safety and efficacy of MK-0431 monotherapy in patients with type 2 diabetes mellitus who have inadequate glycemic control PEDIATRIC CLINICAL TRIALS INTERNATIONAL $67
• William F Miser A multicenter, double-blind, randomized, parallel group study to evaluate the safety and efficacy of Sitagliptin in elderly patients with type 2 diabetes mellitus Merck & Co Inc $6,052
• William F Miser A multicenter, double-blind, randomized, parallel group study to evaluate the safety and efficacy of Sitagliptin in elderly patients with type 2 diabetes mellitus Merck & Co Inc $3,712
• William F Miser A multicenter, double-blind, randomized, parallel group study to evaluate the safety and efficacy of Sitagliptin in elderly patients with type 2 diabetes mellitus Merck & Co Inc $915
• William F Miser A multicenter, double-blind, randomized, parallel group study to evaluate the safety and efficacy of Sitagliptin in elderly patients with type 2 diabetes mellitus Merck & Co Inc $1,372
• William F Miser A multicenter, randomized,double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of Saxagliptin (BMS-477118) in combination with Thiazolidinedione therapy in subjects with type 2 diabetes who have inadequate glycemic control Bristol-Myers Squibb Co $950
• William F Miser A phase III active-comparator (Metformin) controlled, clinical trial to study the efficacy and safety of MK-0431A in patients with type 2 diabetes mellitus. Merck & Co Inc $0
• William F Miser The durability of twice-daily Insulin Lispro low mixture compared to once-daily Insulin Glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control Eli Lilly & Co $306
• William F Miser The durability of twice-daily Insulin Lispro low mixture compared to once-daily Insulin Glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control Eli Lilly & Co $585
• William F Miser The durability of twice-daily Insulin Lispro low mixture compared to once-daily Insulin Glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control Eli Lilly & Co $895
• William F Miser The durability of twice-daily Insulin Lispro low mixture compared to once-daily Insulin Glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control Eli Lilly & Co $1,707
• William F Miser The durability of twice-daily Insulin Lispro low mixture compared to once-daily Insulin Glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control Eli Lilly & Co $3,442
• William F Miser The durability of twice-daily Insulin Lispro low mixture compared to once-daily Insulin Glargine when added to existing oral therapy in patients with type 2 diabetes and inadequate glycemic control Eli Lilly & Co $2,570

Heart and Lung Institute

• Edward Eteshola Protein engineering and biosensing interface materials Nat In Biomedical Imaging&Bioengineering $72,436
• Jeffrey J Chalmers Continuous cell sorting by magnetophoresis Cleveland Clinic Fdn $15,756
• Jeffrey J Chalmers Continuous cell sorting by magnetophoresis Cleveland Clinic Fdn $3,368
• Nicanor I Moldovan Role of oxygenation during C-kit+ progenitor cells engraftment in experimentally infarcted hearts Am Heart Assn-Great Rivers Affiliate $60,500

Internal Medicine

• Charles F Emery Exercise, stress, and wound healing among older adults National Institute on Aging $24,089
• Charles F Emery Exercise, stress, and wound healing among older adults National Institute on Aging $24,089
• Charles F Emery Exercise, stress, and wound healing among older adults National Institute on Aging $24,089
• Charles F Emery Exercise, stress, and wound healing among older adults National Institute on Aging $9,636
• Wiley W "Chip" Souba General clinical research center. Nat Center for Research Resources $2,870,053

Internal Medicine - Cardiovascular Medicine

• Ayesha Khalid Hasan CHAMPION CardioMEMS, Inc $0
• Ayesha Khalid Hasan CM-06-03 CardioMEMS, Inc $0
• Ayesha Khalid Hasan CM-06-03 CardioMEMS, Inc $29,089
• Ayesha Khalid Hasan CM-06-03 CardioMEMS, Inc $1,938
• Ayesha Khalid Hasan FREEDOM Pacesetter Inc $0
• Ayesha Khalid Hasan FREEDOM Pacesetter Inc $4,200
• Ayesha Khalid Hasan Phrenic nerve study Cardiac Concepts, Inc $0
• Barbara Rita Alevriadou Mechanoregulation of endothelial mitochondrial function National Heart, Lung, and Blood Inst $122,100
• Carl V Leier Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (ESCAPE, MECHANISTIC, PAC). Duke Univ $390
• Carl V Leier FHDF01 a phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure Encysive, LP $3,250
• Carl V Leier FHDF01 a phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure Encysive, LP $220
• Carl V Leier FHDF01 a phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure Encysive, LP $1,072
• Carl V Leier FHDF01 a phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure Encysive, LP $487
• Carl V Leier FHDF01 a phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure Encysive, LP $506
• Carl V Leier FHDF01 a phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure Encysive, LP $55,913
• Carl V Leier FHDF01 a phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure Encysive, LP $361
• Charles J Love AV-node ablation with CLS and CRT pacing therapies for the treatment of symptomatic AF (AVAIL CLS/CRT) Biotronik Inc $3,550
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $1,750
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $1,750
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $4,500
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $750
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $250
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $250
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $750
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $1,000
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $3,750
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $750
• Charles J Love Lumos-T safely reduces routine office device follow-up (TRUST) Biotronik Inc $250
• Charles J Love UNITY Pacesetter Inc $0
• Charles J Love UNITY Pacesetter Inc $2,000
• Charles J Love Evaluation of the safety and efficacy of the OPTIMIZER II system with active fixation leads in subjects with heart failure resulting from systolic dysfunction: FIX-HF-5. Impulse Dynamics, Inc $2,548
• Charles J Love Evaluation of the safety and efficacy of the OPTIMIZER II system with active fixation leads in subjects with heart failure resulting from systolic dysfunction: FIX-HF-5. Impulse Dynamics, Inc $1,148
• Charles J Love Evaluation of the safety and efficacy of the OPTIMIZER II system with active fixation leads in subjects with heart failure resulting from systolic dysfunction: FIX-HF-5. Impulse Dynamics, Inc $13,489
• Charles J Love Evaluation of the safety and efficacy of the OPTIMIZER II system with active fixation leads in subjects with heart failure resulting from systolic dysfunction: FIX-HF-5. Impulse Dynamics, Inc $5,306
• Charles J Love MADIT II Risk Univ of Rochester $1,600
• Charles J Love MADIT II Risk Univ of Rochester $0
• Charles J Love MADIT II Risk Univ of Rochester $50
• Charles J Love MADIT II Risk Univ of Rochester $200
• Charles J Love Risk stratification in MADIT II type patients (blood drawings) Univ of Rochester $0
• Charles J Love Risk stratification in MADIT II type patients (blood drawings) Univ of Rochester $125
• Christine E Lawless ICD sports registry: safety of sports for patients with implantable cardioverter-defibrillators: a multi-site study Yale Univ $0
• Chun-An Chen Molecular mechanisms of phosphorylation and oxidative modification of eNOS on the regulation of cardiovascular function Am Heart Assn-Great Rivers Affiliate $42,000
• Curt J Daniels A long-term, open-label study to evaluate the safety of sitaxsentan sodium treatment in patients with pulmonary arterial hypertension. TX Biotechnology Corp $2,433
• Curt J Daniels A long-term, open-label study to evaluate the safety of sitaxsentan sodium treatment in patients with pulmonary arterial hypertension. TX Biotechnology Corp $1,907
• Curt J Daniels An open-label, multi-center study employing a targeted 6-MWT distance threshold approach to guide bosentan-based therapy and to assess the utility of MRI on cardiac remodeling (AC-052-419 COMPASS 3) Actelion Clinical Operations, Inc $0
• Curt J Daniels An open-label, multi-center study employing a targeted 6-MWT distance threshold approach to guide bosentan-based therapy and to assess the utility of MRI on cardiac remodeling (AC-052-419 COMPASS 3) Actelion Clinical Operations, Inc $2,000
• Curt J Daniels An open-label, multi-center study employing a targeted 6-MWT distance threshold approach to guide bosentan-based therapy and to assess the utility of MRI on cardiac remodeling (AC-052-419 COMPASS 3) Actelion Clinical Operations, Inc $11,366
• Curt J Daniels Pulmonary arterial hypertension quality enhancement research initiative (QuERI) MD Primer Inc $0
• Curt J Daniels REVEAL registry CoTherix, Inc $0
• Curt J Daniels REVEAL registry CoTherix, Inc $1,000
• Curt J Daniels REVEAL registry CoTherix, Inc $8,250
• Curt J Daniels REVEAL registry CoTherix, Inc $8,750
• Curt J Daniels REVEAL registry CoTherix, Inc $2,000
• Curt J Daniels REVEAL registry CoTherix, Inc $3,875
• David S Feldman Adrenergically mediated remodeling in non-ischemic heart failure National Heart, Lung, and Blood Inst $262,500
• David S Feldman HARPS Thoratec Corp $0
• David S Feldman Resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) Medtronic Inc $8,000
• David S Feldman Resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) Medtronic Inc $21,881
• David S Feldman Resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) Medtronic Inc $9,645
• David S Feldman Resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) Medtronic Inc $11,300
• David S Feldman TMAC A051 Scios Inc $0
• David S Feldman Adrenergically mediated remodeling in non-ischemic heart failure National Heart, Lung, and Blood Inst $75,000
• Emile Georges Daoud Artic Front Trial/STOP AF/PS-023 CryoCath Technologies Inc $0
• Emile Georges Daoud ENABLE-AF CardioFocus, Inc $0
• Emile Georges Daoud NaviStar ThermoCool catheter for the radiofrequency ablation of symptomatic paroxysmal atrial fibrillation PAF Biosense Webster, Inc $0
• Emile Georges Daoud NaviStar ThermoCool catheter for the radiofrequency ablation of symptomatic paroxysmal atrial fibrillation PAF Biosense Webster, Inc $3,908
• Garrie J Haas Passive acoustics investigation of BSCC heart valve Advanced Computational & Eng Servs, LLC $5,325
• Garrie J Haas A phase 2, randomized, double blind, parallel-group, placebo-controlled, multicenter study to examine the effects of AC2592 administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure Amylin Corp $7,670
• Garrie J Haas Cardiology operating funds Clinical Trials Management $3,900
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $2,500
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $113
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $4,781
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $3,838
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $6,775
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $50
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $17,125
• Garrie J Haas Chronicle(R) implantable cardioverter defibrillator (REDUCE-HF) Medtronic Inc $6,381
• Garrie J Haas Decompensation detection study (DECODE) Cardiac Pacemakers, Inc $0
• Garrie J Haas Fluid accumulation status trial (FAST). Medtronic Inc $4,185
• Garrie J Haas Fluid accumulation status trial (FAST). Medtronic Inc $624
• Garrie J Haas Hemodynamically guided home self-therapy in severe heart failure patients (HOMEOSTASIS II) Savacor, Inc $57,468
• Garrie J Haas MOMENTUM: Multicenter trial of the Orqis Medical CRS for the enhanced treatment of CHF unresponsive to medical therapy ORQIS MEDICAL $5,458
• Garrie J Haas PROTECT Hesperion US, Inc $0
• Garrie J Haas Resynchronization therapy in normal QRS study (RethinQ) St. Jude Medical Co $600
• Garrie J Haas Resynchronization therapy in normal QRS study (RethinQ) St. Jude Medical Co $3,000
• Garrie J Haas Ribose study Bioenergy, Inc $3,360
• Garrie J Haas RISK stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients receiving CRT-D St. Jude Medical Co $3,863
• Garrie J Haas RISK stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients receiving CRT-D St. Jude Medical Co $5,100
• Garrie J Haas RISK stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients receiving CRT-D St. Jude Medical Co $2,850
• Garrie J Haas RISK stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients receiving CRT-D St. Jude Medical Co $1,525
• Glen E Cooke Pharmacogenetic antiplatelet strategies in CHD patients National Heart, Lung, and Blood Inst $139,226
• Govindasamy Ilangovan Heat shock proteins, nitric oxide and oxygen consumption in the heart National Heart, Lung, and Blood Inst $326,620
• Guanglong He Electron paramagnetic resonance imaging of the redox status and oxygenation of the in vivo rat heart Am Heart Assn $65,000
• Guanglong He In vivo EPR imaging of myocardial oxygen consumption National Heart, Lung, and Blood Inst $318,945
• Gunjan Agarwal Myocardial matrix remodeling by DDRs National Heart, Lung, and Blood Inst $72,307
• Gunjan Agarwal Regulation of myocardial fibrosis by discoidin domain receptors Am Heart Assn $32,500
• Jay L Zweier Inflammation and repair in cardiac ischemia-reperfusion Johns Hopkins Univ $447,833
• Jay L Zweier Measurement of free radical generation in the heart National Heart, Lung, and Blood Inst $97,500
• Jay L Zweier Measurement of free radical generation in the heart National Heart, Lung, and Blood Inst $331,054
• Jay L Zweier Measurement of free radical generation in the heart National Heart, Lung, and Blood Inst $119,615
• Jay L Zweier Oxygen radicals and nitric oxide in postischemic injury National Heart, Lung, and Blood Inst $479,464
• Jay L Zweier Oxygen radicals and nitric oxide in postischemic injury National Heart, Lung, and Blood Inst $40,035
• Jay L Zweier Protection of ischemic myocardium Univ of Louisville $95,300
• Jay L Zweier Proton electron double resonance imaging (PEDRI) of free radicals Nat In Biomedical Imaging&Bioengineering $851,888
• John A Larry Effect of LDL-cholesterol lowering beyond currently recommended minimum targets on coronary heart disease recurrence. Icon Clinical Res Inc $3,145
• John David Hummel Catheter ablation versus anti-arrhythmic drug therapy (CABANNA) Duke Univ $0
• John David Hummel Catheter ablation versus anti-arrhythmic drug therapy (CABANNA) Duke Univ $2,000
• John David Hummel Catheter ablation versus anti-arrhythmic drug therapy (CABANNA) Duke Univ $3,000
• John David Hummel Catheter ablation versus anti-arrhythmic drug therapy (CABANNA) Duke Univ $1,000
• John David Hummel Catheter ablation versus anti-arrhythmic drug therapy (CABANNA) Duke Univ $2,400
• John David Hummel Clinical research evaluation of the ASSURE device atrial and ventricular tachyarrhythmia therapies (REASSURE AV) Cardiac Pacemakers, Inc $0
• John David Hummel Clinical research evaluation of the ASSURE device atrial and ventricular tachyarrhythmia therapies (REASSURE AV) Cardiac Pacemakers, Inc $500
• John David Hummel EASYTRAK 3 downsize lead clinical study Cardiac Pacemakers, Inc $0
• John David Hummel EASYTRAK 3 downsize lead clinical study Cardiac Pacemakers, Inc $2,700
• John David Hummel EASYTRAK 3 downsize lead clinical study Cardiac Pacemakers, Inc $11,950
• John David Hummel TTOP-AF Ablation Frontiers, Inc $0
• John David Hummel TTOP-AF Ablation Frontiers, Inc $6,445
• John David Hummel TTOP-AF Ablation Frontiers, Inc $6,441
• John David Hummel TTOP-AF Ablation Frontiers, Inc $2,083
• John David Hummel TTOP-AF Ablation Frontiers, Inc $3,000
• Maqsood Chotani Targeting expression and mobilization of vascular alpha2C-adrenoceptors Am Heart Assn-Great Rivers Affiliate $60,500
• Min Pu Beta-blockade in chronic mitral regurgitation: Moving from laboratory experiment to clinical investigation Am Heart Assn $85,531
• Nicanor I Moldovan Circulating progenitors determine vascular repair and angiogenic outcome in diabetic retinopathy Univ of Florida $34,616
• Orlando P Simonetti Cardiovascular MRI and CT application research Siemens $162,538
• Orlando P Simonetti Cardiovascular MRI and CT application research Siemens $40,635
• Periannan Kuppusamy Biophysical and medical applications of ESR microscopy US-Israel Binational Science Fdn $18,194
• Periannan Kuppusamy Development of spin probes for cell-tagging and oximetry Nat In Biomedical Imaging&Bioengineering $223,262
• Periannan Kuppusamy EPR imaging of tumor heterogeneity and oxygenation. National Cancer Institute $41,372
• Periannan Kuppusamy In vivo EPR imaging and redox status and thiols in tumor. National Cancer Institute $290,595
• Periannan Kuppusamy Noninvasive monitoring of in situ oxygenation and cell therapy in infarct heart Nat In Biomedical Imaging&Bioengineering $270,000
• Periannan Kuppusamy Novel methods for in vivo imaging of tissue oxygenation Nat In Biomedical Imaging&Bioengineering $255,156
• Periannan Kuppusamy Noninvasive monitoring of in situ oxygenation and cell therapy in infarct heart Nat In Biomedical Imaging&Bioengineering $16,875
• Periannan Kuppusamy Development of spin probes for cell-tagging and oximetry Nat In Biomedical Imaging&Bioengineering $31,895
• Periannan Kuppusamy Noninvasive monitoring of in situ oxygenation and cell therapy in infarct heart Nat In Biomedical Imaging&Bioengineering $50,625
• Philip F Binkley Follow-up serial infusions of natrecor (nesiritide) for the management of patients with heart failure FUSION II. Scios Inc $3,317
• Philip F Binkley Study of oral enoximone versus placebo in advanced chronic heart failure subjects. Myogen Inc $8,194
• Philip F Binkley Eliminating barriers to effective training in clinical investigation Nat Center for Research Resources $502,339
• Philip F Binkley Eliminating barriers to effective training in clinical investigation Nat Center for Research Resources $167,446
• Ralph Sayre Augostini Clinical investigation of the prevention of myocardial enlargement and dilatation post myocardial infarction (MENDMI STUDY) Cardiac Pacemakers, Inc $0
• Ralph Sayre Augostini Device evaluation of CONTAK REVEWAL 2/4/4HE and EASYTRAK 2: assessment of safety and effectiveness (DECREASE-HF) study Cardiac Pacemakers, Inc $0
• Ralph Sayre Augostini EASYTRAK 4 steerable LV lead clinical study Cardiac Pacemakers, Inc $0
• Ralph Sayre Augostini Evaluation of intra-atrial conduction time as an indicator of potential CRT non-responders (IACT) St. Jude Medical Co $0
• Ralph Sayre Augostini Tendril FSR model 1699T lead clinical study St. Jude Medical Co $5,281
• Ralph Sayre Augostini Tendril FSR model 1699T lead clinical study St. Jude Medical Co $1,500
• Raul Weiss CONTAK RENEWAL 3AVT device study Cardiac Pacemakers, Inc $0
• Raul Weiss Genetic risk assessment of defibrillator events (GRADE) Univ of Pittsburgh $0
• Raul Weiss Genetic risk assessment of defibrillator events (GRADE) Univ of Pittsburgh $1,800
• Raul Weiss Trends registry Medtronic Inc $0
• Raymond D Magorien A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention/TIMI-38 Quintiles Transnational Corp $21,946
• Raymond D Magorien A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention/TIMI-38 Quintiles Transnational Corp $19,146
• Raymond D Magorien A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention/TIMI-38 Quintiles Transnational Corp $3,773
• Raymond D Magorien A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention/TIMI-38 Quintiles Transnational Corp $6,955
• Raymond D Magorien A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention/TIMI-38 Quintiles Transnational Corp $9,537
• Raymond D Magorien A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention/TIMI-38 Quintiles Transnational Corp $8,578
• Raymond D Magorien Cobalt chromium stent with antiproliferative for restenosis II trial Conor Medsystems, Inc $12,350
• Raymond D Magorien Cobalt chromium stent with antiproliferative for restenosis II trial Conor Medsystems, Inc $2,000
• Raymond D Magorien Cobalt chromium stent with antiproliferative for restenosis II trial Conor Medsystems, Inc $10,950
• Raymond D Magorien Cobalt chromium stent with antiproliferative for restenosis II trial Conor Medsystems, Inc $6,700
• Raymond D Magorien Occluded artery trial. NY UNIVERSITY $140
• Raymond D Magorien PERSEUS Boston Scientific Corporation $0
• Raymond D Magorien The ACUITY trial: A randomized comparison of Angiomax(R) (bivalirudin) versus Lovenox(R) (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation, Protocol No. TMC-BIV-02-08. Medicines Co, The $400
• Raymond D Magorien The ACUITY trial: A randomized comparison of Angiomax(R) (bivalirudin) versus Lovenox(R) (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation, Protocol No. TMC-BIV-02-08. Medicines Co, The $1,200
• Raymond D Magorien Trial to assess chelation therapy (TACT). MOUNT SINAI MEDICAL CENTER $1,200
• Raymond D Magorien Trial to assess chelation therapy (TACT). MOUNT SINAI MEDICAL CENTER $2,300
• Raymond D Magorien Trial to assess chelation therapy (TACT). MOUNT SINAI MEDICAL CENTER $2,300
• Raymond D Magorien Trial to assess chelation therapy (TACT). MOUNT SINAI MEDICAL CENTER $200
• Sanjay Rajagopalan Air pollution and hypertension: vascular mechanisms Nat Inst of Environ Health Scis $471,147
• Sanjay Rajagopalan Air pollution exposure/atherosclerosis: vascular mechanisms Nat Inst of Environ Health Scis $309,943
• Sanjay Rajagopalan Air pollution exposure/atherosclerosis: vascular mechanisms Nat Inst of Environ Health Scis $30,800
• Sanjay Rajagopalan Air pollution exposure/atherosclerosis: vascular mechanisms Nat Inst of Environ Health Scis $243,193
• Sanjay Rajagopalan Engineering capillary networks Harvard Univ $32,731
• Sanjay Rajagopalan MRI core lab frequent dialysis network investigators Cleveland Clinic Fdn $53,820
• Simi Mary Chacko Tagging of mesenchymal stem cells with novel oxygen sensing nanoprobes Am Heart Assn-Great Rivers Affiliate $42,000
• Steven J Kalbfleisch Advancements in ICD therapy (ACT) Registry St. Jude Medical Co $0
• Steven J Kalbfleisch Focus-AF ProRhythm, Inc $0
• Steven J Kalbfleisch Focus-AF ProRhythm, Inc $360
• Steven J Kalbfleisch Response of cardiac resynchronization therapy optimization with V-V timing in heart failure patients (Response-HF) St. Jude Medical Co $0
• Steven J Kalbfleisch WATCHMAN; Left atrial appendage system for embolic protection in patients with atrial fibrillation with roll-in (Protect AF) Atritech, Inc $0
• Subha V Raman Comparison of noninvasive CT angiography for epicardial coronary imaging with catheter-based angiography (CINEMA). Duke Univ $1,500
• Subha V Raman Comparison of noninvasive CT angiography for epicardial coronary imaging with catheter-based angiography (CINEMA). Duke Univ $2,100
• Subha V Raman MONARC CT analysis Edwards Lifesciences LLC $42,311
• Subha V Raman Paracor ventricular support system core lab Paracor Medical, Inc $1,000
• Subha V Raman Paracor ventricular support system core lab Paracor Medical, Inc $19,000
• Subha V Raman REVEAL study Duke Univ $1,800
• Subha V Raman REVEAL study Duke Univ $2,500
• Subha V Raman REVEAL study Duke Univ $9,900
• Subha V Raman REVEAL study Duke Univ $8,100
• Subha V Raman REVEAL study Duke Univ $1,900
• Subha V Raman REVEAL study Duke Univ $15,500
• Subha V Raman SPARC trial Brigham & Women's Hosp Inc $2,188
• Subha V Raman SPARC trial Brigham & Women's Hosp Inc $1,563
• Subha V Raman SPARC trial Brigham & Women's Hosp Inc $3,688
• Subha V Raman SPARC trial Brigham & Women's Hosp Inc $1,563
• Tennille Presley EPR oximetry to study diabetic endothelial dysfunction Nat Inst Gen Medical Scis $33,272
• William Abraham A CHF trial investigating outcomes of exercise training Duke Univ $18,975
• William Abraham A CHF trial investigating outcomes of exercise training Duke Univ $25
• William Abraham A CHF trial investigating outcomes of exercise training Duke Univ $4,850
• William Abraham IHM system technology assessment study. Medtronic Inc $1,050
• William Abraham Management of patients advanced signs and symptoms of heart failure (COMPASS-HF). Medtronic Inc $25,128
• William Abraham Management of patients advanced signs and symptoms of heart failure (COMPASS-HF). Medtronic Inc $1,381
• Yeong-Renn Chen Myocardial injury associated with mitochondria-derived oxygen free radical(s) National Heart, Lung, and Blood Inst $291,300
• Yeong-Renn Chen Myocardial injury associated with mitochondria-derived oxygen free radical(s) National Heart, Lung, and Blood Inst $72,825
• Yong Xia Endothelial dysfunction in postischemic hearts National Heart, Lung, and Blood Inst $350,000
• Yong Xia Superoxide generation from endothelial NO synthase. National Heart, Lung, and Blood Inst $283,506
• Zhenguo Liu The RELY study Boehringer Ingelheim Pharmaceuticals Inc $1,882
• Zhenguo Liu The RELY study Boehringer Ingelheim Pharmaceuticals Inc $4,234
• Zhenguo Liu Asymptomatic AF and stroke evaluation in pacemaker patients and the AF reduction atrial pacing trial St. Jude Medical Co $950
• Zhenguo Liu Asymptomatic AF and stroke evaluation in pacemaker patients and the AF reduction atrial pacing trial St. Jude Medical Co $82
• Zhenguo Liu Asymptomatic AF and stroke evaluation in pacemaker patients and the AF reduction atrial pacing trial St. Jude Medical Co $400
• Zhenguo Liu Asymptomatic AF and stroke evaluation in pacemaker patients and the AF reduction atrial pacing trial St. Jude Medical Co $138
• Zhenguo Liu Asymptomatic AF and stroke evaluation in pacemaker patients and the AF reduction atrial pacing trial St. Jude Medical Co $3,510
• Zhenguo Liu Asymptomatic AF and stroke evaluation in pacemaker patients and the AF reduction atrial pacing trial St. Jude Medical Co $1,500
• Zhenguo Liu Effects of nitric oxide on stem cell differentiation National Heart, Lung, and Blood Inst $134,244

Internal Medicine - Endo, Diabetes & Metabolism

• Joseph J Pinzone BP1 and nuclear hormone signaling in breast cancer National Cancer Institute $27,375
• Joseph J Pinzone BP1 and nuclear hormone signaling in breast cancer National Cancer Institute $133,650
• Kelly K Nichols Dry eye in postmenopause National Eye Institute $16,875
• Kwame Osei A phase III, multicenter, randomized, double-blinded study to evaluate the safety and efficacy of the addition of Sitagliptin (MK-0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combina Merck & Co Inc $6,147
• Kwame Osei A prospective, randomized, two arm study to compare the efficacy of the Medtronic MiniMed Paradigm real-time system versus Multiple Daily Injection (MDI) in subjects with type 1 diabetes mellitus naive to insulin pump therapy (Star 3) Medtronic Inc $36,011
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $0
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $2,000
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,032
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,032
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,548
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $3,143
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,513
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,889
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $3,585
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $4,024
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,032
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,927
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,445
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,489
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,445
• Kwame Osei A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandamet and Metformin after 80 weeks of treatment GlaxoSmithKline $1,007
• Kwame Osei An open-label study to examine the long-term effect on glucose control (HbA1c) and safety and tolerability of Exenatide given two times a day to subjects with type 2 diabetes mellitus. Amylin Corp $677
• Kwame Osei BARI II: Revascularization and glycemic control in NIDDM Univ of Pittsburgh $4,000
• Kwame Osei BARI II: Revascularization and glycemic control in NIDDM. Univ of Pittsburgh $15,400
• Kwame Osei BARI II: Revascularization and glycemic control in NIDDM. Univ of Pittsburgh $1,200
• Kwame Osei Liraglutide effect and action in diabetes (LEAD 4): Effect on glycemic control of liraglutide in combination with rosiglitazone plus metformin versus rosiglitazone plus metformin in Type 2 diabetes Novo Nordisk Pharmaceuticals $9,455
• Kwame Osei Liraglutide effect and action in diabetes (LEAD 4): Effect on glycemic control of liraglutide in combination with rosiglitazone plus metformin versus rosiglitazone plus metformin in Type 2 diabetes Novo Nordisk Pharmaceuticals $3,600
• Kwame Osei Liraglutide effect and action in diabetes (LEAD 4): Effect on glycemic control of liraglutide in combination with rosiglitazone plus metformin versus rosiglitazone plus metformin in Type 2 diabetes Novo Nordisk Pharmaceuticals $4,752
• Kwame Osei Outcome reduction with initial glargine intervention (the ORIGIN trial). Aventis Pharm Prods $2,000
• Kwame Osei Outcome reduction with initial glargine intervention (the ORIGIN trial). Aventis Pharm Prods $8,550
• Kwame Osei Outcome reduction with initial glargine intervention (the ORIGIN trial). Aventis Pharm Prods $2,450
• Kwame Osei Outcome reduction with initial glargine intervention (the ORIGIN trial). Aventis Pharm Prods $2,750
• Kwame Osei Outcome reduction with initial glargine intervention (the ORIGIN trial). Aventis Pharm Prods $1,900
• Kwame Osei Prevention of cardiovascular disease in diabetes mellitus-clinical center network. Case Western Reserve Univ $89,740
• Kwame Osei Prevention of cardiovascular disease in diabetes mellitus-clinical center network. Case Western Reserve Univ $355,204
• Kwame Osei Prevention of cardiovascular disease in diabetes mellitus-clinical center network. Case Western Reserve Univ $164,665
• Lawrence Kirschner Carney complex: A model for PKA-mediated tumorigenesis. National Cancer Institute $235,381
• Lawrence Kirschner Carney complex: A model for PKA-mediated tumorigenesis. National Cancer Institute $26,153
• Martha Belury Fatty acid supplementation in management of type 2 diabetes Nat Ctr Complementary & Alternative Med $11,081
• Martha Belury Inhibition of muscle atrophy by dietary conjugated linoleic acid Cognis $3,100
• Matthew D Ringel Akt intracellular localization in thyroid cancer National Cancer Institute $226,769
• Matthew D Ringel Akt intracellular localization in thyroid cancer National Cancer Institute $25,197
• Matthew D Ringel PTEN Nuclear-Cytoplasmic Localization in Breast Cancer Cleveland Clinic Fdn $43,736
• Rebecca D Jackson Clinical centers for the osteoarthritis initiative. National Heart, Lung, and Blood Inst $1,178,201
• Rebecca D Jackson Genome-wide Association Study to Identify Genetic Components of Hip Fracture National Heart, Lung, and Blood Inst $2,165,577
• Rebecca D Jackson Role of Bone in Osteoarthritis Progression Tufts-New England Medical Ctr $45,330
• Rebecca D Jackson Thrust and meniscal lesions in knee OA in the OAI NORTHWESTERN UNIV $27,999
• Rebecca D Jackson Virtual bone biopsy: Transfer to the clinical area MicroMRI Inc $20,000
• Rebecca D Jackson Virtual bone biopsy: Transfer to the clinical area MicroMRI Inc $34,922
• Rebecca D Jackson Women's health initiative study of cognitive aging. Wake Forest Univ $10,731
• Rebecca D Jackson Thrust and meniscal lesions in knee OA in the OAI NORTHWESTERN UNIV $9,333
• Richard T Kloos Dose, safety and effectiveness of modified-release recombinant human thyroid stimulating hormone (MRrhTSH) when used in conjunction with radioiodine for treatment of multinodular goiter Genzyme Corp $0
• Richard T Kloos Dose, safety and effectiveness of modified-release recombinant human thyroid stimulating hormone (MRrhTSH) when used in conjunction with radioiodine for treatment of multinodular goiter Genzyme Corp $0

Internal Medicine - Gastroenterology, Hepatology and Nutrition

• Sumei Liu Role of enteric corticotropin-releasing factor (CRF) in stress-related gastrointestinal dysfunctions Pharm Res & Manufacture Am Fdn $60,000
• Sumei Liu Stress, enteric corticotropin-releasing factor, and colon dysfunction Univ of North Carolina $37,500
• Tushar Patel Mechanisms of survival signaling in biliary epithelia Nat In Diabetes & Digestive & Kidney Diseases $213,341

Internal Medicine - General Internal Medicine

• Mark W Wurster ICL670A2202: A Phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis Novartis Pharmaceuticals Corp $11,524
• Mark W Wurster ICL670A2202: A Phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis Novartis Pharmaceuticals Corp $1,063
• Mark W Wurster ICL670A2202: A Phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis Novartis Pharmaceuticals Corp $11,524
• Mark W Wurster ICL670A2202: A Phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis Novartis Pharmaceuticals Corp $1,063

Internal Medicine - Hematology and Oncology

• Charles L Shapiro A phase III trial of novel epothilone BMS-247550 plus capacitabine versus capecitabane alone in patients with advanced breast cancer previously treated with an anthracycline and a taxane. (0393) Bristol-Myers Squibb Co $469
• Charles L Shapiro A phase III trial of novel epothilone BMS-247550 plus capacitabine versus capecitabane alone in patients with advanced breast cancer previously treated with an anthracycline and a taxane. (0393) Bristol-Myers Squibb Co $844
• Charles L Shapiro CALGB chair support, symptom intervention subcommittee Univ of Chicago $31,302
• Charles L Shapiro CPT-11 and mytomycin-C (MMC) in metastatic breast cancer. Pharmacia & Upjohn Inc $8,200
• Charles L Shapiro LIVESTRONG Center at OSUCCC Lance Armstrong Fdn $12,521
• Charles L Shapiro CALGB 79809 - DXA scan funding [phase III trial of intravenous Zolendronic Acid (Zometa) in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure] Cancer & Leukemia Group B Fdn $6,556
• Charles L Shapiro CALGB 79809 - DXA scan funding [phase III trial of intravenous Zolendronic Acid (Zometa) in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure] Cancer & Leukemia Group B Fdn $778
• Charles L Shapiro Educational fellowship grant agreement Aventis Pharm Prods $65,000
• Charles L Shapiro LIVESTRONG Center at OSUCCC Lance Armstrong Fdn $237,902
• Charles L Shapiro OSU 0450: Phase II randomized adjuvant trial of dose-dense docetaxel before and after doxorubicin/cyclophosphamide (AC) in axillary node-positive breast cancer BridgeSite Clinical Research, Inc $107,855
• Charles L Shapiro OSU 06012 - A phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer Genentech Inc $35,476
• Charles L Shapiro OSU 06012 - A phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer Genentech Inc $7,987
• Charles L Shapiro OSU 06013 - A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer Genentech Inc $37,948
• Charles L Shapiro OSU 06090 - An open-label expanded access study of Lapatinib and Capecitabine therapy in subjects with ErbB2 overexpressing locally advanced or metastatic breast cancer PHARMANET, INC. $0
• Charles L Shapiro OSU 06090 - An open-label expanded access study of Lapatinib and Capecitabine therapy in subjects with ErbB2 overexpressing locally advanced or metastatic breast cancer PHARMANET, INC. $1,500
• Charles L Shapiro OSU 06090 - An open-label expanded access study of Lapatinib and Capecitabine therapy in subjects with ErbB2 overexpressing locally advanced or metastatic breast cancer PHARMANET, INC. $1,260
• Charles L Shapiro OSU 06027 - A Phase II trial of trastuzumab (herceptin), bevacizumab, and docetaxel trial in Stage IV metastatic breast cancer (MBC) patients Genentech Inc $0
• Charles L Shapiro OSU 06027 - A Phase II trial of trastuzumab (herceptin), bevacizumab, and docetaxel trial in Stage IV metastatic breast cancer (MBC) patients Genentech Inc $5,963
• Clara D Bloomfield CALGB Foundation protocol capitation projects 1997 Cancer & Leukemia Group B Fdn $400
• Clara D Bloomfield CALGB Foundation protocol capitation projects 1997 Cancer & Leukemia Group B Fdn $3,000
• Clara D Bloomfield CALGB Foundation protocol capitation projects 1997 Cancer & Leukemia Group B Fdn $111,900
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $13,850
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $27,600
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $200
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $20,700
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $98,400
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $52,000
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $40,000
• Clara D Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $55,566
• Clara D Bloomfield Cancer and Leukemia Group B - The Ohio State University. National Cancer Institute $434,962
• Clara D Bloomfield CALGB 49909 - Phase III study of doxorubicin-cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for women with HER-2 overexpressing node positive breast cancer Mayo Fdn for Medical Educ & Res $1,425
• Clara D Bloomfield CALGB 49909 - Phase III study of doxorubicin-cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for women with HER-2 overexpressing node positive breast cancer Mayo Fdn for Medical Educ & Res $475
• Clara D Bloomfield CALGB 49909 - Phase III study of doxorubicin-cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for women with HER-2 overexpressing node positive breast cancer Mayo Fdn for Medical Educ & Res $475
• Clara D Bloomfield CALGB 49909 - Phase III study of doxorubicin-cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for women with HER-2 overexpressing node positive breast cancer Mayo Fdn for Medical Educ & Res $475
• Craig C Hofmeister Immune reconstruction after hematopoietic stem cell transplantation for high risk lymphoma Cancer & Leukemia Group B Fdn $29,700
• Craig C Hofmeister Immune reconstruction after hematopoietic stem cell transplantation for high risk lymphoma Cancer & Leukemia Group B Fdn $3,300
• Craig C Hofmeister OSU 05125 Multiple Myeloma Research Consortium (MMRC) ancillary tissue collection project Multiple Myeloma Research Consortium $10,356
• Craig C Hofmeister OSU 06023 - Phase I clinical trial of NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma Nereus Pharmaceuticals, Inc $32,503
• Craig C Hofmeister OSU 06119 - A randomized study to evaluate the efficacy of mycophenolate mofetil added to the systemic immunosuppressive regimen first used for treatment of chronic graft-versus-host disease Fred Hutchinson Cancer Research Center $0
• Craig C Hofmeister OSU 06135 Compassionate Use protocol for the use of AMD3100 to mobilize peripheral blood stem cells for collection and transplantation Genzyme Corp $0
• Craig C Hofmeister OSU 07047 Histone deacetylase (HDAC) inhibition using vorinostat (SAHA) after autologous hematopoietic stem cell transplantation for high risk lymphoma Merck & Co Inc $0
• Craig C Hofmeister OSU 07047 Histone deacetylase (HDAC) inhibition using vorinostat (SAHA) after autologous hematopoietic stem cell transplantation for high risk lymphoma Merck & Co Inc $29,991
• Craig C Hofmeister Phase II trial of pentostatin in steroid refractory acute graft versus host disease. Supergen Inc $11,841
• Don M Benson OSU 07034 An open label, dose escalation safety and tolerability trial assessing multiple dose administrations of anti-KIR (1-7F9) human monoclonal antibody in subjects with multiple myeloma Novo Nordisk Pharmaceuticals $37,914
• Eric H Kraut Region V-east hemophilia comprehensive care network - CDC Award. Hemophilia Fdn of Michigan $2,278
• Eric H Kraut Cascade hemophilia consortium grant Cascade Hemophilia Fdn $97,016
• Eric H Kraut DHHS/MCHB-Region V-east hemophilia comprehensive care network. Hemophilia Fdn of Michigan $14,000
• Eric H Kraut Epidemiology of priapism Cincinnati Children's Hos Med Ctr $0
• Eric H Kraut Epidemiology of priapism Cincinnati Children's Hos Med Ctr $3,520
• Eric H Kraut HIPP Program - Adult hemophilia insurance premium payment program. OH Dept of Health $2,632
• Eric H Kraut HIPP Program - Adult hemophilia insurance premium payment program. OH Dept of Health $279
• Eric H Kraut HIPP Program - Adult hemophilia insurance premium payment program. OH Dept of Health $419
• Eric H Kraut HIPP Program - Adult hemophilia insurance premium payment program. OH Dept of Health $1,820
• Eric H Kraut HTRS Registry The Hemophilia & Thrombosis Research Soc $100
• Eric H Kraut HTRS Registry The Hemophilia & Thrombosis Research Soc $550
• Eric H Kraut Region V-east hemophilia comprehensive care network - CDC Award. Hemophilia Fdn of Michigan $20,503
• Ewa Mrozek A Phase I/II clinical trial assessing safety and efficacy of BZL101 for metastatic breast cancer Bionovo, Inc $0
• Ewa Mrozek OSU0494: Phase II trial of exemestane (Aromasin) in combination with fluvestrant (Faslodex) in postmenopausal women with hormone responsive advanced breast cancer Pfizer Inc $12,600
• Gary D Stoner Prevention of esophageal cancer with berries. National Cancer Institute $453,318
• Gary D Stoner Prevention of esophageal cancer with berries. National Cancer Institute $50,369
• Gregory A Otterson Phase I-II study of inhaled doxorubicin (doxorubicin HCl inhalation solution), Resmycin (TM) plus IV docetaxel and cisplatin in patients with locally advanced or metastatic unresectable non-small cell lung cancer. Zivena Inc $11,110
• Gregory A Otterson 05084 Phase III multicenter placebo controlled double blind random clinical trial to evaluate the efficacy of bevacizumab in combination with Tarceva (TM)compared with Tarceva (TM) alone for treatment of advanced non-small cell lung cancer after ... Genentech Inc $13,807
• Gregory A Otterson 05084 Phase III multicenter placebo controlled double blind random clinical trial to evaluate the efficacy of bevacizumab in combination with Tarceva (TM)compared with Tarceva (TM) alone for treatment of advanced non-small cell lung cancer after ... Genentech Inc $29,295
• Gregory A Otterson 05084 Phase III multicenter placebo controlled double blind random clinical trial to evaluate the efficacy of bevacizumab in combination with Tarceva (TM)compared with Tarceva (TM) alone for treatment of advanced non-small cell lung cancer after ... Genentech Inc $32,584
• Gregory A Otterson Institutional Research Grant Am Cancer Soc Inc $120,000
• Gregory A Otterson Institutional Research Grant Am Cancer Soc Inc $240,000
• Gregory A Otterson OSU 04104: A phase 2 study to evaluate the efficacy and safety of palifermin in the reduction of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for locally advanced non-small cell lung cancer (NSCLC) Amgen Inc $4,335
• Gregory A Otterson OSU 04104: A phase 2 study to evaluate the efficacy and safety of palifermin in the reduction of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for locally advanced non-small cell lung cancer (NSCLC) Amgen Inc $168
• Gregory A Otterson OSU 04104: A phase 2 study to evaluate the efficacy and safety of palifermin in the reduction of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for locally advanced non-small cell lung cancer (NSCLC) Amgen Inc $12,447
• Gregory A Otterson OSU 04104: A phase 2 study to evaluate the efficacy and safety of palifermin in the reduction of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for locally advanced non-small cell lung cancer (NSCLC) Amgen Inc $3,664
• Gregory A Otterson OSU 04104: A phase 2 study to evaluate the efficacy and safety of palifermin in the reduction of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for locally advanced non-small cell lung cancer (NSCLC) Amgen Inc $5,770
• Gregory A Otterson OSU 05040: An open-label, dose-finding study to evaluate the safety of AMG 706 plus panitumumab plus gemcitabine-cisplatin in the treatment of subjects with advanced cancer Amgen Inc $8,056
• Gregory A Otterson OSU 05040: An open-label, dose-finding study to evaluate the safety of AMG 706 plus panitumumab plus gemcitabine-cisplatin in the treatment of subjects with advanced cancer Amgen Inc $3,393
• Gregory A Otterson OSU 05040: An open-label, dose-finding study to evaluate the safety of AMG 706 plus panitumumab plus gemcitabine-cisplatin in the treatment of subjects with advanced cancer Amgen Inc $3,375
• Gregory A Otterson OSU 05040: An open-label, dose-finding study to evaluate the safety of AMG 706 plus panitumumab plus gemcitabine-cisplatin in the treatment of subjects with advanced cancer Amgen Inc $17,913
• Gregory A Otterson OSU 05040: An open-label, dose-finding study to evaluate the safety of AMG 706 plus panitumumab plus gemcitabine-cisplatin in the treatment of subjects with advanced cancer Amgen Inc $844
• Gregory A Otterson OSU 05040: An open-label, dose-finding study to evaluate the safety of AMG 706 plus panitumumab plus gemcitabine-cisplatin in the treatment of subjects with advanced cancer Amgen Inc $844
• Gregory A Otterson OSU 06009-A Phase I open label dose escalation study of continuous oral treatment with BIBF1120ES together with paclitaxel and carboplatin in patients with advanced stage non-small-cell lung cancer Boehringer Ingelheim Pharmaceuticals Inc $3,503
• Gregory A Otterson OSU 06009-A Phase I open label dose escalation study of continuous oral treatment with BIBF1120ES together with paclitaxel and carboplatin in patients with advanced stage non-small-cell lung cancer Boehringer Ingelheim Pharmaceuticals Inc $5,018
• Gregory A Otterson OSU 06009-A Phase I open label dose escalation study of continuous oral treatment with BIBF1120ES together with paclitaxel and carboplatin in patients with advanced stage non-small-cell lung cancer Boehringer Ingelheim Pharmaceuticals Inc $10,035
• Gregory A Otterson OSU 06009-A Phase I open label dose escalation study of continuous oral treatment with BIBF1120ES together with paclitaxel and carboplatin in patients with advanced stage non-small-cell lung cancer Boehringer Ingelheim Pharmaceuticals Inc $10,035
• Gregory A Otterson OSU 06009-A Phase I open label dose escalation study of continuous oral treatment with BIBF1120ES together with paclitaxel and carboplatin in patients with advanced stage non-small-cell lung cancer Boehringer Ingelheim Pharmaceuticals Inc $793
• Gregory A Otterson OSU 06059 - A randomized phase 3 Trial of ALIMTA(R) (Pemetrexed) and carboplatin versus etoposide and carboplatin in extensive-stage small cell lung cancer Eli Lilly & Co $0
• Gregory A Otterson OSU 06059 - A randomized phase 3 Trial of ALIMTA(R) (Pemetrexed) and carboplatin versus etoposide and carboplatin in extensive-stage small cell lung cancer Eli Lilly & Co $23,677
• Gregory A Otterson OSU 06068 - Phase II trial of motexafin gadolinium and pemetrexed (Alimta(R)) for second-line treatment in patients with non-small cell lung cancer Pharmacyclics Inc $18,998
• Gregory A Otterson OSU 06068 - Phase II trial of motexafin gadolinium and pemetrexed (Alimta(R)) for second-line treatment in patients with non-small cell lung cancer Pharmacyclics Inc $11,478
• Gregory A Otterson OSU 06107 - A Phase 2 study of Temozolomide in preselected advanced aerodigestive tract cancers Schering Corp $0
• Gregory A Otterson OSU 07057 - Phase II trial of paclitaxel + carboplatin + bevacizumab with or without apomab in patients with previously untreated, advanced-stage non-small cell lung cancer Genentech Inc $0
• Gregory A Otterson Phase I-II study of inhaled doxorubicin (doxorubicin HCl inhalation solution), Resmycin (TM) plus IV docetaxel and cisplatin in patients with locally advanced or metastatic unresectable non-small cell lung cancer. Zivena Inc $1,234
• Guido Marcucci CALGB 10603 [equipment & supplies purchase]: A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients Cancer & Leukemia Group B Fdn $149,268
• Guido Marcucci Pharmacologic modulation of chromatin remodeling in leukemia National Cancer Institute $233,543
• Guido Marcucci 06101-A Phase II study of MGCD0103 (MG-0103) in patients with acute myelogenous leukemia/high risk MDS who are elderly and have previously untreated disease or who are adult and have relapsed/refractory disease MethylGene Inc $12,643
• Guido Marcucci CALGB 10603 [equipment & supplies purchase]: A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients Cancer & Leukemia Group B Fdn $16,585
• Guido Marcucci Pharmacologic modulation of chromatin remodeling in leukemia National Cancer Institute $12,975
• J Paul Monk III OSU 06006 - A Phase I study of bolus high dose (HD) aldesleukin (Interleukin-2) with sorafenib (bay 43-9006) in patients with unresectable or metastatic clear cell renal carcinoma Novartis Pharmaceuticals Corp $0
• J Paul Monk III OSU 06006 - A Phase I study of bolus high dose (HD) aldesleukin (Interleukin-2) with sorafenib (bay 43-9006) in patients with unresectable or metastatic clear cell renal carcinoma Novartis Pharmaceuticals Corp $17,000
• J Paul Monk III OSU 07019-Randomized, open label multi-center study of XRP6258 at 25 mg/m2 in combination with prednisone every 3 weeks compared to mitoxantrone in combination with... Sanofi-aventis $0
• J Paul Monk III OSU 06006 - A Phase I study of bolus high dose (HD) aldesleukin (Interleukin-2) with sorafenib (Bay 43-9006) in patients with unresectable or metastatic clear cell renal carcinoma Bayer Corp $6,000
• J Paul Monk III OSU 06028 - Randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa) in the treatment of bone metastases in men with hormone-refractory prostate cancer Amgen Inc $0
• J Paul Monk III OSU 06028 - Randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa) in the treatment of bone metastases in men with hormone-refractory prostate cancer Amgen Inc $9,841
• James P Thomas OSU 05018: A randomized, open-label, controlled, clinical trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of subjects with metastatic colorectal cancer Immunex Corp $28,800
• James P Thomas OSU 05018: A randomized, open-label, controlled, clinical trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of subjects with metastatic colorectal cancer Immunex Corp $9,900
• James P Thomas OSU 05018: A randomized, open-label, controlled, clinical trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of subjects with metastatic colorectal cancer Immunex Corp $2,600
• Jeffrey Alan Jones Epidemiology and outcome of serious infections among patients with CLL Am Soc Clinical Oncology $50,000
• John C Byrd Feasibility/phase II trial of fludarabine, rituximab, and alemtuzumab for previously treated B-chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)(0404) Bayer HealthCare Pharmaceuticals Inc $2,500
• John C Byrd Humanized HLA-DR antibody mechanism validation and human tissue sampling Kirin Brewery Co, Ltd $75,000
• John C Byrd 05133-Phase I/II, sequential cohort, dose escalation trial to determine the safety, tolerability, and maximum tolerated dose of weekly administration of GRN163L in patients with refractory or relapsed chronic lymphocytic leukemia Geron Corp $53,313
• John C Byrd 05133-Phase I/II, sequential cohort, dose escalation trial to determine the safety, tolerability, and maximum tolerated dose of weekly administration of GRN163L in patients with refractory or relapsed chronic lymphocytic leukemia Geron Corp $42,475
• John C Byrd Bruton tyrosine kinase (BTK) inhibitor in chronic lymphocytic leukemia and acute lymphoblastic leukemia Pharmacyclics Inc $0
• John C Byrd LBH589, LBY135 experimental plan Novartis Pharmaceuticals Corp $25,000
• John C Byrd OSU 05008: A phase I, open-label, dose-escalation trial of anti-CD40 monoclonal antibody (CHIR12.12) administered intravenously to subjects with advanced chronic lymphocytic leukemia that is refractory or relapsed after prior treatment Chiron Corp $45,147
• John C Byrd OSU 05008: A phase I, open-label, dose-escalation trial of anti-CD40 monoclonal antibody (CHIR12.12) administered intravenously to subjects with advanced chronic lymphocytic leukemia that is refractory or relapsed after prior treatment Chiron Corp $46,382
• John C Byrd OSU 06034 - Phase 1, open-label, dose-escalation study to assess the safety and pharmacokinetics of recombinant Interleukin 21 (rlL-21) administered in combination with rituxan (rituximab) in subjects with B-Cell non-Hodgkin's lymphoma Zymogenetics Inc $8,078
• John C Byrd OSU 06034 - Phase 1, open-label, dose-escalation study to assess the safety and pharmacokinetics of recombinant Interleukin 21 (rlL-21) administered in combination with rituxan (rituximab) in subjects with B-Cell non-Hodgkin's lymphoma Zymogenetics Inc $33,693
• John C Byrd OSU 06123 - A randomized open-label multicenter Phase 2 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab versus fludarabine, cyclophosphamide, and rituximab alone... Biogen IDEC Inc $0
• John C Byrd OSU 07045-Correlative and pharmacodynamic studies for OSU 06124: Weekly alvocidib in patients with previously treated B-Cell chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) Sanofi-aventis $0
• John C Byrd OSU 07045-Correlative and pharmacodynamic studies for OSU 06124: Weekly alvocidib in patients with previously treated B-Cell chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) Sanofi-aventis $100,000
• John C Byrd Pre-clinical analysis of CDK inhibitor SCH727965 in CLL and ALL model systems Schering-Plough Corp $0
• John C Byrd Specialized Center of Research; Experimental therapeutics in CLL. Leukemia & Lymphoma Soc $1,250,000
• John C Byrd Targeting CD37 with small modular immune pharmaceutical TRU16 Leukemia & Lymphoma Soc $200,000
• John C Byrd Targeting CD74 antibody in CLL with the hLL1 antibody CLL Global Res Fdn $5,000
• John C Byrd Trial of cyclosphosphamide, pentostatin and rituximab for previously untreated B-chronic lymphocytic leukemia. Supergen Inc $11,000
• John F Lechner Mixtures of foods with enhanced cancer prevention activity Am Inst for Cancer Res $82,500
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $24,241
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $11,306
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $2,718
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $3,104
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $14,230
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $7,329
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $6,830
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $4,911
• Kari L Kendra OSU 05122: Phase III, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma Pfizer Inc $1,461
• Kristie A Blum CALGB 50303: Phase III study of R-CHOP v. dose-adjusted EPOCH-R with molecular profiling in untreated de novo diffuse large B-cell lymphomas. Univ of Chicago $3,000
• Kristie A Blum OSU 0475: Phase I study of decitabine in combination With valproic acid in patients with relapsed/refractory non-hodgkin's lymphoma MGI Pharma Inc $0
• Kristie A Blum OSU 0475: Phase I study of decitabine in combination With valproic acid in patients with relapsed/refractory non-hodgkin's lymphoma MGI Pharma Inc $28,865
• Kristie A Blum Targeting transcriptional repression in CLL National Cancer Institute $135,076
• Laura A Kresty Targeting histone deacetylation: A tool for chemoprevention of esophageal cancer National Cancer Institute $1,800
• Laura A Kresty Targeting histone deacetylation: A tool for chemoprevention of esophageal cancer National Cancer Institute $1,800
• Laura A Kresty Targeting histone deacetylation: A tool for chemoprevention of esophageal cancer National Cancer Institute $171,000
• Leslie Andritsos Flavopiridol for Treatment of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Cancer & Leukemia Group B Fdn $33,000
• Manisha H Shah A phase III, randomized, double-blind, placebo-controlled study of SU011248 in the treatment of patients with imatinib mesylate-resistant or intolerant malignant gastrointestinal stromal tumor. Pfizer Inc $2,939
• Manisha H Shah OSU 0471: Open-label phase 2 clinical trial of bi-weekly dosing of irofulven plus capecitabine in patients with either anaplastic or locally advanced/metastatic differentiated thyroid cancer MGI Pharma Inc $9,445
• Manisha H Shah OSU 0471: Open-label phase 2 clinical trial of bi-weekly dosing of irofulven plus capecitabine in patients with either anaplastic or locally advanced/metastatic differentiated thyroid cancer MGI Pharma Inc $6,242
• Manisha H Shah An open label, stratefied, single arm Phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Novartis Pharmaceuticals Corp $15,018
• Manisha H Shah An open label, stratefied, single arm Phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Novartis Pharmaceuticals Corp $14,219
• Manisha H Shah An open label, stratefied, single arm Phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Novartis Pharmaceuticals Corp $4,276
• Manisha H Shah An open label, stratefied, single arm Phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Novartis Pharmaceuticals Corp $8,204
• Manisha H Shah An open label, stratefied, single arm Phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Novartis Pharmaceuticals Corp $8,360
• Manisha H Shah OSU 06033 - A Phase I, multicenter, open-label, randomized study assessing the pharmacokinetics, safety, and tolerability of monthly doses of SOM230 i.m., LAR injection in patients with acromegala and patients with carcinoid disease Novartis Pharmaceuticals Corp $4,793
• Manisha H Shah OSU 06033 - A Phase I, multicenter, open-label, randomized study assessing the pharmacokinetics, safety, and tolerability of monthly doses of SOM230 i.m., LAR injection in patients with acromegala and patients with carcinoid disease Novartis Pharmaceuticals Corp $4,276
• Manisha H Shah OSU 06054 - Phase II study of sorafenib (BAY 43-9006) in patients with metastatic medullary thyroid carcinoma Sci Applications Intl Corp $0
• Manisha H Shah OSU 06054 - Phase II study of sorafenib (BAY 43-9006) in patients with metastatic medullary thyroid carcinoma Sci Applications Intl Corp $122,314
• Manisha H Shah OSU 07079 - A randomized double-blind Phase III study of RAD001 10mg/d plus best supportive care vs placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor Novartis Pharmaceuticals Corp $0
• Matthew J Karpenko Epigenetic Changes in Mesothelioma Am Cancer Soc-Ohio $9,600
• Michael A Caligiuri CALGB 10102 - Flow Cytometry Cancer & Leukemia Group B Fdn $13,275
• Michael A Caligiuri CALGB 10102 - Flow Cytometry Cancer & Leukemia Group B Fdn $4,950
• Michael A Caligiuri CALGB leukemia tissue bank suppplement Univ of Chicago $202,292
• Michael A Caligiuri Cancer and leukemia group B - leukemia correlative science National Cancer Institute $994,868
• Michael A Caligiuri IL-15 characterization through experimental immunology. National Cancer Institute $271,102
• Michael A Caligiuri Oncology training grant. National Cancer Institute $394,082
• Michael A Caligiuri The Ohio State University comprehensive cancer support grant. National Cancer Institute $2,868,668
• Michael A Caligiuri The Ohio State University comprehensive cancer support grant. National Cancer Institute $191,386
• Michael A Caligiuri The Ohio State University comprehensive cancer support grant. National Cancer Institute $847,869
• Michael A Caligiuri The Ohio State University comprehensive cancer support grant. National Cancer Institute $41,379
• Michael A Caligiuri The Ohio State University comprehensive cancer support grant. National Cancer Institute $84,897
• Michael A Caligiuri CALGB 10102 - Flow Cytometry Cancer & Leukemia Group B Fdn $1,475
• Michael A Caligiuri CALGB 10102 - Flow Cytometry Cancer & Leukemia Group B Fdn $550
• Michael A Caligiuri CALGB leukemia tissue bank suppplement Univ of Chicago $22,477
• Michael A Caligiuri Prevention of post-transplant lymphoproliferative disorder Leukemia & Lymphoma Soc $200,000
• Michael A Caligiuri Prevention of post-transplant lymphoproliferative disorder Leukemia & Lymphoma Soc $200,000
• Michael A Caligiuri Innate Immunity: Elucidation and Modulation for Cancer Therapy National Cancer Institute $1,987,279
• Michael Pereira Preclinical efficacy and intermediate biomarker assays National Cancer Institute $5,357
• Michael Pereira Preclinical efficacy and intermediate biomarker assays National Cancer Institute $295,850
• Michael Pereira Preclinical efficacy and intermediate biomarker assays National Cancer Institute $51,632
• Michael Pereira Preclinical efficacy and intermediate biomarker assays National Cancer Institute $16
• Michael Pereira Preclinical efficacy and intermediate biomarker assays National Cancer Institute $478,522
• Michael Pereira Preclinical efficacy and intermediate biomarker assays National Cancer Institute $482,871
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $458
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $101
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $107
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $594
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $3,977
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $2,097
• Michael R Grever Phase I trials of anticancer agents. National Cancer Institute $596,978
• Michael R Grever Phase I trials of anticancer agents. National Cancer Institute $104,400
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $2,290
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $504
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $534
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $2,970
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $19,885
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $10,487
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $14,653
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $3,224
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $3,414
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $19,007
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $127,265
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $67,116
• Michael R Grever Project 6: Translational Pharmacologyof novel therapies in CLL CLL Global Res Fdn $35,000
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $27,475
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $6,045
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $6,402
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $35,638
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $238,621
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $125,842
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $916
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $202
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $213
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $1,188
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $7,954
• Michael R Grever Chronic lymphocytic leukemia research consortium Univ of California at San Diego $4,195
• Miguel Villalona A randomized phase II study of single agent erlotinib (Tarceva (TM), OSI-774) versus standard chemotherapy in patients with previously untreated advanced NSCLC and a poor performance status. OSI Pharmaceuticals, Inc $844
• Miguel Villalona OSU 0474: A phase I, open label, dose escalation study of weekly dosing with BB-10901 followed by a phase II efficacy expansion ImmunoGen, Inc $17,873
• Miguel Villalona OSU0486: Phase I dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of KOS-1584 in patients with advanced solid tumors Kosan Biosciences Inc $66,563
• Miguel Villalona OSU0486: Phase I dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of KOS-1584 in patients with advanced solid tumors Kosan Biosciences Inc $167,964
• Miguel Villalona Early therapeutics development with a phase II emphasis National Cancer Institute $15,548
• Miguel Villalona Early therapeutics development with a phase II emphasis National Cancer Institute $46,459
• Miguel Villalona Early therapeutics development with a phase II emphasis National Cancer Institute $100,000
• Miguel Villalona OSU 0443: A phase II randomized study of OSI-774 in African-American patients with advanced and previously treated non-small cell lung cancer Genentech Inc $7,105
• Miguel Villalona OSU 0443: A phase II randomized study of OSI-774 in African-American patients with advanced and previously treated non-small cell lung cancer Genentech Inc $35,965
• Miguel Villalona OSU 0443: A phase II randomized study of OSI-774 in African-American patients with advanced and previously treated non-small cell lung cancer Genentech Inc $8,363
• Miguel Villalona OSU 0443: A phase II randomized study of OSI-774 in African-American patients with advanced and previously treated non-small cell lung cancer Genentech Inc $12,544
• Miguel Villalona OSU 05046: Phase 2 study of the anti-angiogenesis agent AG-013736 as second-line treatment in patients with advanced non-small cell lung cancer Pfizer Inc $7,968
• Peter E Larsen Evaluation of bioadhesive gels for oral cancer chemoprevention NanoMed Pharmaceuticals, Inc $5,980
• Pierluigi Porcu Combined cytokine-monoclonal antibody therapy in lymphoma. National Cancer Institute $135,513
• Pierluigi Porcu Phase I study of CHOP plus humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) in previously untreated T/NK-cell lymphomas and CD20-negative large B-cell lymphomas. Bayer HealthCare Pharmaceuticals Inc $5,000
• Pierluigi Porcu Phase I study of CHOP plus humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) in previously untreated T/NK-cell lymphomas and CD20-negative large B-cell lymphomas. Bayer HealthCare Pharmaceuticals Inc $5,000
• Pierluigi Porcu Phase I study of CHOP plus humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) in previously untreated T/NK-cell lymphomas and CD20-negative large B-cell lymphomas. Bayer HealthCare Pharmaceuticals Inc $15,000
• Pierluigi Porcu OSU 06066 HuMax-CD4, a fully human monoclonal anti-CD4 antibody, in patients with mycosis fungoides type CTCL (stage IB-IVB) who are refractory or intolerant to targretin (bexarotene) and one other standard therapy Genmab, Inc $0
• Pierluigi Porcu OSU 06066 HuMax-CD4, a fully human monoclonal anti-CD4 antibody, in patients with mycosis fungoides type CTCL (stage IB-IVB) who are refractory or intolerant to targretin (bexarotene) and one other standard therapy Genmab, Inc $15,177
• Ramiro Garzon Role of microRNA in the pathogenesis of acute myeloid leukemia LAURI STRAUSS LEUKEMIA FOUNDATION $31,500
• Ramiro Garzon Role of microRNA in the pathogenesis of acute myeloid leukemia LAURI STRAUSS LEUKEMIA FOUNDATION $3,500
• Rebecca B Klisovic OSU 05104 - Phase 1 trial of AVN-944 in patients with advanced hematologic malignancies Avalon Pharmaceuticals $15,545
• Rebecca B Klisovic OSU 05104 - Phase 1 trial of AVN-944 in patients with advanced hematologic malignancies Avalon Pharmaceuticals $6,978
• Rebecca B Klisovic OSU 05104 - Phase 1 trial of AVN-944 in patients with advanced hematologic malignancies Avalon Pharmaceuticals $63,001
• Rebecca B Klisovic OSU 05104 - Phase 1 trial of AVN-944 in patients with advanced hematologic malignancies Avalon Pharmaceuticals $709
• Rebecca B Klisovic OSU 05104 - Phase 1 trial of AVN-944 in patients with advanced hematologic malignancies Avalon Pharmaceuticals $69,153
• Rebecca B Klisovic OSU 07028 - Phase II Simon two-stage multicenter study and pilot pharmacodynamic investigation of GTI-2040 in combination with high dose cytarabine (HiDAC) in refractory and relapsed acute myeloid leukemia (AML) Lorus Therapeutics Inc $0
• Rebecca B Klisovic OSU 07028 - Phase II Simon two-stage multicenter study and pilot pharmacodynamic investigation of GTI-2040 in combination with high dose cytarabine (HiDAC) in refractory and relapsed acute myeloid leukemia (AML) Lorus Therapeutics Inc $18,018
• Rebecca B Klisovic OSU 07028 - Phase II Simon two-stage multicenter study and pilot pharmacodynamic investigation of GTI-2040 in combination with high dose cytarabine (HiDAC) in refractory and relapsed acute myeloid leukemia (AML) Lorus Therapeutics Inc $27,447
• Richard R Love Intergovernmental Personnel Act (IPA) National Cancer Institute $170,585
• Richard R Love Luteal adjuvant oophorectomy in Vietnamese breast cancer National Cancer Institute $465,684
• Richard R Love Luteal adjuvant oophorectomy in Vietnamese breast cancer National Cancer Institute $99,540
• Robert A Baiocchi In vivo and in vitro analysis of anti-CD19 antibodies against EBV+ B-cells Xencor, Inc $60,036
• Robert A Baiocchi In vivo and in vitro analysis of anti-CD19 antibodies against EBV+ B-cells Xencor, Inc $45,027
• Robert A Baiocchi Role of the arginine methyltransferase PRMT5 in B cell transformation Ohio Cancer Res Assoc $25,000
• Robert A Baiocchi Targeting HDAC and Protein Arginine Methyltransferase 5 Enzymes in Mantle Cell Lymphoma Lymphoma Res Fdn of America $140,625
• Robert A Baiocchi Targeting HDAC and Protein Arginine Methyltransferase 5 Enzymes in Mantle Cell Lymphoma Lymphoma Res Fdn of America $15,625
• Romulo Martin Brena Epigenetic contributions to gender-specific differences in lung cancer incidence. Intl Assn for the Study of Lung Cancer $40,000
• Sherif S Farag Phase I/II trial of pegylated liposomal doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in combination with Arsenic Trioxide (Trisenox (R)) in untreated patients with symptomatic multiple myeloma Cell Therapeutics Inc $2,737
• Sherif S Farag Study of Campath-1H followed by non- myeloablative therapy and allogeneic stem cell transplantation in patients with indolent lymphoproliferative diseases. Bayer HealthCare Pharmaceuticals Inc $7,500
• Spero R Cataland Phase II study to evaluate the safety, tolerability, pharmacokinetics and the effects on liver iron concentration of repeated doses of 10 mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Novartis Pharmaceuticals Corp $16,644
• Spero R Cataland A randomized study of concurrent cyclosporine and plasma exchange versus concurrent corticosteroids and plasma exchange as the initial therapy of thrombotic thrombocytopenic purpura National Blood Fdn $30,475
• Spero R Cataland A randomized study of concurrent cyclosporine and plasma exchange versus concurrent corticosteroids and plasma exchange as the initial therapy of thrombotic thrombocytopenic purpura National Blood Fdn $30,733
• Spero R Cataland Study evaluating the efficacy and tolerability of AMG 531 versus medical standard of care as chronic therapy for non-splenectomized subjects with immune (idiopathic) thrombocytopenic purpura Amgen Inc $0
• Spero R Cataland Study evaluating the efficacy and tolerability of AMG 531 versus medical standard of care as chronic therapy for non-splenectomized subjects with immune (idiopathic) thrombocytopenic purpura Amgen Inc $8,142
• Spero R Cataland A randomized study of concurrent cyclosporine and plasma exchange versus concurrent corticosteroids and plasma exchange as the initial therapy of thrombotic thrombocytopenic purpura National Blood Fdn $1,604
• Spero R Cataland A randomized study of concurrent cyclosporine and plasma exchange versus concurrent corticosteroids and plasma exchange as the initial therapy of thrombotic thrombocytopenic purpura National Blood Fdn $1,618
• Steven K Clinton Tomato-soy juice for prostate cancer National Cancer Institute $162,379
• Steven K Clinton Vitamin D status and prostate cancer Purdue Univ $218,300
• Steven K Clinton SWOG (Southwest Oncology Group) prostate cancer prevention trial Cancer Therapy & Res Fdn of South Texas $200
• Steven K Clinton SWOG (Southwest Oncology Group) selenium and vitamin E cancer prevention trial - SELECT Cancer Therapy & Res Fdn of South Texas $4,884
• Steven K Clinton SWOG (Southwest Oncology Group) selenium and vitamin E cancer prevention trial - SELECT Cancer Therapy & Res Fdn of South Texas $200
• Steven K Clinton Tomato-soy juice for prostate cancer National Cancer Institute $19,597
• Steven M Devine (CT portion) NK cells, their receptors and unrelated donor transplant Univ of Minnesota $0
• Steven M Devine (CT portion) NK cells, their receptors and unrelated donor transplant Univ of Minnesota $47,033
• Steven M Devine National marrow donor program transplant center clinical study agreement Nat Marrow Donor Prog $2,937
• Steven M Devine National marrow donor program transplant center clinical study agreement Nat Marrow Donor Prog $11,115
• Steven M Devine National marrow donor program transplant center clinical study agreement Nat Marrow Donor Prog $5,874
• Steven M Devine National marrow donor program transplant center clinical study agreement Nat Marrow Donor Prog $2,937
• Steven M Devine NHLBI blood and bone marrow transplant clinical research network Case Western Reserve Univ $5,000
• Steven M Devine OSU 05086: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...in multiple myeloma AnorMED Inc $1,249
• Steven M Devine OSU 05086: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...in multiple myeloma AnorMED Inc $303
• Steven M Devine OSU 05086: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...in multiple myeloma AnorMED Inc $4,075
• Steven M Devine OSU 05086: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...in multiple myeloma AnorMED Inc $16,782
• Steven M Devine OSU 05086: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...in multiple myeloma AnorMED Inc $2,432
• Steven M Devine OSU 05086: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...in multiple myeloma AnorMED Inc $303
• Steven M Devine OSU 05086: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...in multiple myeloma Genzyme Corp $671
• Steven M Devine OSU 05087: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo ... in non-Hodgkin's lymphoma AnorMED Inc $4,653
• Steven M Devine OSU 05087: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo ... in non-Hodgkin's lymphoma AnorMED Inc $671
• Steven M Devine OSU 05087: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo ... in non-Hodgkin's lymphoma AnorMED Inc $224
• Steven M Devine OSU 05087: Multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo ... in non-Hodgkin's lymphoma AnorMED Inc $303
• Steven M Devine OSU 06139 - Defibrotine for the treatment of severe hepatic veno-occlusive disease in hematopoietic stem cell transplant patients: A historically-controlled, multi-center phase 3 study to determine safety & efficacy Gentium SpA $0
• Steven M Devine OSU 07021 Dendritic cell vaccine production study of leukapheresed cells from patients with acute myelogenous leukemia (AML) in remission Geron Corp $0
• Steven M Devine OSU 07027 Long-term observational follow-up study of comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo ... (multiple myeloma) Genzyme Corp $0
• Steven M Devine OSU 07027 Long-term observational follow-up study of comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo ... (multiple myeloma) Genzyme Corp $908
• Steven M Devine OSU 07027 Long-term observational follow-up study of comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo ... (multiple myeloma) Genzyme Corp $5,363
• Steven M Devine OSU 07032 Long-term observational follow-up study of comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...(Non-Hodgkin's lymphoma) Genzyme Corp $0
• Steven M Devine OSU 07032 Long-term observational follow-up study of comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo...(Non-Hodgkin's lymphoma) Genzyme Corp $303
• Tanios Bekaii-Saab A phase I dose escalation and biological study of capecitabine and mitomycin-C (MMC) in patients with gastrointestinal solid malignancies Roche Labs, Inc $24,000
• Tanios Bekaii-Saab A phase I dose escalation and biological study of capecitabine and mitomycin-C (MMC) in patients with gastrointestinal solid malignancies Roche Labs, Inc $24,000
• Tanios Bekaii-Saab An observational study of avastin (bevacizumab) in combination with chemotherapy for first-line treatment of metastatic colorectal adenocarcinoma Genentech Inc $2,600
• Tanios Bekaii-Saab An observational study of avastin (bevacizumab) in combination with chemotherapy for first-line treatment of metastatic colorectal adenocarcinoma Genentech Inc $1,000
• Tanios Bekaii-Saab An observational study of avastin (bevacizumab) in combination with chemotherapy for first-line treatment of metastatic colorectal adenocarcinoma PRA Intl $2,250
• Tanios Bekaii-Saab OSU 0447: A phase II study of efficacy and tolerability of GW572016 in patients with advanced hepatocellular and biliary carcinomas GlaxoSmithKline $2,700
• Tanios Bekaii-Saab OSU 0447: A phase II study of efficacy and tolerability of GW572016 in patients with advanced hepatocellular and biliary carcinomas GlaxoSmithKline $1,350
• Tanios Bekaii-Saab OSU 0447: A phase II study of efficacy and tolerability of GW572016 in patients with advanced hepatocellular and biliary carcinomas GlaxoSmithKline $675
• Tanios Bekaii-Saab OSU 0447: A phase II study of efficacy and tolerability of GW572016 in patients with advanced hepatocellular and biliary carcinomas GlaxoSmithKline $6,075
• Tanios Bekaii-Saab OSU 05110: A Phase II study of the combination of fixed dose rate gemcitabine, infusional 5-fluorouracil and bevacizumab in patients with advanced pancreas cancer Genentech Inc/BridgeSite Clinical Res $36,000
• Tanios Bekaii-Saab OSU 07058-A phase 1, multicenter, open-label, dose escalation study evaluating the safety and tolerability of intravenous EZN-2208 (PEG SN38) administered weekly for 3 weeks ... Enzon Pharmaceuticals, Inc $0
• Thomas E Olencki OSU 06041: A Phase 1 study of the safety and efficacy of GC1008: A human anti transforming growth factor-beta (TGFb) monoclonal antibody in patients with advanced renal cell carcinoma or malignant melanoma Genzyme Corp $1,704
• Thomas S Lin A phase I study of single agent flavopiridol in B-NHL National Cancer Institute $221,472
• Thomas S Lin Monoclonal antibody therapy in B-cell CLL National Cancer Institute $118,633
• Thomas S Lin OSU 0461: Phase III, randomized, double blind placebo-controlled trial of FavID and GMCSF following rituximab in subjects with follicular B-cell non-Hodgkins lymphoma Favrille Inc $7,031
• Thomas S Lin OSU 0461: Phase III, randomized, double blind placebo-controlled trial of FavID and GMCSF following rituximab in subjects with follicular B-cell non-Hodgkins lymphoma Favrille Inc $1,669
• Thomas S Lin OSU 0461: Phase III, randomized, double blind placebo-controlled trial of FavID and GMCSF following rituximab in subjects with follicular B-cell non-Hodgkins lymphoma Favrille Inc $1,251
• Thomas S Lin OSU 0461: Phase III, randomized, double blind placebo-controlled trial of FavID and GMCSF following rituximab in subjects with follicular B-cell non-Hodgkins lymphoma Favrille Inc $4,643
• Thomas S Lin Specific immunotherapy, compared to non-specific immunotherapy, in patients with non-Hodgkin's lymphoma. Genitope Corp $2,450
• Thomas S Lin Specific immunotherapy, compared to non-specific immunotherapy, in patients with non-Hodgkin's lymphoma. Genitope Corp $1,050
• Thomas S Lin Specific immunotherapy, compared to non-specific immunotherapy, in patients with non-Hodgkin's lymphoma. Genitope Corp $980
• Thomas S Lin 05120 - A CLL Research Consortium (CRC) Phase II Study of Kinetic Biomarker for Chronic Lymphocytic Leukemia (CLL) Prognosis Univ of California at San Diego $82,900
• Thomas S Lin A phase I study of single agent flavopiridol in B-NHL National Cancer Institute $22,911
• Thomas S Lin Monoclonal antibody therapy in B-cell CLL National Cancer Institute $13,181
• Thomas S Lin OSU 04115: A phase I open-label dose-finding study to evaluate the safety, pharmacokinetics and pharmacodynamics of AMG 623 in subjects with B-cell CLL relapsed or refractory to purine nucleoside treatment Amgen Inc $19,174
• Thomas S Lin OSU 04115: A phase I open-label dose-finding study to evaluate the safety, pharmacokinetics and pharmacodynamics of AMG 623 in subjects with B-cell CLL relapsed or refractory to purine nucleoside treatment Amgen Inc $19,681
• Thomas S Lin OSU 04116: Phase II trial of FavId and GM-CSF in subjects who demonstrated progressive disease and did not receive FavId on study FavId-06 Favrille Inc $8,700
• Thomas S Lin OSU 04116: Phase II trial of FavId and GM-CSF in subjects who demonstrated progressive disease and did not receive FavId on study FavId-06 Favrille Inc $15,437
• Thomas S Lin OSU 04116: Phase II trial of FavId and GM-CSF in subjects who demonstrated progressive disease and did not receive FavId on study FavId-06 Favrille Inc $2,206
• Thomas S Lin OSU 04116: Phase II trial of FavId and GM-CSF in subjects who demonstrated progressive disease and did not receive FavId on study FavId-06 Favrille Inc $3,506
• Thomas S Lin OSU 06124 - Multi-center, open-label, single arm study of weekly alvocidib in patients with previously treated B-cell chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) arising from CLL Sanofi-aventis $0
• Thomas S Lin OSU 06124 - Multi-center, open-label, single arm study of weekly alvocidib in patients with previously treated B-cell chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) arising from CLL Sanofi-aventis $6,834
• Thomas S Lin A phase I study of single agent flavopiridol in B-NHL National Cancer Institute $5,091
• Tong Chen Chemoprevention of Azoxymethane and Dextran Sodium Sulfate - Induced Colitis - Related Colon Carcinogenesis in Mice by Strawberries?. California Strawberry Comsn $37,937
• Tong Chen Evaluation of the chemopreventive effects of strawberries on esophageal cancer development California Strawberry Comsn $154,000
• William G Blum Experimental therapeutics in acute leukemias National Cancer Institute $129,720
• William G Blum OSU 06003 - A Phase I study of lenalidomide in acute leukemias and chronic lymphocytic leukemia Celgene Corp $0
• William G Blum OSU 06003 - A Phase I study of lenalidomide in acute leukemias and chronic lymphocytic leukemia Celgene Corp $24,000
• William G Blum OSU 06003 - A Phase I study of lenalidomide in acute leukemias and chronic lymphocytic leukemia Celgene Corp $20,000
• William G Blum OSU 07008 A Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) ... Geron Corp $0

Internal Medicine - Immunology

• Clark L Anderson FcRn binds and transports albumin Nat Inst of Allergy &Infectious Diseases $62,408
• Clark L Anderson FcRn binds and transports albumin Nat Inst of Allergy &Infectious Diseases $283,506
• Kevin V Hackshaw A long-term, open-label safety and efficacy study of Xyrem (sodium oxybate) in subjects with fibromyalgia Jazz Pharmaceuticals, Inc $0
• Kevin V Hackshaw A phase III randomized double blind placebo controlled trial to evaluate the safety and efficacy of Belimumabab (Lymphostat B) Anti Blys Ab in patients with SLE Kendle International Inc $0
• Kevin V Hackshaw A phase III randomized double blind placebo controlled trial to evaluate the safety and efficacy of Belimumabab (Lymphostat B) Anti Blys Ab in patients with SLE Kendle International Inc $7,440
• Kevin V Hackshaw A phase III randomized double blind placebo controlled trial to evaluate the safety and efficacy of Belimumabab (Lymphostat B) Anti Blys Ab in patients with SLE Kendle International Inc $3,000
• Kevin V Hackshaw A phase III, open-label, long-term, safety study of Tramadol Hydrochloride extended release and Meloxicam QD combination in the treatment of moderate to moderately sever pain associated with osteoarthritis Biovail Technologies Ltd $0
• Kevin V Hackshaw A randomized, double blind, parallel-group study of cardiovascular safety in osteoarthritis or rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing celecoxib with naproxen and ibuprofen Pfizer Inc $0
• Kevin V Hackshaw A randomized, double blind, parallel-group study of cardiovascular safety in osteoarthritis or rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing celecoxib with naproxen and ibuprofen Pfizer Inc $5,178
• Kevin V Hackshaw A randomized, double-blind, placebo-controlled, safety and efficacy study of xyrem (sodium oxybate) in subjects with fibromyalgia Jazz Pharmaceuticals, Inc $0
• Kevin V Hackshaw A randomized, double-blind, placebo-controlled, safety and efficacy study of xyrem (sodium oxybate) in subjects with fibromyalgia Jazz Pharmaceuticals, Inc $9,538
• Kevin V Hackshaw A randomized, double-blind, placebo-controlled, safety and efficacy study of xyrem (sodium oxybate) in subjects with fibromyalgia Jazz Pharmaceuticals, Inc $34
• Kevin V Hackshaw Abatacept in rheumatoid arthritis Bristol-Myers Squibb Co $38,235
• Kevin V Hackshaw Abatacept in rheumatoid arthritis Bristol-Myers Squibb Co $1,920
• Kevin V Hackshaw Double blind, parallel-group, randomized, study of the efficacy and safety of continuous use of Celecoxib versus the "usual use" of Celecoxib in the treatment of subjects with chronic osteoarthritis of the hip or knee who require an anti-inflammatory ... Icon Clinical Res Inc $21,737
• Kevin V Hackshaw Protocol U3384g: Phase III randomized double-blind placebo-controlled multicenter study of retreatment with rituximab in subjects with rheumatoid arthritis receiving background methotrexate Genentech Inc $48,961
• Kevin V Hackshaw Protocol U3384g: Phase III randomized double-blind placebo-controlled multicenter study of retreatment with rituximab in subjects with rheumatoid arthritis receiving background methotrexate Genentech Inc $1,200
• Kevin V Hackshaw Protocol U3384g: Phase III randomized double-blind placebo-controlled multicenter study of retreatment with rituximab in subjects with rheumatoid arthritis receiving background methotrexate Genentech Inc $28,877
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $800
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $11,790
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $2,300
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $28,380
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $15,215
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $8,475
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $1,850
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $10,525
• Kevin V Hackshaw Randomized, multicenter, double-blind, placebo-controlled efficacy and safety study of 8 mg PEG-uricase in two dose regimens in hyperuricemic subjects with symptomatic gout Savient Pharmaceuticals, Inc $600

Internal Medicine - Infectious Diseases

• Bradford S McGwire Characterization of an antimicrobial-peptide sensing mechanism of Trypanosoma cruzi Am Heart Assn $65,000
• Gillian L Beamer Chemokines and their receptors in the pathogenesis of tuberculosis Mentored Clinical Scientist Development Award (K08) Nat Inst of Allergy &Infectious Diseases $54,393
• Jesse John Kwiek Viral and placental determinants of HIV-1 subtype C mother-to-child transmission Nat Inst Child Health & HumanDevelopment $174,267
• Joanne Turner CD8 T cells and immunity to tuberculosis in old mice National Institute on Aging $309,061
• Joanne Turner Immune correlates of reactivation tuberculosis Nat Inst of Allergy &Infectious Diseases $367,500
• Joanne Turner In vitro predictors of susceptibility to reactivation tuberculosis Am Lung Assn $60,000
• Julie E Mangino Performance improvement project: implementation of a local pathway for the management of ICU patients with hospital-acquired pneumonia (IMPACT-HAP) Univ of Louisville $74,000
• Kurt B Stevenson Ohio State health network infection control collaborative: Epi-centers for prevention of healthcare related infections Centers for Disease Control & Prevention $23,469
• Kurt B Stevenson Ohio State health network infection control collaborative: Epi-centers for prevention of healthcare related infections Centers for Disease Control & Prevention $74,318
• Kurt B Stevenson Ohio State health network infection control collaborative: Epi-centers for prevention of healthcare related infections Centers for Disease Control & Prevention $3,911
• Kurt B Stevenson Ohio State health network infection control collaborative: Epi-centers for prevention of healthcare related infections Centers for Disease Control & Prevention $289,450
• Larry S Schlesinger Development of a bacteriophage lambda delivery system as a vaccine candidate against intracellular bacterial pathogens PhageVax, Inc $6,650
• Larry S Schlesinger Altered M. tuberculosis mannosylation and the macrophage Nat Inst of Allergy &Infectious Diseases $298,510
• Larry S Schlesinger Altered M. tuberculosis mannosylation and the macrophage Nat Inst of Allergy &Infectious Diseases $63,807
• Larry S Schlesinger Altered M. tuberculosis mannosylation and the macrophage Nat Inst of Allergy &Infectious Diseases $289,848
• Larry S Schlesinger Interdisciplinary study of the microbe-host interface (NIH NRSA T32) Nat Inst of Allergy &Infectious Diseases $134,809
• Larry S Schlesinger Lung innate immune responses to F tularensis: A central role for the macrophage Univ of Chicago $150,000
• Larry S Schlesinger Mycobacterium tuberculosis lipoarabinomannan metabolism within human macrophages Nat Inst of Allergy &Infectious Diseases $187,500
• Larry S Schlesinger TB and innate immune regulation of lung macrophages Nat Inst of Allergy &Infectious Diseases $233,579
• Larry S Schlesinger TB and innate immune regulation of lung macrophages Nat Inst of Allergy &Infectious Diseases $49,927
• Larry S Schlesinger TB and innate immune regulation of lung macrophages Nat Inst of Allergy &Infectious Diseases $226,805
• Larry S Schlesinger The effect of Beta-Glucan preparations from Biothera on the biology of human mononuclear phagocytes Biothera $40,320
• Larry S Schlesinger Development of a bacteriophage lambda delivery system as a vaccine candidate against intracellular bacterial pathogens PhageVax, Inc $6,650
• Larry S Schlesinger Lung innate immune responses to F tularensis: A central role for the macrophage Univ of Chicago $110,000
• Larry S Schlesinger Lung innate immune responses to F tularensis: A central role for the macrophage Univ of Chicago $240,000
• Michael F Para A phase 3, randomized, open-label, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir(R) and efavirenz. GILEAD SCIENCES, INC. $5,916
• Michael F Para A phase 3, randomized, open-label, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir(R) and efavirenz. GILEAD SCIENCES, INC. $1,852
• Michael F Para A phase 3, randomized, open-label, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir(R) and efavirenz. GILEAD SCIENCES, INC. $3,138
• Michael F Para A phase 3, randomized, open-label, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir(R) and efavirenz. GILEAD SCIENCES, INC. $3,134
• Michael F Para A phase 3, randomized, open-label, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir(R) and efavirenz. GILEAD SCIENCES, INC. $975
• Michael F Para A phase 3, randomized, open-label, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir(R) and efavirenz. GILEAD SCIENCES, INC. $7,616
• Michael F Para AIDS education and training center Univ of Pittsburgh $205,000
• Michael F Para Pneumonia cohort study INVERESK RES NC INC $975
• Michael F Para Pneumonia cohort study INVERESK RES NC INC $750
• Michael F Para Vicriviroc (SCH 417690) in combination treatment with optimized ART regimen in experienced subjects (VICTOR-E1) P03672 Schering-Plough Res Inst $1,783
• Michael F Para Vicriviroc (SCH 417690) in combination treatment with optimized ART regimen in experienced subjects (VICTOR-E1) P03672 Schering-Plough Res Inst $2,183
• Michael F Para Vicriviroc (SCH 417690) treatment protocol in HIV-infected subjects: a rollover study for ACTG protocol A5211 Schering-Plough Res Inst $1,450
• Michael F Para Vicriviroc (SCH 417690) treatment protocol in HIV-infected subjects: a rollover study for ACTG protocol A5211 Schering-Plough Res Inst $3,209
• Michael F Para Vicriviroc (SCH 417690) treatment protocol in HIV-infected subjects: a rollover study for ACTG protocol A5211 Schering-Plough Res Inst $1,170
• Michael F Para Vicriviroc (SCH 417690) treatment protocol in HIV-infected subjects: a rollover study for ACTG protocol A5211 Schering-Plough Res Inst $468
• Michael F Para Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects (VICTOR-E4)- P04889 Schering-Plough Corp $2,800
• Michael F Para Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects (VICTOR-E4)- P04889 Schering-Plough Corp $800
• Shu-Hua Wang Evaluation of T-Spot TB assay to identify and monitor patients and health care workers with active tuberculosis and latent tuberculosis infection Oxford Immunotec Limited $18,706
• Susan L Koletar A phase II dose-escalating, placebo-controlled, double-blind parallel group study in HIV treatment-experienced patients to evaluate the safety, tolerability and efficacy of PA103001-04 Panacos Pharmaceuticals Inc $344
• Susan L Koletar A phase II dose-escalating, placebo-controlled, double-blind parallel group study in HIV treatment-experienced patients to evaluate the safety, tolerability and efficacy of PA103001-04 Panacos Pharmaceuticals Inc $1,000
• Susan L Koletar A phase II dose-escalating, placebo-controlled, double-blind, parallel group study in HIV treatment-experienced patients to evaluate the safety, tolerability and efficacy of PA103001-04: A roll-over protocol for study 203 Panacos Pharmaceuticals Inc $2,188
• Susan L Koletar AACTG protocol A5200: a randomized, placebo-controlled, phase I/II trial of the anti-HIV activity and safety of (VGX-410) Mifepristone at three dose levels in HIV-1 infected subjects (reimbursement for participant stipends only) SOCIAL & SCIENTIFIC SYSTEMS, INC $4,500
• Susan L Koletar Chair, performance evaluation committee of the AIDS clinical trials group SOCIAL & SCIENTIFIC SYSTEMS, INC $36,371
• Susan L Koletar Chair, performance evaluation committee of the AIDS clinical trials group SOCIAL & SCIENTIFIC SYSTEMS, INC $18,186
• Susan L Koletar Chair, performance evaluation committee of the AIDS clinical trials group SOCIAL & SCIENTIFIC SYSTEMS, INC $33,077
• Susan L Koletar Family-centered, community-based, coordinated HIV care program (FACES) Research Institute at Nationwide Childrn $78,517
• Susan L Koletar Study of the efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT). Chiron Corp $800
• Susan L Koletar Study of the efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT). Chiron Corp $2,800
• Susan L Koletar Study of the efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT). Chiron Corp $3,200
• Susan L Koletar Study of the efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT). Chiron Corp $2,600
• Susan L Koletar Study of the efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT). Chiron Corp $1,200
• Susan L Koletar The Ohio State University AIDS clinical trials unit Nat Inst of Allergy &Infectious Diseases $1,329,413
• Susan L Koletar The Ohio State University AIDS clinical trials unit Nat Inst of Allergy &Infectious Diseases $496,564

Internal Medicine - Nephrology

• Anil K Agarwal A randomized study of the safety and efficacy of FG-2216 in subjects with renal anemia not requiring dialysis and not receiving recombinant human erythropoietin FibroGen, Inc $1,750
• Anil K Agarwal A randomized study of the safety and efficacy of FG-2216 in subjects with renal anemia not requiring dialysis and not receiving recombinant human erythropoietin FibroGen, Inc $35,713
• Anil K Agarwal A trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension Novartis Pharmaceuticals Corp $2,000
• Anil K Agarwal A trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension Novartis Pharmaceuticals Corp $22,170
• Anil K Agarwal A trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension Novartis Pharmaceuticals Corp $950
• Anil K Agarwal A trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension Novartis Pharmaceuticals Corp $350
• Anil K Agarwal A trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension Novartis Pharmaceuticals Corp $1,592
• Anil K Agarwal A trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension Novartis Pharmaceuticals Corp $13,209
• Anil K Agarwal An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis. HOFFMANN-LAROCHE INC $0
• Anil K Agarwal An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis. HOFFMANN-LAROCHE INC $4,130
• Anil K Agarwal An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis. HOFFMANN-LAROCHE INC $2,340
• Anil K Agarwal An open-label, single-arm study to assess the safety of darbepoetin alfa manufactured by a serum free bioreactor technology in subjects with chronic kidney disease Amgen Inc $600
• Anil K Agarwal An open-label, single-arm study to assess the safety of darbepoetin alfa manufactured by a serum free bioreactor technology in subjects with chronic kidney disease Amgen Inc $12,419
• Anil K Agarwal Evaluation of cinacalcet hcl therapy to lower cardiovascular events (evolve) AMGEN, INC./FRESENIUS MEDICAL CARE $7,500
• Anil K Agarwal Evaluation of cinacalcet hcl therapy to lower cardiovascular events (evolve) AMGEN, INC./FRESENIUS MEDICAL CARE $3,050
• Anil K Agarwal Evaluation of cinacalcet hcl therapy to lower cardiovascular events (evolve) AMGEN, INC./FRESENIUS MEDICAL CARE $1,632
• Anil K Agarwal Evaluation of cinacalcet hcl therapy to lower cardiovascular events (evolve) AMGEN, INC./FRESENIUS MEDICAL CARE $14,326
• Anil K Agarwal Evaluation of cinacalcet hcl therapy to lower cardiovascular events (evolve) AMGEN, INC./FRESENIUS MEDICAL CARE $4,486
• Anil K Agarwal Evaluation of cinacalcet hcl therapy to lower cardiovascular events (evolve) AMGEN, INC./FRESENIUS MEDICAL CARE $12,068
• Anil K Agarwal Prospective, open label, randomized, multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease stage 4 through dialysis Roche Labs, Inc $0
• Anil K Agarwal Protocol 20010184. Amgen Inc $8,625
• Anil K Agarwal Protocol 20010184. Amgen Inc $22,981
• Anil K Agarwal Protocol 20010184. Amgen Inc $18,025
• Anil K Agarwal Protocol 20030153. Amgen Inc $1,750
• Brad H Rovin A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis PPD Dev $8,370
• Brad H Rovin A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis PPD Dev $125
• Brad H Rovin A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis PPD Dev $5,478
• Brad H Rovin A randomized, two-arm, parallel group study of the safety, pharmacokinetics, and pharmacodynamics of TRU-015 added to standard therapy in subjects with membranous nephropathy secondary to systemic lupus erythematosus. WYETH PHARMACEUTICALS INC $0
• Brad H Rovin Lupus clinical trials consortium. Lupus Clinical Trials Consortium, Inc $37,500
• Brad H Rovin Lupus clinical trials consortium. Lupus Clinical Trials Consortium, Inc $32,500
• Brad H Rovin Osprey-leukocyte population modifier program in inflammatory kidney diseases Osprey Pharmaceuticals Limited $16,209
• Brad H Rovin Protocol U2970g: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Rituximab in subjects with ISN/RPS class III or IV lupus nephritis Genentech Inc $13,005
• Brad H Rovin Protocol U2970g: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Rituximab in subjects with ISN/RPS class III or IV lupus nephritis Genentech Inc $25,350
• Brad H Rovin Protocol U2970g: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Rituximab in subjects with ISN/RPS class III or IV lupus nephritis Genentech Inc $37,310
• Brad H Rovin Protocol U2970g: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Rituximab in subjects with ISN/RPS class III or IV lupus nephritis Genentech Inc $41,300
• Brad H Rovin U2971g: A randomized, double-blind, placebo-controlled, multi-center, phase II/III study to evaluate the efficacy and safety of retuximab in subjects with moderate to severe systemic lupus erythematosus Genentech Inc $8,370
• Brad H Rovin U2971g: A randomized, double-blind, placebo-controlled, multi-center, phase II/III study to evaluate the efficacy and safety of retuximab in subjects with moderate to severe systemic lupus erythematosus Genentech Inc $1,130
• Brad H Rovin U2971g: A randomized, double-blind, placebo-controlled, multi-center, phase II/III study to evaluate the efficacy and safety of retuximab in subjects with moderate to severe systemic lupus erythematosus Genentech Inc $3,482
• Brad H Rovin U2971g: A randomized, double-blind, placebo-controlled, multi-center, phase II/III study to evaluate the efficacy and safety of retuximab in subjects with moderate to severe systemic lupus erythematosus Genentech Inc $1,956
• Brad H Rovin U2971g: A randomized, double-blind, placebo-controlled, multi-center, phase II/III study to evaluate the efficacy and safety of retuximab in subjects with moderate to severe systemic lupus erythematosus Genentech Inc $1,800
• Brad H Rovin Osprey-leukocyte population modifier program in inflammatory kidney diseases Osprey Pharmaceuticals Limited $331
• Christopher W Valentine A randomized, double-blind, placebo-controlled study of XL784 administered orally to subjects with albuminuria due to diabetic nephropathy Exelixis Inc $4,000
• Christopher W Valentine A randomized, double-blind, placebo-controlled study of XL784 administered orally to subjects with albuminuria due to diabetic nephropathy Exelixis Inc $8,238
• Ganesh Shidham Comparison of cyclosporine A and mycophenolate in FSGS St Joseph's Hospital & Medical Center $1,100
• Ganesh Shidham FSGS - focal segmental glomerulosclerosis trial Montefiore Medical Center $0
• Lee A Hebert A long-term, post-treatment, safety follow-up, multi-center study in patients with type 2 diabetes mellitus from the GALLANT, GALLEX or ARMOR Studies; G-PLUS (GALLANT, GALLER and ARMOT-post treatment long-term follow-up study) Astrazeneca Lp $2,550
• Lee A Hebert A long-term, post-treatment, safety follow-up, multi-center study in patients with type 2 diabetes mellitus from the GALLANT, GALLEX or ARMOR Studies; G-PLUS (GALLANT, GALLER and ARMOT-post treatment long-term follow-up study) Astrazeneca Lp $1,060
• Lee A Hebert A randomized, double-blind, placebo-controlled, four-arm, parallel-group, multicenter, multinational safety and efficacy trial of 100mg and 300mg of LJP 394 in systemic lupus erythematosus (SLE) patients La Jolla Pharmaceutical Co $2,406
• Lee A Hebert A randomized, double-blind, placebo-controlled, four-arm, parallel-group, multicenter, multinational safety and efficacy trial of 100mg and 300mg of LJP 394 in systemic lupus erythematosus (SLE) patients La Jolla Pharmaceutical Co $2,563
• Lee A Hebert A randomized, double-blind, placebo-controlled, four-arm, parallel-group, multicenter, multinational safety and efficacy trial of 100mg and 300mg of LJP 394 in systemic lupus erythematosus (SLE) patients La Jolla Pharmaceutical Co $2,125
• Lee A Hebert A randomized, double-blind, placebo-controlled, four-arm, parallel-group, multicenter, multinational safety and efficacy trial of 100mg and 300mg of LJP 394 in systemic lupus erythematosus (SLE) patients La Jolla Pharmaceutical Co $3,625
• Lee A Hebert A randomized, double-blind, placebo-controlled, four-arm, parallel-group, multicenter, multinational safety and efficacy trial of 100mg and 300mg of LJP 394 in systemic lupus erythematosus (SLE) patients La Jolla Pharmaceutical Co $2,438
• Lee A Hebert A randomized, double-blind, placebo-controlled, four-arm, parallel-group, multicenter, multinational safety and efficacy trial of 100mg and 300mg of LJP 394 in systemic lupus erythematosus (SLE) patients La Jolla Pharmaceutical Co $2,313
• Lee A Hebert AASK cohort Lenox Hill Hosp $14,025
• Lee A Hebert AASK cohort study Nat In Diabetes & Digestive & Kidney Diseases $41,412
• Lee A Hebert African American study of kidney disease & hypertension cohort study (AASK) Univ of Massachusetts - Worcester $28,151
• Lee A Hebert Genetic and clinical risk for human SLE nephritis Nat In Diabetes & Digestive & Kidney Diseases $143,104
• Lee A Hebert The effect of sulodexide in overt type 2 diabetic nephropathy Medpace, Inc $603
• Lee A Hebert The effect of sulodexide in overt type 2 diabetic nephropathy Medpace, Inc $1,785
• Lee A Hebert The effect of sulodexide in overt type 2 diabetic nephropathy Medpace, Inc $1,264
• Lee A Hebert The effect of sulodexide in overt type 2 diabetic nephropathy Medpace, Inc $541
• Todd E Pesavento A randomized, controlled trial of homocysteine (FAVORIT). Rhode Island Hosp $44,025
• Todd E Pesavento A randomized, controlled trial of homocysteine (FAVORIT). Rhode Island Hosp $2,000
• Todd E Pesavento A randomized, controlled trial of homocysteine (FAVORIT). Rhode Island Hosp $39,361
• Todd E Pesavento Renal transplantation, homocysteine lowering and cognition. TUFTS UNIV $1,735
• Todd E Pesavento Safety, tolerability and efficacy of pegylated inteferon alfa-2b (PEG-Intron) and ribavirin (Rebetol) combination therapy in stable renal transplant recipients with hepatitis C and advanced hepatic fibrosis: A pilot study Mayo Fdn for Medical Educ & Res $0

Internal Medicine - Pulmonary, Allergy, Critical Care, & Sleep Medicine

• Anasuya Sarkar Monocyte caspase-1: role in plaque disease Am Heart Assn-Great Rivers Affiliate $42,000
• Andrea I Doseff Molecular mechanisms of apoptosis in monocytes National Heart, Lung, and Blood Inst $191,360
• Andrea I Doseff Molecular mechanisms of apoptosis in monocytes National Heart, Lung, and Blood Inst $40,903
• Andrea I Doseff Molecular mechanisms of apoptosis in monocytes National Heart, Lung, and Blood Inst $23,114
• Andrea I Doseff Regulation of apoptosis by the interaction of Casp-3 with PKC and small heat shock proteins NSF Molecular & Cellular Biosciences $9,200
• Beth Y Besecker Zinc importer SLC39A8 and lung epithelial cell survival National Heart, Lung, and Blood Inst $57,426
• Clay B Marsh Intracellular pathways of monocyte survival National Heart, Lung, and Blood Inst $16,875
• Clay B Marsh Intracellular pathways of monocyte survival National Heart, Lung, and Blood Inst $1,875
• Clay B Marsh Analysis of circulating microvesicles and their contents in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) Battelle Memorial Inst $188,949
• Clay B Marsh Intracellular pathways of monocyte survival National Heart, Lung, and Blood Inst $320,625
• Clay B Marsh Intracellular pathways of monocyte survival National Heart, Lung, and Blood Inst $35,625
• James M O'Brien The obese critical III: Process and outcome disparities National Heart, Lung, and Blood Inst $65,124
• James M O'Brien A double-blind, placebo-controlled, parallel group phase II dose-ranging study of nebulized Amikacin delivered via the pulmonary drug delivery system (PDDS) in patients with ventilator-associated pneumonia due to gram-negative organisms PPD Dev $1,760
• James M O'Brien The obese critical III: Process and outcome disparities National Heart, Lung, and Blood Inst $65,124
• James N Allen Jr. Linezolid vs. vancomycin or oxacillin/dicloxacillin in the treatment of catheter related gram-positive bloodstream infections. Pharmacia & Upjohn Inc $450
• James N Allen Jr. A randomized, double-blind, placebo-controlled, multinational, phase 3 study of the safety and efficacy of 200 ug subcutaneous interferon gamma-1b (IFN-y 1b) in patients with idiopathic pulmonary fibrosis (GIPF-007) Intermune Inc $12,517
• James N Allen Jr. A randomized, double-blind, placebo-controlled, multinational, phase 3 study of the safety and efficacy of 200 ug subcutaneous interferon gamma-1b (IFN-y 1b) in patients with idiopathic pulmonary fibrosis (GIPF-007) Intermune Inc $10,058
• James N Allen Jr. A randomized, double-blind, placebo-controlled, multinational, phase 3 study of the safety and efficacy of 200 ug subcutaneous interferon gamma-1b (IFN-y 1b) in patients with idiopathic pulmonary fibrosis (GIPF-007) Intermune Inc $500
• James N Allen Jr. A randomized, double-blind, placebo-controlled, multinational, phase 3 study of the safety and efficacy of 200 ug subcutaneous interferon gamma-1b (IFN-y 1b) in patients with idiopathic pulmonary fibrosis (GIPF-007) Intermune Inc $3,063
• James N Allen Jr. A randomized, double-blind, placebo-controlled, multinational, phase 3 study of the safety and efficacy of 200 ug subcutaneous interferon gamma-1b (IFN-y 1b) in patients with idiopathic pulmonary fibrosis (GIPF-007) Intermune Inc $12,468
• James N Allen Jr. A randomized, double-blind, placebo-controlled, multinational, phase 3 study of the safety and efficacy of 200 ug subcutaneous interferon gamma-1b (IFN-y 1b) in patients with idiopathic pulmonary fibrosis (GIPF-007) Intermune Inc $1,000
• James N Allen Jr. PIPF study Intermune Inc $25,292
• James N Allen Jr. PIPF study Intermune Inc $21,172
• James N Allen Jr. PIPF study Intermune Inc $18,597
• James N Allen Jr. PIPF study Intermune Inc $28,556
• James N Allen Jr. PIPF study Intermune Inc $28,973
• James N Allen Jr. PIPF study Intermune Inc $21,149
• John G Mastronarde CQAB149B Study 2335S Site 690 Novartis Pharmaceuticals Corp $0
• John G Mastronarde ACRC clinical trials Johns Hopkins Univ $2,250
• John G Mastronarde ACRC clinical trials Johns Hopkins Univ $4,500
• John G Mastronarde ACRC clinical trials Johns Hopkins Univ $4,500
• John G Mastronarde Asthma clinical research center Am Lung Assn $3,000
• John G Mastronarde Asthma clinical research center Am Lung Assn $154,464
• John G Mastronarde Exercise as an anti-inflammatory therapy for asthma Nat Center for Research Resources $119,326
• John G Mastronarde Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus Omnicare Clinical Res Inc $1,676
• Karen L Wood Lung alloimmunity after bone marrow transplantation National Heart, Lung, and Blood Inst $130,518
• Mark D Wewers Macrophage inflammasome regulation National Heart, Lung, and Blood Inst $62,408
• Mark D Wewers Macrophage inflammasome regulation National Heart, Lung, and Blood Inst $283,506
• Mark D Wewers Molecular mechanisms of lung inflammation National Heart, Lung, and Blood Inst $239,881
• Matthew C Exline Apoptosis in sepsis: the role of humanin, a novel anti-apoptotic peptide Am Lung Assn $40,000
• Melissa G Hunter The role of Ets2 transcription factors in pulmonary fibrosis The Francis Families Foundation $46,000
• Michael Elias Ezzie The role of thrombospondin-1 in emphysema Flight Attendant Med Res Inst $81,375
• Naeem A Ali TSP-1: A mediator of sepsis-induced lung injury Nat Center for Research Resources $65,563
• Naeem A Ali TSP-1: A mediator of sepsis-induced lung injury Nat Center for Research Resources $65,563
• Namita Sood COMPASS 2: drug study Actelion Clinical Operations, Inc $0
• Namita Sood COMPASS 2: drug study Actelion Clinical Operations, Inc $10,000
• Namita Sood Randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of bosentan in patients with symptomatic pulmonary arterial hypertension secondary to sickle cell disease Actelion Clinical Operations, Inc $2,500
• Namita Sood Randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of bosentan in patients with symptomatic pulmonary arterial hypertension secondary to sickle cell disease Actelion Clinical Operations, Inc $5,000
• Namita Sood Randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of bosentan in patients with symptomatic pulmonary arterial hypertension secondary to sickle cell disease Actelion Clinical Operations, Inc $17,500
• Namita Sood Randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of bosentan in patients with symptomatic pulmonary arterial hypertension secondary to sickle cell disease Actelion Clinical Operations, Inc $9,100
• Namita Sood VISION trial CoTherix, Inc $2,750
• Namita Sood VISION trial CoTherix, Inc $6,000
• Namita Sood VISION trial CoTherix, Inc $2,581
• Namita Sood TDE-PH-301 United Therapeutics Corporation $0
• Namita Sood TDE-PH-301 United Therapeutics Corporation $11,007
• Namita Sood TDE-PH-302 United Therapeutics Corporation $0
• Namita Sood TDE-PH-304 United Therapeutics Corporation $0
• Namita Sood TDE-PH-304 United Therapeutics Corporation $150
• Namita Sood TDE-PH-305 United Therapeutics Corporation $0
• Namita Sood TDE-PH-306 United Therapeutics Corporation $0
• Namita Sood TDE-PH-307 United Therapeutics Corporation $0
• Narasimham Parinandi Organic dust epithelial PKC activation and airway disease Univ of Nebraska $25,086
• Oliver Voss Regulation of human monocyte apoptosis by caspase-3 and small heat shock protein 27 Am Heart Assn-Great Rivers Affiliate $16,800
• Patrick Nana-Sinkam Circulating microRNA as a biomarker in lung cancer The CHEST Fdn $75,000
• Patrick Nana-Sinkam Regulation of prostacyclin in pulmonary hypertension National Heart, Lung, and Blood Inst $61,769
• Patrick Nana-Sinkam Regulation of prostacyclin in pulmonary hypertension National Heart, Lung, and Blood Inst $131,490
• Philip T Diaz Smoking cessation and the natural history of HIV-induced emphysema National Heart, Lung, and Blood Inst $38,702
• Philip T Diaz Smoking cessation and the natural history of HIV-induced emphysema National Heart, Lung, and Blood Inst $77,404
• Philip T Diaz Smoking cessation and the natural history of HIV-induced emphysema National Heart, Lung, and Blood Inst $38,702
• Philip T Diaz Alveolar macrophage proteomics in HIV-induced emphysema National Heart, Lung, and Blood Inst $155,928
• Philip T Diaz Smoking cessation and the natural history of HIV-induced emphysema National Heart, Lung, and Blood Inst $77,404
• Philip T Diaz Alveolar macrophage proteomics in HIV-induced emphysema National Heart, Lung, and Blood Inst $194,910
• Philip T Diaz Chronic obstructive pulmonary disease study Battelle Memorial Inst $0
• Philip T Diaz Long-term oxygen treatment trial (LOTT) regional clinical center National Heart, Lung, and Blood Inst $212,759
• Philip T Diaz Pilot study of the Spiration IBV valve system Spiration, Inc $139,454
• Philip T Diaz Smoking cessation and the natural history of HIV-induced emphysema National Heart, Lung, and Blood Inst $425,720
• Philip T Diaz Alveolar macrophage proteomics in HIV-induced emphysema National Heart, Lung, and Blood Inst $19,491
• Philip T Diaz Smoking cessation and the natural history of HIV-induced emphysema National Heart, Lung, and Blood Inst $38,702
• Rami N Khayat Performance of CPAP and bi-Flex in treating SDB in a heart failure population Respironics, Inc $4,000
• Rami N Khayat Performance of CPAP and bi-Flex in treating SDB in a heart failure population Respironics, Inc $4,020
• Ryan D Roberts M-CSF blocking strategies to prevent tumor progression and metastasis in breast cancers Army Medical Res Acquisition Activity $30,000
• Susheela Tridandapani Investigation of signal transduction processes that regulate Fc receptor-mediated effector functions by monocytes using antibody variants with diverse Fc receptor affinity profiles Xencor, Inc $0
• Susheela Tridandapani Investigation of signal transduction processes that regulate Fc receptor-mediated effector functions by monocytes using antibody variants with diverse Fc receptor affinity profiles Xencor, Inc $0
• Susheela Tridandapani SHIP-2 influence on macrophage Fc receptor function Nat Inst of Allergy &Infectious Diseases $233,579
• Susheela Tridandapani SHIP-2 influence on macrophage Fc receptor function Nat Inst of Allergy &Infectious Diseases $49,927
• Susheela Tridandapani SHIP-2 influence on macrophage Fc receptor function Nat Inst of Allergy &Infectious Diseases $226,805
• Thomas L Clanton Redox mechanisms of respiratory muscle stress adaptation National Heart, Lung, and Blood Inst $299,000
• Thomas L Clanton Redox mechanisms of respiratory muscle stress adaptation National Heart, Lung, and Blood Inst $63,911
• Valery V Khramtsov In vivo imaging and spectroscopy of pH and thiols status Nat In Biomedical Imaging&Bioengineering $159,845

Molec & Cellular Biochemistry

• Arthur H Burghes Survival motor neuron genes in spinal muscular atrophy. Nat Inst Neurological Disorders & Stroke $267,660
• Arthur H Burghes Survival motor neuron genes in spinal muscular atrophy. Nat Inst Neurological Disorders & Stroke $57,212
• Arthur H Burghes Testing of MediChem (deCODE)(FSMA) compounds for induction of SMN expression from SMN2 Families of Spinal Muscular Atrophy $50,000
• C Russell Hille Studies of environmentally relevant molybdenum enzymes Nat Inst of Environ Health Scis $302,998
• Charles E Bell Structural studies of RecA-DNA complexes. Nat Inst Gen Medical Scis $244,750
• Craig Alan McElroy Structural and biophysical studies of the molecular interaction between Interleukin-7 and its alpha receptor Am Heart Assn-Great Rivers Affiliate $42,000
• Daniel R Schoenberg Estrogen receptor control of post-transcriptional steps in gene expression Am Heart Assn-Great Rivers Affiliate $42,000
• Daniel R Schoenberg Hormonal regulation of mRNA stability Nat Inst Gen Medical Scis $366,004
• Daniel R Schoenberg Hormonal regulation of mRNA stability Nat Inst Gen Medical Scis $15,000
• Douglas R Pfeiffer Mitochondrial dysfunction in disease of the eye. Alcon Labs Inc $40,000
• Douglas R Pfeiffer Mitochondrial dysfunction in disease of the eye. Alcon Labs Inc $20,000
• Jeffrey A Kuret Structure and genesis of tau filaments National Institute on Aging $235,381
• Jeffrey A Kuret Structure and genesis of tau filaments National Institute on Aging $26,153
• Jinjin Zhang Structure and function of the RecET recombination system. Am Heart Assn-Great Rivers Affiliate $21,000
• Kalpana Ghoshal The role of microRNA in hepatocarcinogenesis National Cancer Institute $138,368
• Kamal D Mehta Role of protein kinase Cbeta in diet-induced hypercholesterol mice. National Heart, Lung, and Blood Inst $49,927
• Kamal D Mehta Role of protein kinase Cbeta in diet-induced hypercholesterol mice. National Heart, Lung, and Blood Inst $226,803
• Lai Chu Wu The role of the large zinc finger protein ZAS3 in the regulation of adult bone formation Columbus Medical Research Foundation $10,000
• Mark R Parthun Chromatin regulation as a therapeutic target to enhance biologic therapies in CLL V Fdn $80,000
• Mark R Parthun Chromatin regulation as a therapeutic target to enhance biologic therapies in CLL V Fdn $5,000
• Mark R Parthun Chromatin regulation as a therapeutic target to enhance biologic therapies in CLL V Fdn $5,000
• Mark R Parthun Type B histone acetyltransferases and the assembly of chromatin structure National Institutes of Health $294,942
• Matthew E Butchbach Mechanisms of butyrate neuroprotection in a mouse model of spinal muscular atrophy Families of Spinal Muscular Atrophy $110,000
• Michael C Ostrowski Genetic Analysis of ras/ets pathways in endothelial cell migration and survival National Institutes of Health $239,346
• Michael C Ostrowski Genetic analysis of the breast tumor microenvironment National Cancer Institute $1,330,813
• Michael C Ostrowski Genetic Analysis of ras/ets pathways in endothelial cell migration and survival National Institutes of Health $26,594
• Patrice P Hamel Molecular genetic dissection of mitochondrial complex I assembly United Mitochondrial Disease Fdn $11,211
• Said Sif Effects of human SWI/SNF-associated PRMT5 on lymphomagenesis National Cancer Institute $20,250
• Said Sif Effects of human SWI/SNF-associated PRMT5 on lymphomagenesis National Cancer Institute $205,200
• Samson T Jacob A research proposal to test novel nucleotide analogs in the DNA methylation machinery Supergen Inc $75,000
• Samson T Jacob Alcohol-induced epigenetic changes in the liver genome Nat Inst on Alcohol Abuse & Alcoholism $175,455
• Samson T Jacob DNA methylation and chromatin modifications: Mechanisms and applications in cancer therapy National Cancer Institute $2,215,284
• Samson T Jacob Role of metallothioneins in hepatocellular carcinoma National Cancer Institute $180,000
• Scott T Walsh Structure and energetic studies of interleukins and receptors Am Heart Assn $65,000
• Sung Ok Yoon Mechanisms of crosstalk between NGF receptors, TrkA and p75. Nat Inst Neurological Disorders & Stroke $295,024
• Sung Ok Yoon Promoting oligodendrocyte survival by disrupting proNGF-p75 interaction in vivo Christopher and Dana Reeve Foundation $37,500
• Sung Ok Yoon Mechanisms of crosstalk between NGF receptors, TrkA and p75. Nat Inst Neurological Disorders & Stroke $32,780
• Sung Ok Yoon Promoting oligodendrocyte survival by disrupting proNGF-p75 interaction in vivo Christopher and Dana Reeve Foundation $37,500
• Sung Ok Yoon Regulation of apoptosis and degeneration after spinal cord injury Nat Inst Neurological Disorders & Stroke $328,125
• Tsonwin Hai ATF3 and iNOS in islet destruction and graft rejection Nat In Diabetes & Digestive & Kidney Diseases $97,908
• Tsonwin Hai ATF3 and iNOS in islet destruction and graft rejection Nat In Diabetes & Digestive & Kidney Diseases $20,928
• Tsonwin Hai Beta cell transcriptional network in stress response Am Diabetes Assn Inc $50,000
• Tsonwin Hai ATF3 and iNOS in islet destruction and graft rejection Nat In Diabetes & Digestive & Kidney Diseases $97,908
• Tsonwin Hai ATF3 and iNOS in islet destruction and graft rejection Nat In Diabetes & Digestive & Kidney Diseases $20,928
• Tsonwin Hai Beta cell transcriptional network in stress response Am Diabetes Assn Inc $50,000
• Yuichi Otsuka The relationship between cytoplasmic capping to translation and mRNA decay Am Heart Assn-Great Rivers Affiliate $44,000

Molecular Vir, Imm & Med Gen

• Albert de la Chapelle BAALC in neurogenesis and hematopoiesis National Cancer Institute $290,595
• Albert de la Chapelle Postdoctoral training in cancer genetics. National Cancer Institute $319,539
• Albert de la Chapelle Postdoctoral training in cancer genetics. National Cancer Institute $298,328
• Albert de la Chapelle Postdoctoral training in cancer genetics. National Cancer Institute $6,872
• Albert de la Chapelle Postdoctoral training in cancer genetics. National Cancer Institute $6,416
• Amanda E Toland Genomic changes and somatic squamous cell susceptibility factors in organ transplant recipients (OTRs) Univ of California San Francisco $18,073
• Amy Elizabeth Lovett-Racke Characterizing therapeutic targets for multiple sclerosis Nat Multiple Sclerosis Soc $121,849
• Amy Elizabeth Lovett-Racke Role of T-bet in immune-mediated demyelinating disease Nat Multiple Sclerosis Soc $101,741
• Carol M Croce Impact of Chemo-Immunotherapy in Relapsed/Refractory B-CLL Mayo Fdn for Medical Educ & Res $128,803
• Carol M Croce Role of microRNAs as oncogenes and tumor suppressor factors in leukemias and lymphomas studied on transgenic and ko mice CLL Global Res Fdn $31,500
• Carol M Croce ALL fusion proteins: Associated with multi-protein complexes and role in transcription National Cancer Institute $298,169
• Carol M Croce Analysis of LNA oligonucleotides in miR155 transgenic mice Santaris Pharma A/S $0
• Carol M Croce FHIT Gene Therapy in Cancer Prevention and Treatment National Cancer Institute $228,000
• Carol M Croce Impact of Chemo-Immunotherapy in Relapsed/Refractory B-CLL Mayo Fdn for Medical Educ & Res $14,311
• Carol M Croce Role of Fhit in apoptosis and susceptibility to therapy Thomas Jefferson Univ $317,082
• Carol M Croce Role of microRNAs as oncogenes and tumor suppressor factors in leukemias and lymphomas studied on transgenic and ko mice CLL Global Res Fdn $3,500
• Caroline C Whitacre Effect of pregnancy on EAE and MS National Institutes of Health $270,076
• Caroline C Whitacre Effect of pregnancy on EAE and MS National Institutes of Health $57,728
• Caroline C Whitacre Migration inhibitory factor in the progression of EAE Nat Inst of Allergy &Infectious Diseases $47,933
• Caroline C Whitacre Migration inhibitory factor in the progression of EAE Nat Inst of Allergy &Infectious Diseases $217,747
• Caroline C Whitacre Migration inhibitory factor in the progression of EAE Nat Multiple Sclerosis Soc $252,473
• Christoph Plass DNA methylation as a therapeutic target in chronic lymphocytic leukemia. Leukemia & Lymphoma Soc $58,500
• Christoph Plass DNA methylation as a therapeutic target in chronic lymphocytic leukemia. Leukemia & Lymphoma Soc $29,250
• Christoph Plass DNA methylation as a therapeutic target in chronic lymphocytic leukemia. Leukemia & Lymphoma Soc $6,500
• Christoph Plass DNA methylation as a therapeutic target in chronic lymphocytic leukemia. Leukemia & Lymphoma Soc $3,250
• Christoph Plass Epigenetic contributions to gender-specific differences in lung cancer National Lung Cancer Partnership $25,000
• Christoph Plass Epigenetic contributions to gender-specific differences in lung cancer National Lung Cancer Partnership $12,500
• Christoph Plass Genomic scanning for genetic and epigenetic alterations in head and neck cancer Nat Inst of Dental & Craniofacial Res $327,375
• Christoph Plass Genomic scanning for genetic and epigenetic alterations in head and neck cancer Nat Inst of Dental & Craniofacial Res $36,375
• Daniel P Ankeny Functional effects of B cells activated by spinal cord injury in mice Nat Inst Neurological Disorders & Stroke $75,000
• Danilo Perrotti Activating phosphatases as therapeutic strategy for leukemias characterized by activated oncogenic tyrosine kinases: Role of PP2A in Chronic Myelogenous Leukemia Leukemia & Lymphoma Soc $99,000
• Danilo Perrotti Activating phosphatases as therapeutic strategy for leukemias characterized by activated oncogenic tyrosine kinases: Role of PP2A in Chronic Myelogenous Leukemia Leukemia & Lymphoma Soc $11,000
• Danilo Perrotti Restoration of PP2A tumor suppressor activity as therapeutic strategy for blast crisis chronic myelogenous leukemia US Department of Defense $225,000
• Deborah S Parris Coordination of HSV lagging strand synthesis Nat Inst Gen Medical Scis $281,281
• Denis C Guttridge NF-kappaB/IKK signaling in myogenesis and disease Nat In Arthritis&Muscoskeletal&Skin Ds $261,225
• Denis C Guttridge NF-kB regulation of muscle wasting in cancer cachexia. National Cancer Institute $232,512
• Denis C Guttridge Early detection of pancreatic cancer cachexia National Cancer Institute $69,184
• Denis C Guttridge NF-kappaB/IKK signaling in myogenesis and disease Nat In Arthritis&Muscoskeletal&Skin Ds $29,025
• Denis C Guttridge Early detection of pancreatic cancer cachexia National Cancer Institute $3,641
• Erich Grotewold The Grass Regulome Initiative: Integrating control of gene expression and agronomic traits across the grasses NSF Biological Infrastructure $92,655
• Frances K Huebner Wwox as a critical signal mediator in breast cancer National Cancer Institute $131,864
• Frances K Huebner FHIT modulation of cell cycle progression and DNA damage response National Cancer Institute $315,000
• Frances K Huebner The effect of Fhit on stabilization of the fragile site following low dose ionizing radiation Thomas Jefferson Univ $45,086
• Frances K Huebner Wwox as a critical signal mediator in breast cancer National Cancer Institute $14,652
• George A Calin Roles of microRN as in familial chronic lymphocytic leukemia CLL Global Res Fdn $100,000
• Gregory Lesinski The role of suppressors of cytokine signaling (SOCS) in mediating the anti-tumor properties of interferon-alpha (IFN-a). (Career Development Research Award) The Melanoma Research Fdn $45,000
• Gregory Lesinski The Role of MicroRNA in the Progression of Malignant Melanoma. V Fdn $100,000
• Gregory Lesinski The role of suppressors of cytokine signaling (SOCS) in mediating the anti-tumor properties of interferon-alpha (IFN-a). (Career Development Research Award) The Melanoma Research Fdn $5,000
• Gustavo W Leone E2F3 and embryonic development Nat Inst Child Health & HumanDevelopment $314,678
• Gustavo W Leone Myc function in t-cell lymphomagenesis. Leukemia & Lymphoma Soc $73,000
• Gustavo W Leone Myc function in t-cell lymphomagenesis. Leukemia & Lymphoma Soc $7,000
• Gustavo W Leone The role of e2f3 in breast cancer Susan G Komen Breast Cancer Fdn $45,000
• Haiyan Qin Wxox-Ap2 signal pathways: effects on life and death of breast cancer cells. Army Medical Res & Materiel Command $59,946
• Harold A Fisk Regulation of the centrosomal degradation of the Mps1 protein kinase Ohio Cancer Res Assoc $5,000
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $38,831
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $212,436
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $569,568
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $2
• Joanna L Groden Characterization of tumor suppression by the APC gene National Cancer Institute $256,926
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $4,315
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $23,604
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $63,285
• Joanna L Groden Mouse models of gastrointestinal cancer National Cancer Institute $0
• John L Gensel A combination therapy for treating cervical spinal cord injury PARALYSIS PROJECT OF AMERICA $34,000
• John S Gunn Regulation of virulence by PmrA in Francisella spp Univ of Chicago $74,750
• John S Gunn Salmonella antimicrobial peptide resistance. National Institutes of Health $233,579
• John S Gunn Salmonella antimicrobial peptide resistance. National Institutes of Health $49,927
• John S Gunn Bile, Biofilms and Salmonella Gallbladder Carriage Nat Inst of Allergy &Infectious Diseases $300,360
• John S Gunn Bile, Biofilms and Salmonella Gallbladder Carriage Nat Inst of Allergy &Infectious Diseases $75,090
• Jonathan P Godbout Neuroimmunology of Age-Associated Depressive Disorders National Institute of Mental Health $37,500
• Jonathan P Godbout Neuroimmunology of Age-Associated Depressive Disorders National Institute of Mental Health $37,500
• Khanh Vannhu Tran Minority predoctoral fellowship program National Institute on Drug Abuse $34,599
• L James Lee Novel micro/nanofluidic electroporation devices for DNA and oligonucleotide delivery Nat In Biomedical Imaging&Bioengineering $8,857
• Louise Y Fong Chemoprevention of upper aerodigestive tract cancer by dietary zinc National Cancer Institute $264,527
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $463,623
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $154,997
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $11,888
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $3,974
• M Ronald Glaser Studies on the etiology of chronic fatigue syndrome The CFIDS Association of America, Inc $32,797
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $59,439
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $19,871
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $59,439
• M Ronald Glaser Stress, the immune system and basal cell carcinoma National Cancer Institute $19,871
• Matthew J During Somatic cell gene transfer/neurological & clinical applications Nat Inst Neurological Disorders & Stroke $294,683
• Matthew J During Somatic cell gene transfer/neurological & clinical applications Nat Inst Neurological Disorders & Stroke $291,292
• Matthew J During An immunological approach to alter the function of neuronal genes Nat Inst Neurological Disorders & Stroke $100,703
• Matthew J During Somatic cell gene transfer/neurological & clinical applications Nat Inst Neurological Disorders & Stroke $32,743
• Matthew J During Somatic cell gene transfer/neurological & clinical applications Nat Inst Neurological Disorders & Stroke $32,366
• Michael A Freitas Assays for screening histone modification in cancer National Cancer Institute $22,326
• Michael A Freitas Assays for screening histone modification in cancer National Cancer Institute $11,163
• Nicola A O Zanesi Mouse models of the most common human cancers Sidney Kimmel Fdn Cancer Res $100,000
• Ning Quan Neuroimmune communication at the blood-brain barrier Nat Inst of Allergy &Infectious Diseases $16,975
• Ning Quan Neuroimmune communication at the blood-brain barrier Nat Inst of Allergy &Infectious Diseases $77,114
• Phillip G Popovich Improving axon regeneration with activated macrophages The Craig H Neilsen Foundation $125,000
• Phillip G Popovich Macrophage heterogeneity in spinal cord injury Nat Inst Neurological Disorders & Stroke $327,804
• Phillip G Popovich Macrophage TLR4 and demyelination in injured spinal cord Nat Inst Neurological Disorders & Stroke $34,360
• Ramana Davuluri Genome wide discovery and analysis of alternative promoters National Human Genome Research Institute $315,575
• Ramana Davuluri Modeling the epigenetic changes in the alternative promoters of cancer genes Am Cancer Soc Inc $162,000
• Ramana Davuluri Modeling the epigenetic changes in the alternative promoters of cancer genes Am Cancer Soc Inc $18,000
• Rami Ishaq Aqeilan Role of the WW domain-containing oxidoreductase (WWOX) gene in skeletal development and bone neoplasia Ohio Cancer Res Assoc $22,500
• Rami Ishaq Aqeilan Role of the WW domain-containing oxidoreductase (WWOX) gene in skeletal development and bone neoplasia Ohio Cancer Res Assoc $2,500
• Richard Allan Fishel Functional studies of the meiotic MutS homologs hMSH4-hMSH5 Nat Inst Gen Medical Scis $249,486
• Richard Allan Fishel Human mismatch repair proteins and carcinogenesis National Cancer Institute $284,355
• Richard Allan Fishel Human mismatch repair proteins and carcinogenesis National Cancer Institute $60,781
• Richard Allan Fishel Recombination/repair complex in human cells Nat Inst Gen Medical Scis $383,244
• Richard Allan Fishel Role of base excision repair genes in HIV infection Merck & Co Inc $0
• Samir Acharya Role of mismatch repair in cell survival Ohio Cancer Res Assoc $22,253
• Samir Acharya Role of mismatch repair in cell survival Ohio Cancer Res Assoc $2,473
• Tim Hui-Ming Huang Interrogating epigenetic changes in cancer genomes National Cancer Institute $1,294,780
• Tim Hui-Ming Huang Interrogating epigenetic changes in cancer genomes National Cancer Institute $135,000
• Tim Hui-Ming Huang OSU-ICBP Undergraudate Summer Research Fellow (Position at the Indiana University subcontract site) Sci Applications Intl Corp $3,150
• Tim Hui-Ming Huang Reactivation of methylation-silenced genes by polyphenols Rutgers Univ $43,483
• Tim Hui-Ming Huang CpG Island Methylator Phenotypes in Breast Cancer National Cancer Institute $8,170
• Tim Hui-Ming Huang Environmental epigenetics and stem/progenitor cell injury Nat Inst of Environ Health Scis $18,225
• Tim Hui-Ming Huang Environmental epigenetics and stem/progenitor cell injury Nat Inst of Environ Health Scis $150
• Tim Hui-Ming Huang CpG Island Methylator Phenotypes in Breast Cancer National Cancer Institute $242,383
• Tim Hui-Ming Huang Environmental epigenetics and stem/progenitor cell injury Nat Inst of Environ Health Scis $309,827
• Tim Hui-Ming Huang Environmental epigenetics and stem/progenitor cell injury Nat Inst of Environ Health Scis $2,550
• Tim Hui-Ming Huang Interrogating epigenetic changes in cancer genomes National Cancer Institute $143,864
• Tim Hui-Ming Huang Interrogating epigenetic changes in cancer genomes National Cancer Institute $15,000
• Tim Hui-Ming Huang OSU-ICBP Undergraudate Summer Research Fellow (Position at the Indiana University subcontract site) Sci Applications Intl Corp $3,150
• Tim Hui-Ming Huang Reactivation of methylation-silenced genes by polyphenols Rutgers Univ $4,831
• Tim Hui-Ming Huang CpG Island Methylator Phenotypes in Breast Cancer National Cancer Institute $13,617
• Virginia M Sanders Immune Regulation of Neuronal Injury and Repair Loyola Univ of Chicago $41,249
• Virginia M Sanders Neuromodulation of the antibody response Nat Inst of Allergy &Infectious Diseases $349,641
• Virginia M Sanders Training program in integrative immunobiology. Nat Inst of Allergy &Infectious Diseases $230,205

Neurological Surgery

• Balveen Kaur Generation of a Novel Oncolytic HSV for Treatment of Pediatric Brain Tumors Alex's Lemonade Stand Foundation $21,000
• Balveen Kaur Generation of a Novel Oncolytic HSV for Treatment of Pediatric Brain Tumors Alex's Lemonade Stand Foundation $9,000
• Balveen Kaur Oncolytic HSV Cancer Therapy: Enhancement by Vasculostatin Gene Therapy Nat Inst Neurological Disorders & Stroke $196,875
• E Antonio Chiocca Biology of tauopathies studied with HSV amplicons. Nat Inst Neurological Disorders & Stroke $273,324
• E Antonio Chiocca Development of an Oncolytic Virus with Prodrug-Activating Gene Therapy Alliance for Cancer Gene Therapy $1,000,000
• E Antonio Chiocca Dose response and dynamics of ultrasound mediated BBB opening Perfusion Technology, LLC $13,625
• E Antonio Chiocca Gene Therapy for Brain Tumors Massachusetts General Hospital $40,392
• E Antonio Chiocca Gene therapy of brain tumors Massachusetts General Hospital $268,500
• E Antonio Chiocca Imaging of gene expression in glioblastoma Case Western Reserve Univ $53,072
• E Antonio Chiocca Imaging of gene expression in glioblastoma Case Western Reserve Univ $51,652
• E Antonio Chiocca OSU 0455: A phase Ib study of Adv-Tk + Valacyclovir gene therapy in combination with standard radiation therapy for malignant gliomas Advantagene, Inc $7,500
• E Antonio Chiocca OSU 0455: A phase Ib study of Adv-Tk + Valacyclovir gene therapy in combination with standard radiation therapy for malignant gliomas Advantagene, Inc $708
• E Antonio Chiocca OSU 07006 - A Phase I/II clinical trial to evaluate dose limiting toxicity and efficacy of intralesional administration of REOLYSIN(R) for the treatment of patients with histologically confirmed recurrent malignant gliomas Oncolytics Biotech Inc $0
• E Antonio Chiocca Validation of GSK-3 as an anti-invasive target in glioma National Brain Tumor Fdn $50,000
• Ehud Mendel A prospective, multi-center, randomized controlled study to compare the spinal sealant system as an adjunct to sutured dural repair with standard of care methods during spinal surgery Confluent Surgical, Inc $0
• Ehud Mendel A prospective, multi-center, randomized controlled study to compare the spinal sealant system as an adjunct to sutured dural repair with standard of care methods during spinal surgery Confluent Surgical, Inc $2,320
• Kazuhiko Kurozumi Glioma ECM modulation to enhance OV therapy American Assoc of Neurological Surgeons $50,000
• Michal Oskar Nowicki Investigating the role of GSK-3 in Glioma Invasion American Brain Tumor Association $80,000
• Yoshinaga Saeki HSV amplicon vectors for Neuroscienceresearch National Institute of Mental Health $202,500

Neurology

• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $188
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $150
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $9,844
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $1,200
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $990
• Andrew P Slivka Jr. Carotid occlusion surgery study (COSS) Washington Univ $98
• Andrew P Slivka Jr. Carotid occlusion surgery study (COSS) Washington Univ $32
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $7,650
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $9,720
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $8,636
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $6,885
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $673
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $4,894
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $2,482
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $903
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $759
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $706
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $416
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $1,231
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $0
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $5,247
• Andrew P Slivka Jr. Insulin resistance intervention after stroke trial (IRIS) Yale Univ $5,901
• Andrew P Slivka Jr. Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20mg OD for reducing risk of major cardiovascular events in abdominally obese patients with clustering risk factors Sanofi-aventis $0
• Andrew P Slivka Jr. Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20mg OD for reducing risk of major cardiovascular events in abdominally obese patients with clustering risk factors Sanofi-aventis $1,500
• Andrew P Slivka Jr. Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20mg OD for reducing risk of major cardiovascular events in abdominally obese patients with clustering risk factors Sanofi-aventis $1,920
• Andrew P Slivka Jr. Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20mg OD for reducing risk of major cardiovascular events in abdominally obese patients with clustering risk factors Sanofi-aventis $4,500
• Andrew P Slivka Jr. Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20mg OD for reducing risk of major cardiovascular events in abdominally obese patients with clustering risk factors Sanofi-aventis $1,980
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $6,870
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $3,320
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $1,060
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $11,130
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $51,650
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $2,540
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $7,270
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $2,940
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $6,140
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $3,770
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $4,460
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $1,720
• Andrew P Slivka Jr. Secondary prevention of small subcortical strokes. UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $2,260
• Andrew P Slivka Jr. Siblings with ischemic stroke study (SWISS). Mayo Fdn for Medical Educ & Res $299
• Andrew P Slivka Jr. Siblings with ischemic stroke study (SWISS). Mayo Fdn for Medical Educ & Res $3,673
• Andrew P Slivka Jr. Siblings with ischemic stroke study (SWISS). Mayo Fdn for Medical Educ & Res $299
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $555
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $503
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $405
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $600
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $1,613
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $705
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $750
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $1,080
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $8
• Andrew P Slivka Jr. A double-blind, active and placebo controlled study of Aggrenox(R) vs. clopidogrel + aspirin, with and without Micardis(R). Boehringer Ingelheim Pharmaceuticals Inc $2,160
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $1,065
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $850
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $55,784
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $6,800
• Andrew P Slivka Jr. RESPECT: Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care AGA Medical Corp $5,610
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $850
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $1,080
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $960
• Andrew P Slivka Jr. DIAS - 2: Desmoteplase (INN) in acute ischaemic stroke: Phase III study of Desmoteplase (INN) in the indication of acute stroke Forest Labs Inc $765
• Bassel F Shneker A 14-month open-label extension phase of the double-blind, placebo-controlled, dose escalation, parallel-group study of E2007 as an adjunctive therapy in patients with refractory partial seizures Parexel Intl Corp $14,282
• Bassel F Shneker A 14-month open-label extension phase of the double-blind, placebo-controlled, dose escalation, parallel-group study of E2007 as an adjunctive therapy in patients with refractory partial seizures Parexel Intl Corp $10,095
• Bassel F Shneker A 14-month open-label extension phase of the double-blind, placebo-controlled, dose escalation, parallel-group study of E2007 as an adjunctive therapy in patients with refractory partial seizures Parexel Intl Corp $6,567
• Bassel F Shneker A double-blind, placebo-controlled, dose escalation, parallel-group study of E2007 given as adjunctive therapy in patients with refractory partial seizures INC Research, Inc $20,895
• Bassel F Shneker A double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of RWJ-333369 as adjunctive therapy in subjects with refractory partial seizures JOHNSON & JOHNSON $2,071
• Bassel F Shneker A double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of RWJ-333369 as adjunctive therapy in subjects with refractory partial seizures JOHNSON & JOHNSON $313
• Bassel F Shneker A double-blind, placebo-controlled, parallel-group study of rufinamide given as adjunctive therapy in patients with refractory partial seizures PRA Intl $9,993
• Bassel F Shneker A double-blind, placebo-controlled, parallel-group study of rufinamide given as adjunctive therapy in patients with refractory partial seizures PRA Intl $1,500
• Bassel F Shneker A double-blind, placebo-controlled, parallel-group study of rufinamide given as adjunctive therapy in patients with refractory partial seizures PRA Intl $68,059
• Bassel F Shneker A double-blind, placebo-controlled, parallel-group study of rufinamide given as adjunctive therapy in patients with refractory partial seizures PRA Intl $23,342
• Bassel F Shneker A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures PRA Intl $0
• Bassel F Shneker A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures PRA Intl $6,919
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,117
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,026
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,005
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $2,035
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,005
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,123
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,049
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,128
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,098
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,090
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,391
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,077
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,080
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,038
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,372
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,360
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,026
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,090
• Bassel F Shneker A multicenter, double-blind, randomized conversion to monotherapy comparison of two doses of lamotrigine for the treatment of partial seizures GlaxoSmithKline $1,613
• Bassel F Shneker A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study JOHNSON & JOHNSON $0
• Bassel F Shneker A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study JOHNSON & JOHNSON $2,188
• Bassel F Shneker A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study JOHNSON & JOHNSON $3,545
• Bassel F Shneker A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study JOHNSON & JOHNSON $13,142
• Bassel F Shneker A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study JOHNSON & JOHNSON $5,212
• Bassel F Shneker A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study JOHNSON & JOHNSON $7,645
• Bassel F Shneker An assessment of behavioral changes associated with lamotrigine and levetiracetam in patients with epilepsy. GlaxoSmithKline $500
• Bassel F Shneker An international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (greater than or equal to 16 to 70 years old) with partial onset seizures PPD Dev $0
• Bassel F Shneker An open-label extension study of rufinamide given as adjunctive therapy in patients with refractory partial seizures PRA Intl $0
• Bassel F Shneker An open-label extension study of rufinamide given as adjunctive therapy in patients with refractory partial seizures PRA Intl $1,500
• Bassel F Shneker An open-label extension study of rufinamide given as adjunctive therapy in patients with refractory partial seizures PRA Intl $1,192
• Bassel F Shneker An open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures PRA Intl $0
• Bassel F Shneker An open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures PRA Intl $4,219
• Bassel F Shneker An open-label, drug-drug interaction study between RJW-333369 and Phenytoin following multiple oral administrations in subjects with epilepsy, with a long-term open-label extension study Johnson & Johnson Pharmaceutical R&D $0
• Bassel F Shneker An open-label, drug-drug interaction study between RJW-333369 and Phenytoin following multiple oral administrations in subjects with epilepsy, with a long-term open-label extension study Johnson & Johnson Pharmaceutical R&D $2,142
• Bassel F Shneker An open-label, long-term follow-up study with Keppra XR for treatment of partial-onset seizures PRA Intl $0
• Bassel F Shneker Examining the safety, tolerability, and efficacy of UCB 44212 (seletracetam) in adult subjects (18-65 years) with refractory epilepsy suffering from partial onset seizures who are currently receiving levetiracetam (LEV) but still experiencing seizures UCB Pharma, Inc $2,445
• Bassel F Shneker Examining the safety, tolerability, and efficacy of UCB 44212 (seletracetam) in adult subjects (18-65 years) with refractory epilepsy suffering from partial onset seizures who are currently receiving levetiracetam (LEV) but still experiencing seizures UCB Pharma, Inc $9,791
• Bassel F Shneker Lamotrigine extended release in elderly patients with epilepsy (LEP105972) GlaxoSmithKline $0
• Bassel F Shneker Lamotrigine extended release in elderly patients with epilepsy (LEP105972) GlaxoSmithKline $1,500
• Bassel F Shneker Lamotrigine extended release in elderly patients with epilepsy (LEP105972) GlaxoSmithKline $1,448
• Bassel F Shneker Progesterone therapy for women with Epilepsy Beth Israel Deaconess Medical Center $0
• Bassel F Shneker Study examining the efficacy, safety and tolerability of UCB 44212 in adult subjects with refractory epilepsy suffering from partial onset seizures and treated with 1, 2 or 3 approved antiepileptic drugs UCB Pharma, Inc $1,956
• Bassel F Shneker Study examining the efficacy, safety and tolerability of UCB 44212 in adult subjects with refractory epilepsy suffering from partial onset seizures and treated with 1, 2 or 3 approved antiepileptic drugs UCB Pharma, Inc $489
• David Q Beversdorf Semantic network flexibility modulation/autism spectrum. Nat Inst Neurological Disorders & Stroke $170,035
• Deborah J Lynn A multicenter, randomized, blinded, parallel-group study of Avonex compared with Avonex in combination with oral methotrexate, intravenous methylprednisolone, or both in subjects with relapsing-remitting multiple sclerosis who have breakthrough disease. Cleveland Clinic Fdn $50,980
• Deborah J Lynn A multicenter, randomized, blinded, parallel-group study of Avonex compared with Avonex in combination with oral methotrexate, intravenous methylprednisolone, or both in subjects with relapsing-remitting multiple sclerosis who have breakthrough disease. Cleveland Clinic Fdn $3,600
• Deborah J Lynn A multicenter, randomized, blinded, parallel-group study of Avonex compared with Avonex in combination with oral methotrexate, intravenous methylprednisolone, or both in subjects with relapsing-remitting multiple sclerosis who have breakthrough disease. Cleveland Clinic Fdn $200
• Deborah J Lynn A two arm, open-label, 12 week phase IIIb study to evaluate the tolerability of Rebif and Betaseron in IFN-naive subjects with RRMS; followed by a single-arm, 24 week, Rebif-only safety extension Serono Inc $0
• Deborah J Lynn A two arm, open-label, 12 week phase IIIb study to evaluate the tolerability of Rebif and Betaseron in IFN-naive subjects with RRMS; followed by a single-arm, 24 week, Rebif-only safety extension Serono Inc $2,375
• Deborah J Lynn A two arm, open-label, 12 week phase IIIb study to evaluate the tolerability of Rebif and Betaseron in IFN-naive subjects with RRMS; followed by a single-arm, 24 week, Rebif-only safety extension Serono Inc $270
• Deborah J Lynn Combination trial of Copaxone plus Estriol in relapsing remitting Multiple Sclerosis Univ of California at Los Angeles $128,711
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $2,500
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $4,114
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $3,513
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $3,544
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $5,369
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $4,998
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $4,204
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $3,896
• Douglas W Scharre A 54-week,double-blind,randomized,placebo-controlled,parallel-group study to investigate the effects of rosiglitazone(extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response GlaxoSmithKline $2,340
• Douglas W Scharre A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease PHARMANET, INC. $5,017
• Douglas W Scharre A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease PHARMANET, INC. $8,128
• Douglas W Scharre A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8 week treatment of rozerem 8mg(QHS) in sleep disturbed, community dwelling, mild to moderately severe Alzheimer's disease subjects PPD Dev $4,326
• Douglas W Scharre A one-year, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in subjects with mild cognitive impairment Parexel Intl Corp $80
• Douglas W Scharre A prospective, open-label, randomized, multi-center, parallel-group study of 5 weeks, with a 20-week extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5cm2 rivastigmine patch Novartis Pharmaceuticals Corp $0
• Douglas W Scharre A prospective, open-label, randomized, multi-center, parallel-group study of 5 weeks, with a 20-week extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5cm2 rivastigmine patch Novartis Pharmaceuticals Corp $2,020
• Douglas W Scharre A prospective, open-label, randomized, multi-center, parallel-group study of 5 weeks, with a 20-week extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5cm2 rivastigmine patch Novartis Pharmaceuticals Corp $4,995
• Douglas W Scharre A prospective, open-label, randomized, multi-center, parallel-group study of 5 weeks, with a 20-week extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5cm2 rivastigmine patch Novartis Pharmaceuticals Corp $3,911
• Douglas W Scharre A randomized double-blind placebo-controlled trial of the effects of docosahexaenoic acid(DHA)in slowing the progression of Alzheimer's disease Univ of California at San Diego $0
• Douglas W Scharre A randomized double-blind placebo-controlled trial of the effects of docosahexaenoic acid(DHA)in slowing the progression of Alzheimer's disease Univ of California at San Diego $1,750
• Douglas W Scharre A randomized double-blind placebo-controlled trial of the effects of docosahexaenoic acid(DHA)in slowing the progression of Alzheimer's disease Univ of California at San Diego $49,450
• Douglas W Scharre A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of zaliproden in patients with mild-to-moderate dementia of the Alzheimer's type Sanofi Winthrop Pharmaceuticals $26,200
• Douglas W Scharre Alzheimer's disease cooperative study (ADNI) Univ of California at San Diego $36,269
• Douglas W Scharre Alzheimer's disease cooperative study (ADNI) Univ of California at San Diego $31,904
• Douglas W Scharre Alzheimer's disease cooperative study (ADNI) Univ of California at San Diego $32,217
• Douglas W Scharre Alzheimer's disease cooperative study (ADNI) Univ of California at San Diego $20,039
• Douglas W Scharre Double-blind, parallel-group comparison of 23 mg donepezil sustained release to 10 mg donepezil immediate release in patients with moderate to severe Alzheimer's disease Icon Clinical Res Inc $0
• Douglas W Scharre Double-blind, parallel-group comparison of 23 mg donepezil sustained release to 10 mg donepezil immediate release in patients with moderate to severe Alzheimer's disease Icon Clinical Res Inc $14,211
• Douglas W Scharre Open label study of the effect of daily treatment with MPC-7869 in subjects with dementia of the Alzheimer's type PPD Dev $3,304
• Douglas W Scharre Study of rasagiline 1mg and 2mg added to aricept 10mg in patients with mild to moderate dementia of the Alzheimer's type. PRA Intl $4,249
• Douglas W Scharre Study of rasagiline 1mg and 2mg added to aricept 10mg in patients with mild to moderate dementia of the Alzheimer's type. PRA Intl $1,518
• Douglas W Scharre Study of rasagiline 1mg and 2mg added to aricept 10mg in patients with mild to moderate dementia of the Alzheimer's type. PRA Intl $7,645
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $1,798
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $32,297
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $41,457
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $24,497
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $24,497
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $13,922
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $2,032
• Douglas W Scharre Study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type PPD Dev $10,682
• Douglas W Scharre Study of VP4896 for the treatment of mild to moderate Alzheimer's disease Quintiles Transnational Corp $7,925
• Herbert B Newton OSU 05112-Phase III randomized, double-blind, dexamethasone-sparing study comparing human corticotropin-releasing factor (hCRF) to placebo for control of symptoms associated with peritumoral brain edema in patients with malignant brain tumor... Celtic Pharma Development Services, Ltd $10,416
• Herbert B Newton OSU 05114 - Phase III randomized, double-blind study comparing human corticotropin-releasing factor (hCRF) to dexamethasone for control of symptoms associated with peritumoral brain edema in patients with primary malignant glioma [0302] Celtic Pharma Development Services, Ltd $9,977
• Herbert B Newton Intra-arterial carboplatin and oral temozolomide for the treatment of recurrent and symptomatic residual brain metastases. Schering Corp $10,000
• Herbert B Newton OSU 05112-Phase III randomized, double-blind, dexamethasone-sparing study comparing human corticotropin-releasing factor (hCRF) to placebo for control of symptoms associated with peritumoral brain edema in patients with malignant brain tumor... Celtic Pharma Development Services, Ltd $3,472
• Herbert B Newton OSU 05113 - An open-label, extended-use study of human corticotropin-releasing factor (hCRF) intended for patients who participate in the dexamethasone-sparing studies NTI 0302 or NTI 0303 Celtic Pharma Development Services, Ltd $11,736
• Herbert B Newton OSU 05114 - Phase III randomized, double-blind study comparing human corticotropin-releasing factor (hCRF) to dexamethasone for control of symptoms associated with peritumoral brain edema in patients with primary malignant glioma [0302] Celtic Pharma Development Services, Ltd $3,326
• James L Moore A historical-controlled, multicenter, double-blind, randomized trial to assess the efficacy and safety of conversion to Lacosamide 400 mg/day monotherapy in subjects with partial-onset seizures Schwarz BioSciences, Inc $0
• James L Moore A multi-center, open-label extension trial to assess the long-term use of Lacosamide monotherapy and safety of lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures Schwarz BioSciences, Inc $0
• James L Moore Efficacy and safety of SPM927 (400 and 600 mg/day) as adjunctive therapy in subjects with partial seizures with or without secondary generalization. SCIREX CORPORATION $6,330
• James L Moore LAM100034: A multicenter, double-blind, randomized, parallel-group evaluation of LAMICTAL extended-release adjunctive therapy in patients with partial seizures GlaxoSmithKline $1,605
• James L Moore Lamotrigine extended release in elderly patients with epilepsy LEP105972 GlaxoSmithKline $0
• James L Moore Neurodevelopmental effects of antiepileptic drugs Univ of Florida $4,255
• James L Moore Neurodevelopmental effects of antiepileptic drugs Univ of Florida $2,766
• James L Moore Neurodevelopmental effects of antiepileptic drugs Univ of Florida $1,495
• James L Moore SP756: An open-label extension trial to determine safety and efficacy of long-term oral SPM 927 in patients with partial seizures SCIREX CORPORATION $2,239
• James L Moore Tolerability and efficacy of long-term oral SPM 927 as adjunctive therapy in patients with partial seizures. Quintiles Transnational Corp $1,018
• Jerry R Mendell Long-term safety and tolerability study in patients with Amyotrophic Lateral Sclerosis (ALS). Sanofi Winthrop Pharmaceuticals $2,505
• John T Kissel A double-blind, placebo-controlled, randomized, multiple ascending dose, safety study of MYO-29 administered to adult patients with Becker, facioscapulohumeral and limb-girdle muscular dystrophy Research Institute at Nationwide Childrn $102,860
• John T Kissel A double-blind, placebo-controlled, randomized, multiple ascending dose, safety study of MYO-29 administered to adult patients with Becker, facioscapulohumeral and limb-girdle muscular dystrophy Research Institute at Nationwide Childrn $17,385
• John T Kissel A trial of mycophenolate mofetil in mysathenia gravis. Duke Univ $33,250
• John T Kissel A trial of mycophenolate mofetil in mysathenia gravis. Duke Univ $1,000
• John T Kissel Prospective controlled trial of valproic acid in ambulant adults with spinal muscular atrophy (VALIANT Adult SMA Study) Families of Spinal Muscular Atrophy $205,059
• John T Kissel Prospective controlled trial of valproic acid in ambulant adults with spinal muscular atrophy (VALIANT Adult SMA Study) Families of Spinal Muscular Atrophy $5,000
• John T Kissel Thymectomy in non-thymomatous MG patients on prednisone Univ of Alabama at Birmingham $1,350
• John T Kissel Thymectomy in non-thymomatous MG patients on prednisone Univ of Alabama at Birmingham $150
• Karen M Thomas Study with blinded raters to evaluate the effects of immediate versus delayed switch to Stalevo on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off Novartis Pharmaceuticals Corp $1,528
• Karen M Thomas A multi-center, open label extension study to evaluate the long-term safety, tolerablility, and efficacy of E2007 as an adjunctive therapy in levodopa treated Parkinson's disease patients with motor fluctuations Quintiles Transnational Corp $0
• Karen M Thomas A multi-center, open label extension study to evaluate the long-term safety, tolerablility, and efficacy of E2007 as an adjunctive therapy in levodopa treated Parkinson's disease patients with motor fluctuations Quintiles Transnational Corp $12,272
• Karen M Thomas A multi-center, randomized, double-blind, placebo-controlled, parallel group study of the efficacy , safety and tolerablility of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations Quintiles Transnational Corp $11,088
• Karen M Thomas A multi-center, randomized, double-blind, placebo-controlled, parallel group study of the efficacy , safety and tolerablility of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations Quintiles Transnational Corp $14,052
• Karen M Thomas A multi-center, randomized, double-blind, placebo-controlled, parallel group study of the efficacy , safety and tolerablility of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations Quintiles Transnational Corp $866
• Karen M Thomas A multi-center, randomized, double-blind, placebo-controlled, parallel group study of the efficacy , safety and tolerablility of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations Quintiles Transnational Corp $51,002
• Karen M Thomas A randomized, double-blind, active (pramipexole 0.5 mg tid)and placebo controlled, efficacy study of pramipexole given 0.5 mg and 0.75 mg bid over a 12-week treatment phase in early Parkinson's disease patients (PramiBID) Univ of Rochester $0
• Kathleen S Hawker A double blind, placebo controlled multi-center study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis Quintiles Transnational Corp $0
• Kathleen S Hawker A double blind, placebo controlled multi-center study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis Quintiles Transnational Corp $23,280
• Kathleen S Hawker Phase II, multi-center, randomized, double-blind, placebo controlled, safety, tolerability and efficacy study of add-on cladribine tablet therapy with rebif new formulation in multiple sclerosis subjects with active disease Serono Inc $0
• Kathleen S Hawker Phase II, multi-center, randomized, double-blind, placebo controlled, safety, tolerability and efficacy study of add-on cladribine tablet therapy with rebif new formulation in multiple sclerosis subjects with active disease Serono Inc $6,500
• Kathleen S Hawker Phase II, multi-center, randomized, double-blind, placebo controlled, safety, tolerability and efficacy study of add-on cladribine tablet therapy with rebif new formulation in multiple sclerosis subjects with active disease Serono Inc $1,494
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $5,000
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $8,250
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $8,250
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $1,979
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $1,979
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $5,193
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $1,844
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $688
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $3,958
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $1,979
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $19,899
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $16,500
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $19,899
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $344
• Kottil W Rammohan 24-month double-blind, randomized, multicenter, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily vs. placebo in patients with RRMS Novartis Pharmaceuticals Corp $4,208
• Kottil W Rammohan A multicenter, doubleblind, randomized study comparing the combined use of interferon beta 1-a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III) MOUNT SINAI MEDICAL CENTER $19,425
• Kottil W Rammohan A multicenter, doubleblind, randomized study comparing the combined use of interferon beta 1-a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III) MOUNT SINAI MEDICAL CENTER $720
• Kottil W Rammohan A multicenter, doubleblind, randomized study comparing the combined use of interferon beta 1-a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III) MOUNT SINAI MEDICAL CENTER $640
• Kottil W Rammohan A multicenter, doubleblind, randomized study comparing the combined use of interferon beta 1-a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III) MOUNT SINAI MEDICAL CENTER $22,545
• Kottil W Rammohan A multicenter, doubleblind, randomized study comparing the combined use of interferon beta 1-a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III) MOUNT SINAI MEDICAL CENTER $720
• Kottil W Rammohan A multicenter, doubleblind, randomized study comparing the combined use of interferon beta 1-a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III) MOUNT SINAI MEDICAL CENTER $9,975
• Kottil W Rammohan A phase 3 randomized, rater-blinded study comparing two annual cycles of intravenous alemtuzumab to three-times weekly subcutaneous interferon beta-1a (rebif) in treatment-naive patients with RRMS Genzyme Corp $0
• Kottil W Rammohan A phase 3, randomized, rater- and dose-blinded study comparing two annual cycles of intravenous low- and high-dose alemtuzumab to three-times weekly subcutaneous interferon beta-1a (rebif) in patients with RRMS who have relapsed on therapy Genzyme Corp $0
• Kottil W Rammohan A randomized, multicenter, placebo-controlled and active reference (Glatiramer Acetate) comparison study to evaluate the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis Biogen IDEC Inc $0
• Kottil W Rammohan Controlled high risk multiple sclerosis prevention study in ongoing neurological surveillance. Biogen IDEC Inc $2,000
• Kottil W Rammohan Double-blind, placebo controlled, parallel group study to evaluate the safety and efficacy of oral Fampridine-SR (10 mg BID) in patients with multiple sclerosis Acorda Therapeutics $0
• Kottil W Rammohan Double-blind, placebo-controlled, 21-week, parallel group study to evaluate safety and efficacy of oral fampridine-SR (10 mg B.I.D.) in subjects with multiple sclerosis Acorda Therapeutics $9,929
• Kottil W Rammohan Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with RRMS to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks UCB Pharma, Inc $0
• Kottil W Rammohan Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with RRMS to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks UCB Pharma, Inc $3,000
• Kottil W Rammohan Effect of early glatiramer acetate treatment in delaying the conversion to clinically definite multiple sclerosis, of patients presenting with a clinically isolated syndrome. Teva NeuroscienceInc $1,094
• Kottil W Rammohan Effect of early glatiramer acetate treatment in delaying the conversion to clinically definite multiple sclerosis, of patients presenting with a clinically isolated syndrome. Teva NeuroscienceInc $2,656
• Kottil W Rammohan Impact of neutralizing antibodies on interferon responsive genes highlights biomarker response Biogen IDEC Inc $319
• Kottil W Rammohan Impact of neutralizing antibodies on interferon responsive genes highlights biomarker response Biogen IDEC Inc $319
• Kottil W Rammohan MS-F203 extension: Open label extension study to evaluate the safety, tolerability and activity of oral fampridine-SR in subjects with multiple sclerosis who participated in the MS-F203 trial Acorda Therapeutics $3,560
• Kottil W Rammohan MS-F203 extension: Open label extension study to evaluate the safety, tolerability and activity of oral fampridine-SR in subjects with multiple sclerosis who participated in the MS-F203 trial Acorda Therapeutics $3,510
• Kottil W Rammohan Multicenter phase 2 study 307000A to further evaluate the safety and tolerability of Betaseron (R) 500 mcg subcutaneously every other day and Betaseron (R) 250 mcg subcutaneously every other day in patients with relapsing-remitting multiple sclerosis. Bayer HealthCare Pharmaceuticals Inc $2,156
• Kottil W Rammohan Multicenter, phase III study of drugs for relapsing remitting multiple sclerosis: Betaseron/Betaferon 8MIU and 16 MIU, and Betaseron/Betaferon s.c. and Copaxone 20 mg s.c. Bayer HealthCare Pharmaceuticals Inc $22,119
• Kottil W Rammohan Multicenter, phase III study of drugs for relapsing remitting multiple sclerosis: Betaseron/Betaferon 8MIU and 16 MIU, and Betaseron/Betaferon s.c. and Copaxone 20 mg s.c. Bayer HealthCare Pharmaceuticals Inc $22,119
• Kottil W Rammohan Multicenter, phase III study of drugs for relapsing remitting multiple sclerosis: Betaseron/Betaferon 8MIU and 16 MIU, and Betaseron/Betaferon s.c. and Copaxone 20 mg s.c. Bayer HealthCare Pharmaceuticals Inc $48,575
• Kottil W Rammohan Open-label extension study to evaluate the safety, tolerability and activity of oral Fampridine-SR in patients with multiple sclerosis who participated in the MS-F204 trial Acorda Therapeutics $0
• Kottil W Rammohan Open-label extension study to evaluate the safety, tolerability, and activity of oral fampridine-SR in subjects with multiple sclerosis. Acorda Therapeutics $5,180
• Kottil W Rammohan Open-label extension study to evaluate the safety, tolerability, and activity of oral fampridine-SR in subjects with multiple sclerosis. Acorda Therapeutics $3,825
• Kottil W Rammohan Study of Rebif (R) 44 mcg administered three times per week by subcutaneous injection compared with Copaxone (R) 20 mg administered daily by subcutaneous injection in the treatment of relapsing remitting multiple sclerosis. Serono Inc $875
• Kottil W Rammohan Study of Rebif (R) 44 mcg administered three times per week by subcutaneous injection compared with Copaxone (R) 20 mg administered daily by subcutaneous injection in the treatment of relapsing remitting multiple sclerosis. Serono Inc $2,000
• Kottil W Rammohan Study of the human anti-IL-12 antibody ABT-874 in subjects with multiple sclerosis with a 24-week double blind active extension phase Abbott Laboratories $14,001
• Kottil W Rammohan Study of the human anti-IL-12 antibody ABT-874 in subjects with multiple sclerosis with a 24-week double blind active extension phase Abbott Laboratories $152
• Kottil W Rammohan Study to compare the efficacy, tolerability and safety of glatiramer acetate injection 40 mg/ml to 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting multiple sclerosis Teva NeuroscienceInc $2,470
• Kottil W Rammohan Study to compare the efficacy, tolerability and safety of glatiramer acetate injection 40 mg/ml to 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting multiple sclerosis Teva NeuroscienceInc $15,347
• Kottil W Rammohan Study to compare the efficacy, tolerability and safety of glatiramer acetate injection 40 mg/ml to 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting multiple sclerosis Teva NeuroscienceInc $68,647
• Kottil W Rammohan Study to compare the efficacy, tolerability and safety of glatiramer acetate injection 40 mg/ml to 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting multiple sclerosis Teva NeuroscienceInc $6,870
• Kottil W Rammohan Study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS) Serono Inc $10,106
• Kottil W Rammohan Study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS) Serono Inc $6,513
• Kottil W Rammohan Study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS) Serono Inc $6,069
• Kottil W Rammohan Study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS) Serono Inc $5,030
• Kottil W Rammohan Study to evaluate the safety and efficacy of rituximab in adults with primary-progressive multiple sclerosis Genentech Inc $11,966
• Kottil W Rammohan Study to evaluate the safety and efficacy of rituximab in adults with primary-progressive multiple sclerosis Genentech Inc $15,364
• Kottil W Rammohan Study to evaluate the safety and efficacy of rituximab in adults with primary-progressive multiple sclerosis Genentech Inc $9,096
• Kottil W Rammohan Study to evaluate the safety and efficacy of rituximab in adults with primary-progressive multiple sclerosis Genentech Inc $17,258
• Kottil W Rammohan Study to evaluate the safety and efficacy of rituximab in adults with primary-progressive multiple sclerosis Genentech Inc $16,860
• Kottil W Rammohan Study to evaluate the safety and efficacy of rituximab in adults with primary-progressive multiple sclerosis Genentech Inc $15,837
• Kottil W Rammohan Study to evaluate the safety and efficacy of rituximab in adults with primary-progressive multiple sclerosis Genentech Inc $8,763
• Maria Kataki A randomized, double-blind, placebo-controlled evaluation of the safety and effectiveness of memantine in nursing home residents with possible Alzheimer's disease Forest Labs Inc $43,194
• Michael Karl Racke PPARalpha agonists as treatment for autoimmune demyelination Nat Multiple Sclerosis Soc $67,436
• Michael Karl Racke International, multicenter, phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250ug or 500ug or open-label Betaseron/Betaferon 250ug and (Phase B) open Bayer HealthCare Pharmaceuticals Inc $0
• Michael Karl Racke International, multicenter, phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250ug or 500ug or open-label Betaseron/Betaferon 250ug and (Phase B) open Bayer HealthCare Pharmaceuticals Inc $11,525
• Michael Karl Racke LXR agonists as treatment for autoimmune demyelination Univ of Arkansas $35,000
• Michael Karl Racke Multiple sclerosis and infection: Molecular mechanisms Nat Multiple Sclerosis Soc $381,708
• Michael Karl Racke PPARalpha agonists as treatment for autoimmune demyelination Nat Multiple Sclerosis Soc $382,140
• Michael Karl Racke PPAR-gamma, Immune regulation and multiple sclerosis Univ of Arkansas $50,000
• Miriam L Freimer A randomized-withdraw phase III study evaluating the safety and efficacy of CG5503 extended-release (ER) in subjects with painful diabetic peripheral neuropathy (DPN) INC Research, Inc $0
• Robert Cavaliere OSU 06022 - A randomized phase 3 study of enzastaurin versus lomustine in the treatment of recurrent, intracranial glioblastoma multiforme Eli Lilly & Co $10,031
• Sandra K Kostyk A multi-center phase 1-2A open-label dosage-escalation and randomized, double-blinded, placebo-controlled study of Dimebon in subjects with Huntington's Disease (DIMOND) Univ of Rochester $1,182
• Sandra K Kostyk A multi-center, double-blind randomized, parallel group, placebo-controlled trial of Ethyl-EPA (Miraxion) in patients with mild to moderate Huntington's disease, study "TREND-HD" Univ of Rochester $8,111
• Sandra K Kostyk A multi-center, double-blind randomized, parallel group, placebo-controlled trial of Ethyl-EPA (Miraxion) in patients with mild to moderate Huntington's disease, study "TREND-HD" Univ of Rochester $7,551
• Sandra K Kostyk A multi-center, double-blind randomized, parallel group, placebo-controlled trial of Ethyl-EPA (Miraxion) in patients with mild to moderate Huntington's disease, study "TREND-HD" Univ of Rochester $5,046
• Sandra K Kostyk A multi-center, double-blind randomized, parallel group, placebo-controlled trial of Ethyl-EPA (Miraxion) in patients with mild to moderate Huntington's disease, study "TREND-HD" Univ of Rochester $3,364
• Sandra K Kostyk A randomized, double-blind, placebo-controlled study of tetrabenazine in patients with Huntington's disease. Univ of Rochester $1,125
• Sandra K Kostyk Cooperative Huntington's Observational Research Trial (COHORT) Univ of Rochester $0
• Sandra K Kostyk Cooperative Huntington's Observational Research Trial (COHORT) Univ of Rochester $10,425
• Sandra K Kostyk Cooperative Huntington's Observational Research Trial (COHORT) Univ of Rochester $4,125
• Sandra K Kostyk Cooperative Huntington's Observational Research Trial (COHORT) Univ of Rochester $0
• Sandra K Kostyk Efficacy and safety of the rotigotine CDS patch in subjects with idiopathic Parkinson's disease. Schwarz BioSciences, Inc $2,952
• Sandra K Kostyk Efficacy and safety of the rotigotine CDS patch in subjects with idiopathic Parkinson's disease. Schwarz BioSciences, Inc $4,924
• Sandra K Kostyk Efficacy and safety of the rotigotine CDS patch in subjects with idiopathic Parkinson's disease. Schwarz BioSciences, Inc $4,933
• Sandra K Kostyk Efficacy and safety of the rotigotine CDS patch in subjects with idiopathic Parkinson's disease. Schwarz BioSciences, Inc $3,807
• Sandra K Kostyk Parkinson's research: The organized genetics initiative. Univ of Rochester $4,750
• Sandra K Kostyk Parkinson's research: The organized genetics initiative. Univ of Rochester $0
• Sandra K Kostyk PHAROS prospective Huntington at risk observational study Univ of Rochester $2,734
• Sandra K Kostyk PHAROS prospective Huntington at risk observational study Univ of Rochester $3,746
• Sandra K Kostyk PHAROS prospective Huntington at risk observational study Univ of Rochester $2,835
• Sandra K Kostyk PHAROS prospective Huntington at risk observational study Univ of Rochester $0
• Sandra K Kostyk PHAROS prospective Huntington at risk observational study Univ of Rochester $2,025
• Sandra K Kostyk Pharos prospective Huntington's at risk observational study Univ of Rochester $350
• Sandra K Kostyk Pharos prospective Huntington's at risk observational study Univ of Rochester $425
• Sandra K Kostyk Pharos prospective Huntington's at risk observational study Univ of Rochester $300
• Sandra K Kostyk Pharos prospective Huntington's at risk observational study Univ of Rochester $450
• Steven M Nash A trial of insulin-like growth factor-1 (IGF-1) in amyotrophic lateral sclerosis. Mayo Fdn for Medical Educ & Res $31,680
• Wendy M King Strength testing in neuromuscular disease: A validation study. Mayo Fdn for Medical Educ & Res $4,368
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $11,080
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $6,565
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $4,460
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $6,015
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $1,795
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $5,320
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $7,115
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $2,500
• Yousef M Mohammad A phase III randomized, double-blind, parallel group, sham-controlled study evaluating the efficacy and safety of non-invasive, non-repetitive transcranial TMS stimulation for the acute preemptive treatment of the aura phase of migraine headache NEURALIEVE, INC. $11,585

Neuroscience

• Andrew J Fischer Muller glia and neuronal regeneration in the retina National Eye Institute $290,329
• Anthony Brown Axonal transport of neurofilaments. Nat Inst Neurological Disorders & Stroke $298,944
• Brandon A Miller The effects of microglia on oligodendrocyte cell death Nat Inst Neurological Disorders & Stroke $45,482
• Candice C Askwith Molecular and functional analysis of the acid-sensing ion channels NSF Integrative Organismal Biology $6,000
• Candice C Askwith Neuropeptides and acid sensing ion channels in acidosis-induced neuronal injury Am Heart Assn $65,000
• Chen Gu Targeting and function of voltage-gated potassium channel in myelinated axons Nat Multiple Sclerosis Soc $68,750
• Chen Gu Targeting and function of voltage-gated potassium channel in myelinated axons Nat Multiple Sclerosis Soc $68,750
• Chien-Liang Glenn Lin Consequence of RNA oxidation National Institute on Aging $154,238
• Chien-Liang Glenn Lin RNA oxidation in Alzheimer's disease Alzheimer's Assn $80,000
• Chien-Liang Glenn Lin Stimulation of Glial Glutamate Transporter EAAT2 Expression Brigham & Women's Hosp Inc $44,762
• Chien-Liang Glenn Lin Stimulation of Glial Glutamate Transporter EAAT2 Expression Brigham & Women's Hosp Inc $31,972
• Christine E Beattie Spinal muscular atrophy: Is it a motor axon disease? Nat Inst Neurological Disorders & Stroke $262,243
• Christine E Beattie The generation of transgenic zebrafish carrying mutations in the zebrafish sod1 gene Amyotrophic Lateral Sclerosis Assn $13,500
• Christine E Beattie Spinal muscular atrophy: Is it a motor axon disease? Nat Inst Neurological Disorders & Stroke $32,780
• Christine E Beattie The generation of transgenic zebrafish carrying mutations in the zebrafish sod1 gene Amyotrophic Lateral Sclerosis Assn $15,000
• Christine E Beattie Spinal muscular atrophy: Is it a motor axon disease? Nat Inst Neurological Disorders & Stroke $32,780
• Christine E Beattie The generation of transgenic zebrafish carrying mutations in the zebrafish sod1 gene Amyotrophic Lateral Sclerosis Assn $1,500
• Dana M McTigue PPAR agonist treatment for spinal cord injury Christopher and Dana Reeve Foundation $75,000
• James D Jontes Role of protocadherins in neural development studied in living zebrafish embryos Burroughs Wellcome Fund $50,000
• James D Jontes Role of protocadherins in neural development studied in living zebrafish embryos Burroughs Wellcome Fund $50,000
• John D Oberdick Ohio State NeuroscienceCenter core Nat Inst Neurological Disorders & Stroke $360,208
• John D Oberdick Ohio State NeuroscienceCenter core Nat Inst Neurological Disorders & Stroke $83,125
• John D Oberdick Ohio State NeuroscienceCenter core Nat Inst Neurological Disorders & Stroke $41,562
• John J Enyeart Properties of ion channels that control secretion Nat In Diabetes & Digestive & Kidney Diseases $266,496
• Karl H Obrietan CREB and synaptic reorganization Nat Inst Neurological Disorders & Stroke $265,935
• Karl H Obrietan The ERK/MAPK pathway and circadian clock entrainment National Institute of Mental Health $318,750
• Michael Xi Zhu High throughput screening of ligands of TRP channels Nat Inst Neurological Disorders & Stroke $37,500
• Michael Xi Zhu The role of PTX-sensitive G proteins in the activation of TRPC5 Am Heart Assn-Great Rivers Affiliate $60,500
• Paul D Henion Development of distinct neural crest and hematopoietic subpopulations Nat Inst Gen Medical Scis $144,771
• Paul D Henion Development of distinct neural crest and hematopoietic subpopulations Nat Inst Gen Medical Scis $144,771
• Stuart C Mangel Neuronal plasticity in the retina National Eye Institute $362,923
• Thomas W Sherwood Interactions between dynorphin & the acid-sensing ion channel 1a in neuronal death Am Heart Assn-Great Rivers Affiliate $21,000
• Yun Sik Choi Neuroprotection by CREB/CRE transcriptional pathway in Huntington's disease Hereditary Disease Fdn $56,000

Nisonger Center

• Betsey A Bentson CCOE: dual diagnosis MI/MRDD Wright State Univ $35,700
• Edward S Sterling The Nisonger Center - Johnstown Road Dental Program United Way of Central Ohio $44,233
• Edward S Sterling Safety net dental care program OH Dept of Health $75,000
• L Eugene Arnold A phase III, multi-center, open-label study of Methylphenidate Transdermal System (MTS) in pediatric patients aged 6-13 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $5,693
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $0
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $5,766
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $29,396
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $3,493
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $30,381
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $1,008
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $2,016
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $16,836
• L Eugene Arnold A Phase IV, Multi-center, Open-label Study of Daytrana, Methylphenidate Transdermal System (MTS) to characterize the dermal reactions in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder (ADHD) Shire Pharmaceutical Development, Inc $1,477
• L Eugene Arnold Long term safety study of tomoxetine HCl in patients 6 years and older. Eli Lilly & Co $434
• L Eugene Arnold Long term safety study of tomoxetine HCl in patients 6 years and older. Eli Lilly & Co $837
• L Eugene Arnold Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine Autism Speaks $59,913
• L Eugene Arnold Pilot explorations of zinc effects in ADHD National Institute of Mental Health $90,899
• L Eugene Arnold Pilot explorations of zinc effects in ADHD National Institute of Mental Health $15,468
• L Eugene Arnold Risperidone and Behavior Therapy in Children with Pervasive Developmental Disorder: Long Term Follow-up Autism Speaks $97,659
• L Eugene Arnold Study of Fluoxetine in Autism: A randomised, double-blind, placebo-controlled, parallel-group, 14-week study to investigate the effect of Fluoxetine orally dissolving tablet on repetitive behaviors in childhood & adolescent Autistic Spectrum Disorder NeuroPharm Ltd $0
• L Eugene Arnold Study of Fluoxetine in Autism: A randomised, double-blind, placebo-controlled, parallel-group, 14-week study to investigate the effect of Fluoxetine orally dissolving tablet on repetitive behaviors in childhood & adolescent Autistic Spectrum Disorder NeuroPharm Ltd $5,723
• Margaretha V Izzo Access Tomorrow: Using E-mentoring, web-based, and assistive technologies for increasing achievement and transition outcomes US Department of Education $199,814
• Margaretha V Izzo Coordinating Center for Excellence in Transition Kent State Univ $15,000
• Margaretha V Izzo Enhanced academic achievement and transition outcomes through technology: Phase 2, steppingstones of technology innovation US Department of Education $299,515
• Margaretha V Izzo Transition weekends 2006-07 OH Rehabilitation Services Commission $4,500
• Margaretha V Izzo Transition weekends 2006-07 OH Rehabilitation Services Commission $30,000
• Margaretha V Izzo Way to work: An electronic mentoring model for youth and young adults with sensory disabilities OH Rehabilitation Services Commission $14,749
• Margaretha V Izzo Way to work: An electronic mentoring model for youth and young adults with sensory disabilities OH Rehabilitation Services Commission $98,471
• Margaretha V Izzo Workforce Investment Act subcontract J Ashburn Jr Youth Center Inc $2,000
• Marilee Ann Martens Williams Syndrome Regional Conference OH DEVELOPMENTAL DISABILITIES PLNG CNCL $500
• Michael G Aman A 52-week, open-label, multicenter study of the safety and tolerability of Aripiprazole flexibility dosed in the treatment of children and adolescents with autistic disorder Bristol-Myers Squibb Co $0
• Michael G Aman A 52-week, open-label, multicenter study of the safety and tolerability of Aripiprazole flexibility dosed in the treatment of children and adolescents with autistic disorder Bristol-Myers Squibb Co $4,350
• Michael G Aman A 52-week, open-label, multicenter study of the safety and tolerability of Aripiprazole flexibility dosed in the treatment of children and adolescents with autistic disorder Bristol-Myers Squibb Co $31,169
• Michael G Aman A multicenter, double-blind, randomized, placebo-controlled, parallel-group study with three fixed doses of Aripiprazole in the treatment of children and adolescents with Autistic Disorder Bristol-Myers Squibb Co $2,000
• Michael G Aman A multicenter, double-blind, randomized, placebo-controlled, parallel-group study with three fixed doses of Aripiprazole in the treatment of children and adolescents with Autistic Disorder Bristol-Myers Squibb Co $5,100
• Michael G Aman A multicenter, double-blind, randomized, placebo-controlled, parallel-group study with three fixed doses of Aripiprazole in the treatment of children and adolescents with Autistic Disorder Bristol-Myers Squibb Co $24,056
• Michael G Aman A multicenter, double-blind, randomized, placebo-controlled, parallel-group study with three fixed doses of Aripiprazole in the treatment of children and adolescents with Autistic Disorder Bristol-Myers Squibb Co $54,581
• Michael G Aman A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism targeting motor skills Mount Sinai Sch of Medicine $0
• Michael G Aman Development of an Interpersonal Aggression Scale for People with Intellectual Disability OH Dept of Mental Health $4,845
• Steven Reiss AUCD administration and operation. Admin Children, Youth, & Families $500,000
• Steven Reiss Nisonger Center UCEDD Administration and Operation Admin Developmental Disabilities $490,000
• Thomas R Fish Ohio Adult Sibling Project OH DEVELOPMENTAL DISABILITIES PLNG CNCL $18,000
• Thomas R Fish Ohio Adult Sibling Project OH DEVELOPMENTAL DISABILITIES PLNG CNCL $2,000
• Thomas R Fish The Next Chapter book club Columbus Fdn $5,000
• Thomas R Fish TRANSITION CORPS OH Community Service Council $50,000
• Thomas R Fish Young Adult Transition Corps OH Community Service Council $100,741

Obstetrics & Gynecology

• Cynthia B Evans A randomized, multicenter, double-blind, placebo-controlled trial to compare the effects of 12 weeks treatment with DR-2041 vaginal cream vs. placebo vaginal cream on vulvovaginal atrophy in healthy postmenopausal women Duramed Research, Inc $3,947
• David Cohn A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of Pertuzumab (RhuMAb 2C4) in combination with Gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary ... Genentech Inc $636
• David Cohn A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of Pertuzumab (RhuMAb 2C4) in combination with Gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary ... Genentech Inc $13,689
• David Cohn A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of Pertuzumab (RhuMAb 2C4) in combination with Gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary ... Genentech Inc $1,425
• David Cohn A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of Pertuzumab (RhuMAb 2C4) in combination with Gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary ... Genentech Inc $3,804
• David Cohn A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of Pertuzumab (RhuMAb 2C4) in combination with Gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary ... Genentech Inc $3,804
• David Cohn Phase II trial of weekly gemcitabine and docetaxel combination therapy for relapsed ovarian and peritoneal cancer Wayne State Univ $14,025
• David Cohn Phase II trial of weekly gemcitabine and docetaxel combination therapy for relapsed ovarian and peritoneal cancer Wayne State Univ $2,080
• David Cohn Phase II trial of weekly gemcitabine and docetaxel combination therapy for relapsed ovarian and peritoneal cancer Wayne State Univ $4,430
• David M O'Malley Phase III trial of Patupilone (EPO906)versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer Novartis Pharmaceuticals Corp $1,450
• Deborah A Bartholomew A multi-center prospective clinical study to evaluate the performance and clinical predictive value of the Invader HPV HR molecular assay and Invader HPV 126/18 molecular assay for the detection of human papillomavirus in cervical cytology samples Third Wave Technologies, Inc $8,957
• Deborah A Bartholomew A multi-center prospective clinical study to evaluate the performance and clinical predictive value of the Invader HPV HR molecular assay and Invader HPV 126/18 molecular assay for the detection of human papillomavirus in cervical cytology samples Third Wave Technologies, Inc $8,372
• Deborah A Bartholomew A multi-center prospective clinical study to evaluate the performance and clinical predictive value of the Invader HPV HR molecular assay and Invader HPV 126/18 molecular assay for the detection of human papillomavirus in cervical cytology samples Third Wave Technologies, Inc $5,000
• Deborah A Bartholomew A multi-center prospective clinical study to evaluate the performance and clinical predictive value of the Invader HPV HR molecular assay and Invader HPV 126/18 molecular assay for the detection of human papillomavirus in cervical cytology samples Third Wave Technologies, Inc $35,603
• Deborah A Bartholomew A randomized, international, double-blinded (with in-house blinding), controlled with GARDASIL, dose-ranging, tolerability, immunogenicity, and efficacy study of Multivalent Human Papillomavirus (HPV) L1 virus-like particle (VLP) vaccine administered to Merck & Co Inc $2,500
• Deborah A Bartholomew A randomized, international, double-blinded (with in-house blinding), controlled with GARDASIL, dose-ranging, tolerability, immunogenicity, and efficacy study of Multivalent Human Papillomavirus (HPV) L1 virus-like particle (VLP) vaccine administered to Merck & Co Inc $11,553
• Douglas R Danforth Effect of GnRH antagonist on primordial follicle survival in the primate ovary Nat Inst Child Health & HumanDevelopment $72,582
• Jay D Iams Multicenter network of maternal-fetal medicine units Nat Inst Child Health & HumanDevelopment $67,574
• Jay D Iams Multicenter network of maternal-fetal medicine units Nat Inst Child Health & HumanDevelopment $258,022
• Jay D Iams Multicenter network of maternal-fetal medicine units Nat Inst Child Health & HumanDevelopment $37,339
• Jay D Iams Multicenter network of maternal-fetal medicine units Nat Inst Child Health & HumanDevelopment $43,243
• Jay D Iams Multicenter network of maternal-fetal medicine units Nat Inst Child Health & HumanDevelopment $137,876
• Jay D Iams Vaginal ultrasound cerclage trial Univ of Alabama at Birmingham $65,184
• Jeffrey M Fowler Cost of cancer treatment study. Rand Corp $22,900
• Jeffrey M Fowler Gynecological cancer center for health disparities Henry M Jackson Fdn for the Advn Mil Med $36,031
• Jeffrey M Fowler Clinical trials in gynecologic oncology. Am Coll Obstetricians & Gynecologists $159,909
• Jeffrey M Fowler Clinical trials in gynecologic oncology. Am Coll Obstetricians & Gynecologists $73,593
• Jeffrey M Fowler Clinical trials in gynecologic oncology. Am Coll Obstetricians & Gynecologists $155,580
• Jeffrey M Fowler Clinical trials in gynecologic oncology. Am Coll Obstetricians & Gynecologists $147,426
• Jeffrey M Fowler Clinical trials in gynecologic oncology. Am Coll Obstetricians & Gynecologists $58,200
• Jeffrey M Fowler Clinical trials in gynecologic oncology. Am Coll Obstetricians & Gynecologists $142,230
• Jeffrey M Fowler Gynecological cancer center for health disparities Henry M Jackson Fdn for the Advn Mil Med $18,016
• Jeffrey M Fowler Gynecological cancer center for health disparities Henry M Jackson Fdn for the Advn Mil Med $36,031
• Jonathan A Schaffir A forty-eight week, randomized discontinuation trial of flibanserin in women with hypoactive sexual desire disorder containing an open-label, flexible dose period followed by a double-blind, randomized, placebo-controlled period Boehringer Ingelheim Pharmaceuticals Inc $415
• Jonathan A Schaffir A forty-eight week, randomized discontinuation trial of flibanserin in women with hypoactive sexual desire disorder containing an open-label, flexible dose period followed by a double-blind, randomized, placebo-controlled period Boehringer Ingelheim Pharmaceuticals Inc $615
• Jonathan A Schaffir A placebo-controlled, randomized, double-blind, parallel group, at-home exploratory study to evaluate the efficacy and safety of intranasally administered PT-141 in subjects with female sexual arousal disorder (FSAD) Palatin Technologies Inc $6,338
• Jonathan A Schaffir A placebo-controlled, randomized, double-blind, parallel group, at-home exploratory study to evaluate the efficacy and safety of intranasally administered PT-141 in subjects with female sexual arousal disorder (FSAD) Palatin Technologies Inc $9,194
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $3,500
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $3,245
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $594
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $250
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $700
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $81
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $594
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $81
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $17,318
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $9,461
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $15,719
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $4,779
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $12,040
• Jonathan A Schaffir A twenty four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin 50 milligrams daily and, with Uptitration 100 milligrams daily in premenopausal women with hypoactive sexual desire disorder Boehringer Ingelheim Pharmaceuticals Inc $6,593
• Larry J Copeland A phase II study of Gemcitabine/Carboplatin/Bevacizumab in platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer patients Genentech Inc/Eli Lilly & Co $3,000
• Larry J Copeland A phase II study of Gemcitabine/Carboplatin/Bevacizumab in platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer patients Genentech Inc/Eli Lilly & Co $21,000
• Larry J Copeland Vice-chair of the GOG GYNECOLOGIC ONCOLOGY GROUP $3,937
• Larry J Copeland Vice-chair of the GOG GYNECOLOGIC ONCOLOGY GROUP $12,597
• Larry J Copeland Vice-chair of the GOG GYNECOLOGIC ONCOLOGY GROUP $53,470
• Larry J Copeland Vice-chair of the GOG GYNECOLOGIC ONCOLOGY GROUP $5,905
• Lisa M Keder A multicenter, open-label study on the efficacy, cycle control & safety of a contraceptive vaginal ring delivering a daily odose of 150ug of Nestorone and 15 ug of ethinyl estradiol EASTERN VIRGINIA MEDICAL SCHOOL $67,704
• Lisa M Keder A multicenter, open-label study to evaluate the efficacy and safety of an extended cycle, low dose, combination oral contraceptive regimen, DP3-Lo 84/10, which utilizes Ethinyl Estradiol during the seven day interval between each 84-day cycle of ... Duramed Research, Inc $82
• Lisa M Keder A multicenter, open-label study to evaluate the efficacy and safety of an extended cycle, low dose, combination oral contraceptive regimen, DP3-Lo 84/10, which utilizes Ethinyl Estradiol during the seven day interval between each 84-day cycle of ... Duramed Research, Inc $592
• Lisa M Keder A multicenter, open-label study to evaluate the efficacy and safety of an extended cycle, low dose, combination oral contraceptive regimen, DP3-Lo 84/10, which utilizes Ethinyl Estradiol during the seven day interval between each 84-day cycle of ... Duramed Research, Inc $3,696
• Lisa M Keder A multicenter, open-label study to evaluate the efficacy and safety of an extended cycle, low dose, combination oral contraceptive regimen, DP3-Lo 84/10, which utilizes Ethinyl Estradiol during the seven day interval between each 84-day cycle of ... Duramed Research, Inc $20,586
• Lisa M Keder DR-DSG-301: A prospective, multicenter, open-label study to evaluate the safety and efficacy of the 28-day oral contraceptive DR-1021 Duramed Research, Inc $15,000
• Lisa M Keder DR-DSG-301: A prospective, multicenter, open-label study to evaluate the safety and efficacy of the 28-day oral contraceptive DR-1021 Duramed Research, Inc $4,020
• Lisa M Keder Treatment of iron deficiency anemia secondary to heavy uterine bleeding PEDIATRIC CLINICAL TRIALS INTERNATIONAL $7,179
• Wanjiku Kabiru A multicenter, randomized, double-blind phase III study of the efficacy and safety of the Misoprostol Vaginal Insert (MVI) compared to Cervidil for women requiring cervical ripening and induction of labor Cytokine PharmaSciences Inc $22,500
• Wanjiku Kabiru A multicenter, randomized, double-blind phase III study of the efficacy and safety of the Misoprostol Vaginal Insert (MVI) compared to Cervidil for women requiring cervical ripening and induction of labor Cytokine PharmaSciences Inc $4,500
• Wanjiku Kabiru A multicenter, randomized, double-blind phase III study of the efficacy and safety of the Misoprostol Vaginal Insert (MVI) compared to Cervidil for women requiring cervical ripening and induction of labor Cytokine PharmaSciences Inc $1,500
• Wanjiku Kabiru A multicenter, randomized, double-blind phase III study of the efficacy and safety of the Misoprostol Vaginal Insert (MVI) compared to Cervidil for women requiring cervical ripening and induction of labor Cytokine PharmaSciences Inc $4,000
• Wayne C Trout A randomized, multicenter, double-blind study to evaluate the efficacy of an extended cycle combination oral contraceptive, DP3-84/10, during the usual hormone-free interval, compared to conventional oral contraceptive therapy for cyclic pelvic pain Duramed Research, Inc $700
• Wayne C Trout A randomized, multicenter, double-blind study to evaluate the efficacy of an extended cycle combination oral contraceptive, DP3-84/10, during the usual hormone-free interval, compared to conventional oral contraceptive therapy for cyclic pelvic pain Duramed Research, Inc $525
• William E Ackerman Lipid bodies and prostaglandin production in labor Nat Inst Child Health & HumanDevelopment $125,336
• Young C Lin Epigenetic modulation of PTPG by Zeranol in beef increases breast cancer risk Nat Inst of Environ Health Scis $10,699
• Young C Lin Epigenetic modulation of PTPG by Zeranol in beef increases breast cancer risk Nat Inst of Environ Health Scis $10,567

Ophthalmology

• Alan D Letson A phase IV, open label, multicenter trial of maintenance intravitreous injections of Macugen given every 6 weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a modality resulting in maculopathy improvement OSI Pharmaceuticals, Inc $3,040
• Alan D Letson A phase IV, open label, multicenter trial of maintenance intravitreous injections of Macugen given every 6 weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a modality resulting in maculopathy improvement OSI Pharmaceuticals, Inc $275
• Alan D Letson A phase IV, open label, multicenter trial of maintenance intravitreous injections of Macugen given every 6 weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a modality resulting in maculopathy improvement OSI Pharmaceuticals, Inc $8,369
• Alan D Letson AREDS II: A multi-centered, randomized trial of Lutein, Zeaxanthin, and Omega-3 fatty acids in age-related macular degeneration The EMMES Corp $224
• Alan D Letson AREDS II: A multi-centered, randomized trial of Lutein, Zeaxanthin, and Omega-3 fatty acids in age-related macular degeneration The EMMES Corp $1,419
• Alan D Letson AREDS II: A multi-centered, randomized trial of Lutein, Zeaxanthin, and Omega-3 fatty acids in age-related macular degeneration The EMMES Corp $3,063
• Alan D Letson AREDS II: A multi-centered, randomized trial of Lutein, Zeaxanthin, and Omega-3 fatty acids in age-related macular degeneration The EMMES Corp $6,500
• Alan D Letson Phase III double masked multicenter randomized sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus Genentech Inc $0
• Alan D Letson Phase III double masked multicenter randomized sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus Genentech Inc $1,700
• Alan D Letson Phase III double masked multicenter randomized sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus Genentech Inc $5,340
• Cynthia J Roberts Master agreement for thought leaders Battelle Memorial Inst $0
• Cynthia J Roberts Measurement and evaluation of the elastic and viscous properties of the cornea in glaucoma Columbus Fdn $23,760
• Deborah M Grzybowski An in-vitro model of CSF outflow through the arachnoid membrane for IIH North American Neuro-Ophthalmology Soc $25,000
• Deborah M Grzybowski Comparison of novel antiproliferatives to improve the long term success of glaucoma filtration surgery Columbus Fdn $36,500
• Frederick H Davidorf The diabetic retinopathy clinical research network Jaeb Ctr for Health Res $8,711
• Frederick H Davidorf The diabetic retinopathy clinical research network Jaeb Ctr for Health Res $5,681
• Paul A Weber Ocular Hypertension Treatment Study (OHTS). National Eye Institute $62,222
• Paul A Weber Study to evaluate the effectiveness and safety of oral memantine. Allergan Inc $175
• Paul A Weber Study to evaluate the effectiveness and safety of oral memantine. Allergan Inc $163
• Richard G Lembach Evaluation of the utility of intra-operative topography to optimize corneal shape during penetrating keratoplasty. BIOMEC, INC. $12,700
• Richard G Lembach Evaluation of the utility of intra-operative topography to optimize corneal shape during penetrating keratoplasty. BIOMEC, INC. $5,250
• Robert B Chambers A phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Genentech Inc $10,307
• Robert B Chambers A phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Genentech Inc $20,358
• Robert B Chambers A phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Genentech Inc $26,022
• Robert B Chambers A phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Genentech Inc $19,138
• Robert B Chambers A phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Genentech Inc $19,138
• Robert B Chambers A phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Genentech Inc $250
• Robert B Chambers A phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) Genentech Inc $52
• Robert B Chambers Phase IIIB study comparing PDT with verteporfin plus two different dose regimens of intravitreal triamcinolone acetonide versus Visudyne plus intravitreal pegaptanib in patients with subfoveal CNV secondary to AMD Novartis Pharmaceuticals Corp $612
• Robert B Chambers Phase IIIB study comparing PDT with verteporfin plus two different dose regimens of intravitreal triamcinolone acetonide versus Visudyne plus intravitreal pegaptanib in patients with subfoveal CNV secondary to AMD Novartis Pharmaceuticals Corp $5,305
• Robert B Chambers Phase IIIB study comparing PDT with verteporfin plus two different dose regimens of intravitreal triamcinolone acetonide versus Visudyne plus intravitreal pegaptanib in patients with subfoveal CNV secondary to AMD Novartis Pharmaceuticals Corp $1,563
• Thomas F Mauger A double-masked, randomized study of the safety and effectiveness of DYME as an agent for selective staining of the anterior capsule during cataract surgery Aqumen Biopharmaceuticals, KK $0
• Thomas F Mauger Protocol #433, a study to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to vehicle in the treatment of bacterial conjunctivitis Bausch & Lomb $2,450
• Thomas F Mauger Protocol #433, a study to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to vehicle in the treatment of bacterial conjunctivitis Bausch & Lomb $2,450
• Thomas F Mauger Protocol #433, a study to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to vehicle in the treatment of bacterial conjunctivitis Bausch & Lomb $1,250
• Thomas F Mauger Protocol #433, a study to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to vehicle in the treatment of bacterial conjunctivitis Bausch & Lomb $3,450
• Thomas F Mauger Protocol #433, a study to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to vehicle in the treatment of bacterial conjunctivitis Bausch & Lomb $60
• Thomas F Mauger Protocol #433, a study to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to vehicle in the treatment of bacterial conjunctivitis Bausch & Lomb $1,012

Orthopaedics

• Christopher C Kaeding Prospective multicenter study of ACL reconstruction outcomes Vanderbilt Univ $12,401
• Christopher C Kaeding Prospective multicenter study of ACL reconstruction outcomes Vanderbilt Univ $10,891
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $3,802
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $458
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $2,338
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $51,100
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $479
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $1,901
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $9,268
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $2,479
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing allograft anterior cruciate ligament reconstruction Omeros Corp $3,972
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $7,642
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $4,240
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $4,402
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $6,970
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $16,761
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $7,742
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $8,831
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $7,656
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $6,303
• Christopher C Kaeding Double-blind, multicenter phase 3 study comparing the efficacy and safety of OMS103HP with vehicle in patients undergoing autograft anterior cruciate ligament reconstruction Omeros Corp $5,851
• Cornel Christian Van Gorp Embolic events detected during total knee arthroplasty with the use of RIA (Reamer-Irrigator-Aspirator): A randomized, controlled clinical study Synthes, Inc $0
• Cornel Christian Van Gorp Embolic events detected during total knee arthroplasty with the use of RIA (Reamer-Irrigator-Aspirator): A randomized, controlled clinical study Synthes, Inc $115,000
• Grant L Jones Recover kit for treating chronic elbow tendinosis Biomet, Inc $0
• Grant L Jones Recover kit for treating chronic elbow tendinosis Biomet, Inc $6,500
• Laura Senunas Phieffer Fluid irrigation techniques in patients with open fracture wounds (FLOW): A multi-centre blinded randomized controlled trial McMaster University $0

Otolaryngology

• Abraham Jacob Preclinical testing of a novel AKT inhibitor OSU-03012 using a VS xenograft model Children's Tumor Fdn $27,500
• D Bradley Welling Phenotypic determinants of vestibular Schwannomas Nat In Deafness&Other Commnctn Disorders $61,114
• D Bradley Welling Phenotypic determinants of vestibular Schwannomas Nat In Deafness&Other Commnctn Disorders $244,456
• David E Schuller American College of Surgeons oncology group Duke Univ $1,000
• Susan N Nittrouer Early development of children with hearing loss Nat In Deafness&Other Commnctn Disorders $557,074
• Susan N Nittrouer Ontogeny of segmental speech organization Nat In Deafness&Other Commnctn Disorders $37,445
• Susan N Nittrouer Ontogeny of segmental speech organization Nat In Deafness&Other Commnctn Disorders $170,104

Pathology

• Allan J Yates Integrative training in biomedical systems. Nat Inst Gen Medical Scis $196,459
• Carl D Morrison Expression of FOLR1 antibody in a large cohort of endometrial samples. Henry M Jackson Fdn $15,000
• F Jason Duncan Black Raspberry Extracts in the Inhibition of Post-transplant Skin Cancer